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Abstract   
 
  Cutaneous metastatic melanoma remains largely untreatable, likely due to 
resistance to apoptosis and/or the activation of pro-survival signalling. Incidence 
continues to increase highlighting the urgent need for more effective treatment 
strategies. Many chemotherapeutic drugs induce autophagy, the principle lysosomal-
mediated mechanism for the degradation/recycling of cellular products, as a 
compensatory mechanism to counteract apoptotic signals leading to the 
development of autophagy inhibition as a treatment for metastatic cancer. However, 
how to modulate autophagy for therapeutic benefit remains debatable since recent 
approaches demonstrate autophagy induction may also result in cell death in some 
tumour types. In line with the increasing evidence linking autophagy and apoptosis, 
including the discovery of interactions between anti-apoptotic Bcl-2 proteins and the 
autophagy regulatory protein Beclin-1, the principle aim of this study was thus to 
determine how autophagy modulation in metastatic melanoma may be harnessed for 
clinical benefit. To this aim drugs which activate pro-survival (bortezomib) or 
cytotoxic (Tetrahydrocannabinol, THC) autophagy were combined with a number of 
approaches to dissect the role of autophagy during cell death in response to these 
agents. Results demonstrated that while the anti-apoptotic protein Mcl-1 was able to 
limit autophagy, its over-riding function was the direct regulation of apoptosis. 
Furthermore, results confirmed autophagy was required for THC-induced death of 
melanoma cells, but that neither Beclin-1 nor Ambra 1 were required for autophagy, 
suggesting non-canonical autophagy activation in response to THC. Finally, THC was 
shown to promote lysosome membrane permeabilization (LMP) which was required 
for cell death. 
  In conclusion, these data suggest THC-induced apoptosis of melanoma cells 
requires induction of autophagy which, coupled with the activation of LMP that is 
also dependent on autophagic signalling, suggests a novel link between the processes 
of autophagy and apoptosis, ultimately translating into novel strategies through 
which to harness autophagy for the therapeutic benefit of melanoma.  
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1.1: Melanogenesis 
 
In day to day activities our skin is exposed to high levels of ultraviolet radiation (UV-
R), a major cause of DNA damage and a proven factor in skin cancer development 
(Thompson, Scolyer et al. 2005). In order to reduce the damaging effects of UV-R exposure a 
process known as melanogenesis is required in which photoprotective melanins are 
produced within melanocytes. These cells are pigment producing cells specialised for this 
purpose which are located in the basal layer of the epidermis known as the stratum basale 
(Fig. 1.1) (Costin and Hearing 2007). These cells function primarily to provide 
photoprotection for the skin against exposure to ultraviolet radiation. 
             
Figure 1.1: The location of melanocytes within the epidermis (Costin and Hearing 2007). Melanocytes are 
located within the stratum basale of the epidermis where they function to produce melanin and transport 
melanin containing melanosomes to adjacent keratinocytes via dendritic extensions.                                                                                                    
 
Melanocytes are derived from highly migratory embryonic cells of the neural crest 
arising during gastrulation, an early stage of embryogenesis where the embryo is 
reorganised to form three germ layers; the ectoderm, mesoderm and endoderm (Erickson 
and Reedy 1998). Neural crest cells are pluripotent cells derived between the surface 
ectoderm and the neural plate, which give rise to many cell types including neurons, glial 
cells, adrenal medulla, cardiac cells and craniofacial tissue (Lin and Fisher 2007). It is these 
neural crest cells that specifically give rise to melanoblasts (the melanocyte precursor) which 
subsequently migrate, proliferate and differentiate en route to their final destination in both 
the basal epidermis and hair follicles (Lin and Fisher 2007).  
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Differentiation of melanoblasts into melanocytes requires the receptor tyrosine 
kinase c-Kit and the basic helix loop helix leucine zipper Microphthlamia-associated 
transcription factor (Mitf). C-Kit is activated by its associated ligand, Kit-ligand, which leads 
to activation of RAS/RAF signalling as well as post-translational modification of Mitf 
(Hemesath, Price et al. 1998). Both c-Kit and Mitf have been shown to be essential for 
melanocyte development and survival (Steingrimsson, Copeland et al. 2004; Vance and 
Goding 2004), and loss of Mitf results in almost complete loss of melanocytes in zebrafish 
and mice models (Lister, Robertson et al. 1999), likely explained by previous studies 
demonstrating that melanoblast survival involves transcriptional upregulation of anti-
apoptotic members of the Bcl-2 protein family by Mitf (McGill, Horstmann et al. 2002). At 
this point melanoblasts are committed to form either fully differentiated melanocytes or 
melanocyte stem cells which are found in the bulge region of hair follicles (Fig. 1.2) 
(Nishimura, Jordan et al. 2002). Fully differentiated melanocytes function to produce 
melanin (of which there are two types, the red/yellow pheomelanin and the brown/black 
eumelanin (Fig. 1.3)) which is then transferred to keratinocytes.                        
                                              
Figure 1.2: Development pathway of melanocytes and melanoma (Goding 2007). Pluripotent neural crest cells 
develop to form the precursor cells of melanocytes known as melanoblasts. These melanoblasts become 
committed to form both melanocytes and melanocyte stem cells and are thus lineage restricted. When fully 
differentiated, melanocytes function to produce melanin which is transferred to keratinocytes to protect 
against UV-induced DNA damage. 
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Melanin is derived from the same amino acid precursor, tyrosine, which undergoes 
hydroxylation to form dopaquinone (Land and Riley 2000). It is from dopaquinone that the 
eumelanin and pheomelanin pathways diverge, with the G-protein-coupled melanocortin 1 
receptor (MC1R) being implicated in the switch between eumlanin and pheomelanin 
production. Eumelanogenesis is the process for producing eumelanin from dopaquinone and 
involves tyrosinase related proteins 1 and 2 (TRP 1 and TRP2). Pheomelanin is derived from 
the conjugation (by the thiol-containing cysteine) of glutathione rendering melanin much 
more photolabile, and often resulting in the production of hydrogen peroxide, superoxide, 
and hydroxyl radicals, all of which cause oxidative stress and possible DNA damage (Land 
and Riley 2000). These melanins are then packaged into melanosomes (a lysosome-like 
structure) and exported into adjacent keratinocytes via dendritic extensions (Fig. 1.1), with 
the keratinocytes using a 7 transmembrane receptor known as protease-activated receptor-
1 (PAR2) for this process (Boissy 2003). This exportation of melanosomes to keratinocytes 
thus forms the basis for skin and hair pigmentation. In humans, pigmentation acts primarily 
to protect the skin from UV-R induced DNA damage and highly pigmented skin has been 
shown to be protected from carcinogenesis by a factor of 500-1000 times compared to that 
of skin with little pigmentation (Kollias, Sayre et al. 1991). Furthermore, melanocytes are 
able to respond to UV-R by increasing the amount of pigment manufactured in 
melanosomes as well as the number of melanosomes exported to adjacent keratinocytes 
and by the activation of many keratinocyte-to-melanocyte signalling pathways. Once inside 
keratinocytes, melanosomes are distributed and positioned over the ‘sun exposed’ side of 
the nucleus in response to UV-R exposure (Boissy 2003). However, rather than acting as a UV 
block, melanin likely acts as a sink for reactive oxygen species (ROS), which would otherwise 
lead to DNA damage (Rozanowska, Sarna et al. 1999). 
Despite extensive preventative measures being in place to stop mutations occurring 
within melanocytes, occasionally atypical melanocytes develop. Atypical melanocytes are 
hyper-proliferative, often due to mutations in RAS/RAF signalling, and are able to escape 
from their usual location within the epidermis by overcoming their regulation by 
surrounding keratinocytes. The clustering of these cells within the same location leads to the 
formation of a benign naevus, more commonly known as a mole.  
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Figure 1.3: Structures of Eumelanin and Pheomelanin (Arrows represent sites for attachment to other units) 
(Ito and Wakamatsu 2008). 
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1.2: Cutaneous Melanoma 
 
  Cutaneous melanoma arises from the malignant transformation of melanocytes 
derived from either melanocytic naevi (Figure 1.4) or from previously normal looking skin. A 
stepwise model for melanoma development has been suggested in which a tumour arises 
from a cutaneous melanocyte to become a naevus and then a dysplastic naevus, which later 
develops into melanoma and eventually invasive disease. However, development of 
melanoma from a naevus only accounts for a quarter of cases, as roughly three quarters of 
melanomas develop in normal skin (Bevona, Goggins et al. 2003), suggesting  melanoma may 
arise from melanocyte stem cells within the skin, (Grichnik 2008). Nevertheless, to date 
there is no direct evidence to support this theory; a specific stem cell type involved in 
transformation to melanoma has yet to be defined. 
Melanoma is classified as a neuroectodermal tumour which is based on the lineage of 
melanocytes from neural crest cells. Although one of the rarer types of skin cancer, second 
to Merkel cell carcinoma only (Miller and Rabkin 1999), melanoma is the most aggressive 
and remains largely untreatable. With melanoma cases increasing by 3-8% per year since the 
mid 1960s for people of European decent (Thompson, Scolyer et al. 2005), melanoma is 
hence a major public health problem. Increased incidence of melanoma has been linked to 
environmental exposure to UV-R, where the highest age-standardised incidence and 
mortality rates are in countries with a higher UV index and a large Caucasian population (e.g. 
Australia and the USA) (Thompson, Scolyer et al. 2005). Additionally, genetic susceptibility of 
individuals, as well as the presence of many atypical or benign naevi, has been strongly 
linked with increased risk of melanoma (Thompson, Scolyer et al. 2005). 
In the traditionally proposed model, it is suggested that melanoma development is 
classified in different stages arising from atypical melanocytes forming benign naevi and 
resulting in pre-malignant melanoma (Fig. 1.4).  A radial growth phase then occurs due to 
further mutations within these naevi resulting in a radial growth pattern, primarily confined 
to the epidermis (Chin, Merlino et al. 1998). Malignant melanoma (Fig. 1.4 and Fig. 1.5) 
however, undergoes a vertical growth pattern resulting in the invasion of the tumour deep 
into the dermis and the subcutaneous fat layers of the skin (Fig. 1.4) which in many cases 
leads to further invasion into systemic metastasis (frequently involving the liver, bone, brain, 
lung and small intestine (Elder 1987)).  
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Figure 1.4: The progression of melanocyte transformation to metastatic malignant melanoma (Chin, Merlino 
et al. 1998). A: Normal melanocytes within the epidermis that are evenly distributed throughout the stratum 
basale. B: The benign proliferation of melanocytes due to mutations where they cluster together, forming 
benign naevi. C: Melanocyte dysplasia with many large atypical melanocytes. D: Radial growth phase (RGP) 
melanoma occurring due to further mutations. E: Metastatic malignant melanoma known as vertical growth 
phase (VGP).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Progression of melanoma development from a benign naevus to malignant melanoma. A) A 
common benign naevus or mole (from Sydney Melanoma Diagnostic Centre, 
http://www.melanoma.net.au/Melanoma/melanoma.htm). B) A dysplastic naevus. (Cancer Research UK, 
http://www.cancerresearchuk.org) C) A malignant melanoma lesion with distinctive change in size and colour. 
(Melanoma Diagnostic Centre). 
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  Prior to 2002 mainly two methods of diagnosis (one known as the Clark’s 
classification system and the other described by Breslow) were used to classify the 
pathology of melanoma. Breslow’s method measures tumour thickness from the granular 
cell layer to the peak depth of tumour invasion (Fig. 1.6) and is still widely used in diagnostic 
procedures while Clark’s method, more recently abolished, considered the anatomical level 
of tumour invasiveness (Chin, Merlino et al. 1998) (Fig. 1.6). A recently updated staging by 
the American Joint Committee on cancer (AJCC) incorporating Breslow depth together with 
mitotic rate, micro-metastases and ulceration as well as metastatic spread now forms the 
basis of current melanoma diagnosis and staging. (Balch, Gershenwald et al. 2009). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Pathological classification of melanoma (Chin, Merlino et al. 1998). The Clark’s classification 
system (where anatomical invasion of melanoma in the skin is used rated from levels I-V) along with Breslow 
thickness (which measures the absolute thickness of melanoma invasion) are commonly used in the prognosis 
of melanoma. 
 
While the prognosis for melanoma patients with early stage disease (Stage I and II)  is 
highly favourable, the prognosis for patients with late stage disease (where either 
metastases to regional lymph nodes or systemic metastases have occurred) is extremely 
poor with associated 2 year survival rates of 18-40% (Balch, Gershenwald et al. 2009). 
Typically, systemic therapeutic treatment has been the most widely utilized approach for 
treatment of metastatic melanoma (Kasper, D'Hondt et al. 2007) where single-agent-therapy 
with dacarbazine, temozolomide or fotomustine are the most common therapeutic 
approaches for disseminated melanoma (Atallah and Flaherty 2005). However, despite 
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combination with chemokines such as interferon-α (INF- α) and interleukin 2 (IL2) (Kasper, 
D'Hondt et al. 2007), monoclonal antibodies, cancer-specific vaccines or immune adjuvants, 
response rates to any treatment combination remain poor with a median survival rate of 7.5 
months. Poor response to current treatment regimes likely reflects the resistance of 
metastatic melanoma tumours to apoptosis, underpinning the serious need for novel and 
more effective systemic therapies. Recent breakthroughs have lead to the development of 
novel inhibitors specifically designed to exploit key signalling pathways known to be 
deregulated in melanoma. More specifically the RAS/RAF/MEK/ERK signalling pathway has 
been targeted by using a combination of BRAF and MEK inhibitors (Flaherty, Infante et al. 
2012). These therapies have been designed to target specific patients bearing BRAF
V600E
 
mutant tumours providing the greatest therapeutic breakthrough in melanoma for more 
than 20 years. However, despite promising results within the first few months of treatment 
ultimately tumour resistance emerges with the long term survival rate for patients hence, 
ultimately unchanged (Flaherty, Infante et al. 2012; Nazarian, Shi et al. 2010; Poulikakos, 
Persaud et al. 2011; Sullivan and Flaherty 2013; Wagle, Emery et al. 2011). Additionally, the 
specificity of BRAF inhibitors to BRAF
V600E
 mutant tumours limits their usage with still no 
effective therapies for BRAF wild-type or NRAS mutant tumours and highlighting the serious 
need for alternative and more effective systemic therapies.  
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1.3: Oncogenic BRAF signalling in melanoma 
 
Progress in understanding the underlying molecular basis for melanoma 
pathogenesis has led to the development of numerous molecular based strategies for 
metastatic melanoma (Klinac, Gray et al. 2013). Increased knowledge of the underlying 
molecular biology of melanoma has shown that its development is strongly associated with 
the subversion of the pathways involved in development and proliferation of normal 
melanocytes. The two main pathways regulated by receptor tyrosine kinases are the 
PI3K/Akt/mTOR pathway and the RAS/RAF/MEK/ERK pathway. The RAS/RAF/MEK/ERK 
signalling pathway is a major stimulator of melanocyte proliferation which is often required 
to react to changes in conditions of the extracellular environment (Fig. 1.7) (Hocker, Singh et 
al. 2008). Under normal conditions this process is highly regulated and controlled, however 
(as is the case in many cancer types) activating mutations occur in key members of this 
cascade resulting in the loss of proliferative control, including those frequently mutated in 
melanoma (Garnett and Marais 2004). Of particular note are the RAF family of 
serine/threonine protein kinases, of which there are three members; ARAF, BRAF and CRAF. 
Additionally, the RAS subfamily of GTPases consisting of HRAS, KRAS and NRAS, has been 
implicated in many human cancers (Bos 1989). Activating mutations in BRAF, as well as NRAS 
which lies upstream of this pathway, have been found in 50-70% and 20% of melanoma 
cases respectively, and both BRAF and NRAS are oncogenes implicated in melanoma 
development (Davies, Bignell et al. 2002; Dong, Phelps et al. 2003; Uong and Zon 2009). The 
presence of both NRAS and BRAF mutation in the same tumour is rare and it is thought that 
cellular transformation occurs through a common mechanism involving the 
RAS/RAF/MEK/ERK signalling pathway (Sensi, Nicolini et al. 2006). The most common 
mutation in BRAF is the mutagenesis of a valine to a glutamic acid at the 600
th
 residue 
(BRAF
V600E
) resulting in a 700-fold hyper-activation of BRAF kinase activity allowing for the 
enhanced survival and division properties of melanoma (Davies, Bignell et al. 2002). Other 
mutations in BRAF have also been identified in melanoma including BRAF
V600K
 and BRAF
V600D
 
present in 16.3% and 3.4% of melanoma cases bearing a BRAF mutation, respectively 
(Davies, Bignell et al. 2002; Rubinstein, Sznol et al. 2010). Although mutated BRAF has been 
shown to protect melanoma cells from apoptosis and is very likely required for development 
of melanoma, mutated BRAF is present in the majority of benign naevi and has been shown 
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to induce senescence after an ‘initial burst’ of proliferation when expressed in normal 
melanocytes (Pollock, Harper et al. 2003; Michaloglou, Vredeveld et al. 2005), suggesting 
BRAF is not the only factor required. The most convincing evidence for melanoma 
development being driven by mutant BRAF was described by Dhomen et al (Dhomen, Reis-
Filho et al. 2009) in which an inducible BRAF
V600E
 transgenic mouse model was used to model 
melanoma development. Melanocyte-specific expression of this oncogene resulted in 
several melanocytic lesions such as benign neavi and areas of skin hyperpigmentation, as 
well as melanoma (Dhomen, Reis-Filho et al. 2009). However, the authors suggested that 
melanoma development only occurs following the acquisition of additional mutations. This 
has been validated experimentally using a zebrafish model to show that while BRAF 
activation leads to development of benign naevi, further progression to melanoma required 
inactivation of p53 (Patton, Widlund et al. 2005). As such, other molecular factors have been 
implicated in melanoma development in animal models including the inhibition of p53 and 
regulation of Mitf expression by activating transcription factor 2 (ATF2) (Patton, Widlund et 
al. 2005; Shah, Bhoumik et al. 2010). Based on RAS signalling, it has been suggested that a 
multistep process occurs in the development of malignancies with three distinctive events; 
low level oncogene activation to stimulate proliferation, the spontaneous upregulation of 
activated RAS levels to induce senescence, followed by evasion of senescence by other 
molecular events resulting in tumour progression (Sarkisian, Keister et al. 2007). It is 
therefore very likely that a similar multistep process is involved in melanoma with activating 
mutations in BRAF or NRAS. In support of this hypothesis it was reported that progression 
from benign melanocytic hyperplasia to metastatic melanoma could only occur in the 
presence of both BRAF
V600E
 and silenced PTEN, whereas BRAF
V600E
 expression alone was 
insufficient to promote melanoma development (Dankort, Curley et al. 2009).  
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Figure 1.7: RAF/MEK/ERK signalling cascade (Image adapted from (Chin and D'Mello 2005)). Receptor 
tyrosine kinases (e.g. fibroblast growth factor, epidermal growth factor, and insulin receptors) are stimulated 
by an extracellular stimulus such as a ligand resulting in activation of the membrane bound Ras-GTPase through 
the action of the guanine nucleotide exchange factor SOS. RAS then activates RAF, MEK and ERK to change 
cellular gene expression. 
 
  The importance of BRAF signalling in melanoma progression in many tumours has 
lead to development of specific BRAF targeted therapies now used as adjuvant therapy in 
the treatment of patients bearing BRAF
V600E
 mutant tumours, however mechanisms of 
resistance to BRAF specific therapies have been proposed. Several studies have attributed 
this resistance to several possible mechanisms which ultimately reults in reactivation of the 
MAPK pathway. These mechanisms include; upregulation of NRAS through activating 
mutations (Q61K/R) (Nazarian, Shi et al. 2010); activation of MEK1 by the C121S mutation 
(Wagle, Emery et al. 2011); alternative splicing of the BRAF gene (Poulikakos, Persaud et al. 
2011) and increased BRAF
V600E
 gene amplification (Shi, Moriceau et al. 2012). Additionally, 
more recent findings have suggested that use of BRAF inhibitors may induce high rates of 
autophagy which may act as a key mechanism of resistance to these drugs (Ahn JH 2013) 
highlighting the importance of this pathway in therapeutic resistance.  
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1.4: Autophagy 
 
1.4.1: Autophagy in health and disease 
 
The process of autophagy (literally meaning to eat oneself) was first identified by 
Clark et al in the late 1950’s where the formation of autophagosomes was shown in kidney 
cells of newborn mice by electron microscopy (Clark 1957). It wasn’t until 1963 however, 
that de Duve, who published an article describing the discovery of the lysosome in 1955, 
coined the word autophagy (Klionsky 2007). Despite its discovery many years ago, the role of 
autophagy in health and disease has only recently emerged. The main role of autophagy is to 
maintain cellular energy levels and hence its role in advanced tumours is thought to be a 
mechansism of maintaining cellular energy and hence survival (Bertout, Patel et al. 2008; 
Zhang, Bosch-Marce et al. 2008). However additional evidence has implicated autophagy in a 
cell death process that is independent of apoptosis (Shimizu, Kanaseki et al. 2004; Yu, Alva et 
al. 2004). Inhibition of the pro-survival function of autophagy, or induction of autophagic cell 
death, is therefore an attractive target for the treatment of many diseases, particularly 
cancer (Gozuacik and Kimchi 2004; Voss, Senft et al. 2010).  
Ordinarily, autophagy plays a key physiological role in cells in which the bulk 
degradation of cytoplasmic macromolecules as well as damaged organelles, such as 
mitochondria, occurs via the lysosomal system. Three mechanisms have been described; 
macro-autophagy, micro-autophagy and chaperone-mediated autophagy, which differ in 
their physiological function, cargo specificity and how the autophagic vesicles (also known as 
autophagosomes) ultimately transfer their cargo to the lysosomes. Macro-autophagy, 
termed autophagy from here on, is a highly regulated process which has been shown to be 
induced during starvation, differentiation, and normal growth control to maintain energy 
homeostasis and cell survival (Kuma, Hatano et al. 2004; Shintani and Klionsky 2004; 
Komatsu, Waguri et al. 2005). Autophagy has since been classified by Mizushima as either 
‘induced’ autophagy (which is for production of amino acids under conditions of starvation) 
or ‘basal’ autophagy (which is for the constitutive turnover of components of the cytoplasm) 
(Mizushima 2005; Mizushima 2007). However if autophagy becomes highly accelerated it 
can promote cell death rather than cell survival, a process known as type II autophagic cell 
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death. Type II autophagic cell death is easily distinguishable from type I apoptotic cell death 
(Gozuacik and Kimchi 2004); unlike apoptosis, autophagic cell death does not result in DNA 
laddering or nuclear fragmentation, with only partial chromatin condensation and the 
nucleus remaining relatively intact until much later on in the process. An increase in 
autophagic vesicles and autolysosomes is observed, which does not occur during apoptosis, 
and caspases (which are an essential component of apoptosis) are not activated during 
autophagic cell death, further revealing that this takes place independently of apoptosis 
(Table 1.1). However, whether non-apoptotic cell death is induced by autophagy or simply 
occurs in the presence of autophagy is still a matter of debate (Kroemer and Levine 2008). 
To date the most convincing data in support of type II autophagic cell death has involved the 
prevention of this process by knockdown of key autophagy genes in vitro by use of small 
interfering RNA (siRNA) in which the characteristics of type II autophagic cell death are 
observed. Lenardo et al reported that in L929 fibrosarcoid cells and in U937 monocytoid 
cells, siRNA knockdown of two essential autophagy genes (Atgs) (Becn1, which encodes 
Beclin-1, or Atg7) resulted in blockade of non-apoptotic cell death which had previously 
been induced as an alternative mechanism of cell death upon caspase 8 inhibition (Yu, Alva 
et al. 2004). Similarly Tsujimoto et al reported in 2004 that Bax
-/-
Bak
-/-
 mouse embryotic 
fibroblasts undergo non-apoptotic cell death in response to staurosporine or etoposidea, 
where large-scale autophagic vacuolization was observed (Shimizu, Kanaseki et al. 2004). 
This process is then reduced by knockdown of either Becn1 or Atg5 indicating this non-
apoptotic cell death is regulated by autophagy (Shimizu, Kanaseki et al. 2004). In further 
support of cell death induced by autophagy, a more recent report by Salazar et al showed 
that cannabinoids (in particular tetrahydrocannabinol (THC)) induced cell death of glioma 
cells through the stimulation of autophagy by an early endoplasmic reticulum (ER) stress 
response (Salazar, Carracedo et al. 2009), as described in this report as autophagy-mediated 
cell death. However this process involved stimulation of apoptosis through autophagy rather 
than autophagic cell death specifically.   
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Table 1.1: A table detailing a comparison between the two types of programmed cell death. (Gozuacik and 
Kimchi 2004). 
 
 Type I apoptotic Type II autophagic 
Nucleus Chromatin Condensation Partial chromatin condensation 
 Pyknosis of nucleus Sometime pyknosis of nucleus 
 DNA laddering/nuclear 
fragmentation 
Nucleus intact until late stages 
  No DNA laddering 
   
Cytoplasm Cytoplasmic condensation Increased autophagic vesicle number 
 Ribosome loss from RER Increased autolysosome number 
 Fragmentation of 
apoptotic bodies 
Increased lysosomeal activity 
 MOMP Enlarged Golgi, sometimes ER dilation 
 Caspase activation MOMP may be involved 
  Caspase-independent 
   
Cell 
membrane 
Blebbing Blebbing 
   
Corps 
clearance 
Heterophagy by other cells Late and occasional heterophagy by other 
cells 
   
Detection 
methods 
Electron microscopy Electron microscopy 
 Caspase activation tests LC3 flux assays 
 TUNEL staining Test increased lysosomal activity (Acridine 
orange) 
 Annexin V staining Test increased long-lived protein 
degradation 
 DNA laddering detection  
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1.4.2: Regulation of autophagy 
   
  A total of 34 Atg genes have been identified so far in yeast and most of the 
mammalian orthologues for these have also been identified.  To date, 18 of these genes 
have been shown to be required for the regulation autophagy.  Autophagy is characterised 
by the induction, nucleation, extension and completion of an isolation membrane, or 
phagophore, to form an autophagosome which ultimately fuses with a lysosome for the 
degradation of its constituents (Roy and Debnath 2010). The exact origin of the membrane 
has yet to be completely defined, however recent publications suggest the initial stages of 
phagophore development occurs at a sub-domain of the endoplasmic reticulum with the 
formation of a ‘cradle’ like structure (Hayashi-Nishino, Fujita et al. 2009).   
The induction of autophagy in mammals occurs via the ULK complex which is 
composed of FIP200/mAtg13/unc-51-like kinase (ULK). This complex is regulated by the 
mammalian target of rampamycin (mTOR), a serine/threonine kinase belonging to the 
phosphatidylinositol 3-kinase-related kinase (PIKK) protein family. mTOR plays a crucial role 
in maintaining a balance between autophagy and cell growth in response to signals that 
stimulate autophagy, such as insulin, growth factors (e.g. IGF-1 and IGF-2) and mitogens (Hay 
and Sonenberg 2004). Two complexes of mTOR have been identified known as mTORC1 
(composed of mTOR, GßL, raptor, Deptor and PRAS40) and mTORC2 (composed of mTOR, 
GßL, rictor, Deptor, Sin1 and PRR5) (Wullschleger, Loewith et al. 2006). mTORC1 primarily 
mediates growth factor signalling in response to the Akt pathway (Hay and Sonenberg 2004) 
and is involved in the regulation of autophagy. The role of mTORC2 is less clear, although it 
has been shown to activate the Akt pathway (Sarbassov, Guertin et al. 2005) but a role for 
this protein in autophagy has not been identified. Under normal conditions mTORC1 
negatively regulates autophagy by phosphorylating ULK1/2 to prevent autophagy induction 
(Ganley, Lam et al. 2009) (Fig 1.8), however, upon nutrient deprivation it dissociates from 
the ULK complex. When this occurs ULK1/2 become dephosphorylated resulting in their 
activation, the phosphorylation of FIP200 and mAtg13 and the initiation of starvation-
induced autophagy (Jung, Jun et al. 2009). The ULK complex is then localised to the 
phagophore for the subsequent stages of autophagosome formation.  
After autophagy is induced, nucleation of the phagophore occurs, requiring 
phosphatidylinositol 3-phosphate (PI3P) generation by a class III PI3K complex. This complex 
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is composed of p150/Vps34/Beclin-1 (Simonsen and Tooze 2009), and recent studies have 
identified UVRAG, Atg14L and Ambra-1 (activating molecule in Beclin-1 regulated autophagy 
protein 1) (Liang, Feng et al. 2006; Fimia, Stoykova et al. 2007; Itakura, Kishi et al. 2008; 
Matsunaga, Saitoh et al. 2009; Zhong, Wang et al. 2009) as binding partners of Beclin-1 
which positively regulate its activity in addition to their role in regulating different steps of 
autophagosome formation and maturation. Elongation occurs after phagophore nucleation 
and requires two ubiquitin-like systems (Ohsumi 2001; Ohsumi and Mizushima 2004). The 
first system involves the conjugation of Atg5 to Atg12 via the E1-like activity of Atg7 and the 
E2-like activity of Atg10. Once this has taken place the Atg5/Atg12 complex binds to Atg16 to 
form Atg16L, a large multimeric complex which localises to the outer surface of the 
autophagosome membrane. The second ubiquitin-like system involves cleavage of Atg8 (a 
ubiquitin-like molecule for which the mammalian homologue is microtubule-associated 
protein light chain 3 (LC3)) by the protease Atg4. The subsequent exposure of a C-terminal 
glycine residue is required for conjugation with phosphatidylethanolamine (PE), producing 
lipidated LC3 (LC3-II) which is necessary for formation of the autophagosome and which can 
be measured in tissue or cells through detection of the lipidated form of LC3, LC3-II, by 
immunohistochemistry (IHC) or inmmunoflourescence (IF) (characterised by a punctate 
staining pattern when LC3-II is localised to the autophagosome), as well as by, 
immunoblotting (IB) (Kabeya, Mizushima et al. 2000; Roy and Debnath 2010). Completion 
and maturation of the autophagosome membrane is followed by fusion of this membrane 
structure with a lysosome to form an autophagolysosome, via the action of the lysosomal 
proteins LAMP1 and LAMP2 as well as Rab7 and UVRAG (Fig 1.8) (Liang, Lee et al. 2008). 
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1.5: Autophagy in Cancer and Melanoma 
 
Autophagy has been shown to have a paradoxical role in cancer progression, with 
data supporting both tumour promoting and tumour suppressive functions (Roy and 
Debnath 2010). Mathew et al revealed that, in autophagy-defective cells, an inability to 
eliminate p62 altered NF-κB regulation and promoted tumourigenesis, suggesting that 
autophagy suppresses cancer initiation by preventing accumulation of p62 (Mathew, Karp et 
al. 2009). As p62 is often up-regulated in human tumours (Zatloukal, French et al. 2007) this 
points towards a role for defective autophagy in cancer development. Genetic evidence also 
suggests that the tumour suppressive functions of autophagy act in the early stages of 
tumour development (Qu, Yu et al. 2003; Yue, Jin et al. 2003). For example, spontaneous 
tumour development occurs in Beclin-1 
+
/
- 
mutant (Qu, Yu et al. 2003; Yue, Jin et al. 2003). 
Conversely, there is evidence that autophagy is used as a survival strategy in established and 
more advanced tumours, allowing these tumours to maintain an energy supply and survive 
the harsh microenvironments and stress conditions it encounters in advanced stages 
(Bertout, Patel et al. 2008, Zhang; Bosch-Marce et al. 2008). As such, the general opinion is 
that autophagy suppresses growth early during tumour development but promotes tumour 
survival at more advanced stages (Figure 1.9, Corazzai, Fimia et al). Prevention of the 
autophagy process for advanced stage cancer therefore represents a viable therapeutic 
strategy and has included the use of lysosomal inhibitors such hydroxychloroquinone (HCQ), 
a lysosomotropic drug that raises intralysosomal pH (Poole and Ohkuma 1981) as well as 
impairing autophagic protein degradation (Amaravadi, Yu et al. 2007; Glaumann and Ahlberg 
1987). Combined HCQ treatment with several anticancer drugs in preclinical models, is now 
incorporated into a number of phase I and II clinical trials in tumours associated with high 
basal levels of autophagy (Garber 2011). However HCQ is nevertheless a non-specific 
inhibitor of autophagy with both undesirable side-effects as well as off target effects 
Additionally although responses to HCQ may be effective in vitro, this is not always 
refelected in vivo (Swampillai, Salomoni et al. 2012) leading to the need for development of 
more specific autophagy inhibitors. Many autophagy-inducing agents are also currently 
being used for the treatment of different human cancers, for example Rapamycin which 
targets and inhibits mTOR as well as 2
nd
 generation mTOR inhibitors (RAD001, CC1-779, and 
AP23573) (Faivre, Kroemer et al. 2006).  These chemotherapeutics have shown to result in 
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significant anti-tumour properties in several cancer models (Faivre, Kroemer et al. 2006), 
though clinical trails of mTOR inhibitors have been generally disappointing, perhaps due to 
the activation of autophagy and its effect on the maintainance of cell survival. However, 
cannabinoids, and in particular THC, are able to promote potent cell death mediated by 
autophagy as a result of ER stress in human glioma cells (Salazar, Carracedo et al. 2009), and 
hence show promise as an alternative approach to exacerbating autophagy to promote 
tumour cell death.  
  Evidence for autophagy in melanoma includes the presence of autophagosomes 
containing melanized melanosomes with ‘coarse melanin’ in some tumours (Handerson and 
Pawelek 2003; Lazova, Klump et al. 2009) as well as evidence for altered Beclin-1 and LC3 
expression in primary melanocytic neoplasms (Miracco, Cevenini et al. 2010). P62 expression 
has also been found to be significantly increased in melanoma compared to naevi (Ellis, et al. 
submitted data to J Invest Dermatol). Furthermore, Atg5 (a key autophagy regulator gene) is 
often down-regulated in primary melanomas compared to benign nevi, leading to a 
reduction of basal autophagy as evidenced by a reduced expression of LC3-I/II (Liu, He et al. 
2013). Liu et al also demonstarted in a study of 158 primary melanomas low tumoural Atg5 
expression correlated with reduced progression-free survival (Liu, He et al. 2013). 
Additionally, using melanocytes with transduced mutated BRAF, the authors found reducing 
the expression of Atg5 in these cells promoted proliferation by preventing oncogene-
induced senescence suggesting down-regulated Ag5 contributes to tumourigenesis of 
cutaneous melanoma (Liu, He et al. 2013). In metastatic melanoma however, autophagy has 
been shown to be increased, likely providing these cells with an essential energy source 
under the nutrient deprived environments encountered (Lazova, Klump et al. 2009). Data 
has also revealed that hyperactivation of BRAF results in induction of autophagy in 
melanoma through down-regulation of mTOR signalling due to increased phosphorylation of 
mTOR at serine 2481 (Maddodi, Huang et al. 2010), suggesting activated BRAF promotes 
autophagy. However, Armstrong et al reported that although autophagy can be  induced 
beyond basal levels in BRAF wild-type melanoma cells in response to treatment with 
chemotherapeutic drugs, such agents could not induce autophagy beyond basal levels in 
melanoma cells bearing mutant BRAF (Armstrong, Corazzari et al. 2011), suggesting 
oncogenic BRAF prevents autophagy induction. Furthermore, use of the BH3 mimetic 
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ABT737 was able to partially reactivate autophagy in BRAF mutant melanoma cells 
(Armstrong, Corazzari et al. 2011). As ABT737 has previously been shown to activate 
autophagy through disrupting the interaction between Beclin-1 and anti-apoptotic Bcl-2 
protein family members (Maiuri, Criollo et al. 2007), these data suggest that resistance to 
autophagy induction in BRAF mutated melanoma cells is mediated, at least in part, by 
inhibition of Beclin-1 function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: The autophagy paradox (Corazzari, Fimia et al. 2013) Loss of autophagy in early disease can result 
in the build up of toxic cellular components/DNA damage/genomic stress leading to development and 
progression of tumours. Reacquisition of autophagy in later stages of disease can aid in tumour survival by 
recycling of cellular components and removal of stress elements at sites of metastasis and hypoxia.  
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1.6 The Beclin-1 complex 
 
  Belcin-1 was first identified as a BH3 only Bcl-2 family member acting as a coiled-
coil protein that is involved in autophagy regulation (Liang, Kleeman et al. 1998). In canonical 
autophagy Beclin-1 binds to hVps34/PI(3)K and p150 which it achieves through its 
evolutionarily conserved domain (Liang, Kleeman et al. 1998; Liang, Jackson et al. 1999). The 
hVps34/PI(3)K generates PI(3)P which is required for the regulation of autophagy as 
confirmed by studies of the PI(3)K inhibitor wortmannin which subsequently inhibited 
autophagy (Blommaart, Krause et al. 1997). Additional proteins have since been discovered 
to associate with Beclin-1 which aid in the autophagy process including UVRAG, Ambra 1, 
Bif-1 and Vps15 which have a positive role in autophagy regulation although each may not 
be in fact be complexed to the same Beclin-1 complex (Fimia, Stoykova et al. 2007: Itakura, 
Kishi et al. 2008; Liang, Feng et al. 2006; Matsunaga, Saitoh et al. 2009; Zhong, Wang et al. 
2009). Further interactors of Beclin-1 have also been identified resulting in the formation of 
additional complexes with differing functional roles in autophagy is a specific substrate of 
the Beclin-1/Ambra 1 complex which functions in the targeting of this complex to the site of 
autophagosome formation (Matsunaga, Saitoh et al. 2009). Atg14 C terminus contains an 
Barkor/Atg14(L) autophagosome-targeting sequence (BATS) domain which preferentially 
binds to curved membranes containing PI(3)P and targets the Beclin-1 complex to the 
isolation membrane (Obara and Ohsumi 2011). Additional Beclin-1 complexes identified 
contain the interacting protein rubicon (Matsunaga, Saitoh et al. 2009). Rubicon binds to a 
subpopulation of UVRAG complexes separate to Atg14L forming a different Beclin-1 complex 
to that previously described (Sun Q 2010). Knockdown of Rubicon results in the 
enhancement of autophagy, especially at the maturation step, as well as enhancement of 
endocytic trafficking revealing the complex Beclin-1 forms with this protein has a negative 
role in autophagy regulation. These data also suggest that the Beclin-1-hVps34 complex 
functions in two different steps of autophagy by altering the subunit composition 
(Matsunaga, Saitoh et al. 2009, Zhong, Wang et al. 2009). As such at least three different 
functional Beclin-1 complexes have been identified; the Beclin-1/Vps34/Vps15/Ambra 
1/Atg14L complex; the Beclin-1/Vps34/Vps15/UVRAG complex; and the Beclin-
1/Vps34/Vps15/UVRAG/Rubicon complex (Figure 1.10).  
24 
 
  Articles have emerged over recent years which highlight additional functions of 
Beclin-1. A large scale study of protein-protein interactions for many of the key autophagy 
genes has increased of yet more interactions, providing a platform for future studies 
(Behrends, Sowa et al. 2010). Since its initial discovery, the importance of Beclin-1 in 
pathways additional to autophagy have also emerged, including its role in cell cycle 
regulation where Beclin-1 is required for chromosome congression and proper outer 
kinetochore assembly (Frémont S 2013). Additionally, recent observations show under 
certain conditions Beclin-1 may be cleaved by caspases thus preventing its pro-autophagic 
activity (Wirawan, Vande Walle et al. 2010). Interestingly further studies also revealed the C-
terminal fragment produced as a result of this cleavage event has a function of its own in 
which it amplifies mitochondrial mediated apoptosis suggesting cross talk between 
apoptosis and autophagy (Djavaheri-Mergny, Maiuri et al. 2010). 
  Recent data has already shown the ability of Beclin-1 to form multiple complexes 
with differing functions in autophagy, including its complex with Ambra 1. Ambra 1 is a 
WD40-containing protein which functions in autophagy as a protein-protein interacting 
platform (Fimia, Corazzari et al. 2012) with the Beclin-1/Vps34 complex. When complexed to 
these proteins Ambra 1 is involved in the nucleation phase of autophagy causing the 
formation of phospatidyl inositol 3 kinase rich membranes thus acting as a positive regulator 
of autophagy (Roy and Debnath, 2010; Fimia et al., 2011). Interestingly, members of the 
Beclin-1/Ambra 1/Vps34 complex associate with each other independently of autophagy 
induction which suggests and additional regulatory element is needed to stimulate Beclin-1 
activity to function in the induction of autophagy (Fimia, Di Bartolomeo et al. 2011). A 
further interaction of Ambra 1 has been identified with dynein light chains 1 and 2 
associated with the dynein motor complex where Ambra 1 is bound under conditions of  
basal autophagy (Di Bartolomeo, Corazzari et al. 2010). Under conditions of starvation 
however, the activity of ULK1 becomes dissociated with mTORC1 resulting in the release 
Ambra 1 from dynein by phosphorylation. Ambra 1 then localizes to the endoplasmic 
reticulum to prime autophagosome formation and nucleation thus revealing a role for 
Ambra 1 in autophagy induction in addition to nucleation. (Di Bartolomeo, Corazzari et al. 
2010; Fimia, Di Bartolomeo et al. 2011).  
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More recently, autophagy independent interactions with Ambra 1 have been found 
which are linked to apoptosis. In this context, mitochondrial Bcl-2 has been shown to directly 
interact with Ambra 1 independently of Beclin-1; an event which is disrupted by the 
induction of either autophagy or apoptosis (Strappazzon, Vietri-Rudan et al. 2011). Ambra 1 
and Bcl-2 actually bind to Beclin-1 at the same location suggesting that Ambra 1 competes 
with Bcl-2 to bind to Beclin-1.   
 
 
 
 
Figure 1.10: Beclin-1 and its complexs. A) Beclin-1/Vps34/Vps15/Ambra 1/Atg14L complex; B) Beclin-
1/Vps34/Vps15/UVRAG complex C) Beclin-1/Vps34/Vps15/UVRAG/Rubicon complex 
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1.7 Apoptosis, Endoplasmic Reticulum Stress and induction by the 
proteosomal inhibitor, Bortezomib 
   
  The word apoptosis, first coined by Kerr, Wyllie and Currie in 1972, was used to 
describe a distinct form of cell death observed by key morphological changes observed in 
these studies (Kerr, Wyllie et al. 1972). Since then apoptosis has become recognised and 
accepted as an important mode of cell death involving a highly regulated and genetically 
determined process for the elimination of cells. Important for homeostasis, apoptosis is 
crucial for normal development and ageing however, it may also act as a defence mechanism 
in immune reactions or for the elimination of cells damaged by disease (Norbury and 
Hickson 2001). However, different cells may die in response to different apoptotic stimuli. 
Typically, light and electron microscopy are employed to observe the classical morphological 
features of apoptosis which include cell shrinkage and pyknosis (or chromatin condensation) 
(Table 1.1) as well as plasma blebbing, karyohexis, apoptotic bodies and budding. 
Interestingly, inflammatory responses during this process are absent, which has been 
attributed to three potential possibilities; 1) as apoptotic cells don’t release their cellular 
constituents into surrounding tissue they do not induce an inflammatory response; 2) 
apoptotic cells are quickly phagocytosed; 3) engulfing cells don’t produce any anti-
inflammatory cytokines during this process (Savill and Fadok 2000). In terms of biochemical 
events, several events are also classically observed during the process of apoptosis including 
protein cleavage, protein cross linking and DNA breakdown to name a few (Hengartner 
2000). 
  In terms of its regulation, apoptosis is prinicipally mediated through two pathways 
involving either extrinsic and intrinsic mechanisms, however, evidence suggests that these 
pathways are linked and molecules in one pathway may influence the other (Igney and 
Krammer 2002). Furthermore, both mechanisms are mediated by caspases, a family of 
aspartic proteases  (Cohen 1997; Rai, Tripathi et al. 2005) widely expressed as inactive 
proenzymes in most cells which when activated initiate a cascade of caspase activation 
events, amplifying the apoptotic process and leading to rapid cell death. Caspases have been 
classified into different groups termed initiators (caspases 2, 8, 9 and 10), 
effectors/executioners (caspases 3, 6 and 7) and inflammatory caspases (caspases 1, 4, and 
5) (Cohen 1997; Rai, Tripathi et al. 2005). Other caspases have been identified such as; 
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caspase 11 which regulates apoptosis by acting during septic shock and cytokine maturation; 
caspase 12 which mediates endoplasmic reticulum specific apoptosis; caspase 13, which was 
identified as a gene in bovine DNA and caspase 14, found to be highly expressed in 
embryonic but not in adult tissues (Hu, Snipas et al. 1998; Kang, Wang et al. 2002; Koenig, 
Eckhart et al. 2001; Nakagawa, Zhu et al. 2000) 
  Apoptosis mediated by extrinsic signalling involves transmembrane receptor-
mediated interactions with death receptors, which are members of the tumor necrosis 
factor (TNF) receptor family (Locksley, Killeen et al. 2001). This family of receptor proteins all 
have cysteine-rich extracellular domains as well as a cytoplasmic domain known as a death 
domain, typically about 80 amino acids in length (Ashkenazi and Dixit 1998). This death 
domain is required for the transmission of pro-death intracellular signalling events 
stimulated by specific extracelluar ligands including; FasL/FasR, TNF-α/TNFR1, Apo3L/DR3, 
Apo2L/ DR4 and Apo2L/DR5 (Ashkenazi and Dixit 1998 (Ashkenazi and Dixit 1998; 
Chicheportiche, Bourdo et al. 1997; Peter and Krammer 1998; Rubio-Moscardo, Blesa et al. 
2005; Suliman, Lam et al. 2001) of which FasL/FasR and TNF-α/TNFR1 have been the most 
extensively studied. During extrinsic apoptosis death receptors cluster causing binding of 
trimeric ligands. Cytoplasmic adapter proteins are then recruited which activate 
corresponding death domains. An example of this includes the binding of Fas ligand to the 
Fas receptor causing recruitment of FADD (the Fas adaptor protein) or the binding of TNF 
ligand to the TNF receptor resulting in binding of the adapter protein TRADD and the 
recruitment of FADD and RIP (Hsu, Xiong et al. 1995). FADD then associates with procaspase 
8 due to dimerization of the death domain forming what is known as a death-inducing 
signaling complex (DISC) which causes the activation of procaspase 8 (Kischkel, Hellbardt et 
al. 1995) and downstream activation of the extrinsic apoptotic pathway. Extrinsic apoptosis 
may also be activated by the perforin/granzyme pathway, regulated by CD8+ T-cell 
lymphocyte induced apoptosis. Typically these cells exert there effect through the FasL/FasR 
ligand receptors (Bratton, Fadok et al. 1997) however, they have also been found to induce 
apoptosis by secretion of perforin (transmembrane pore-forming molecule), typically used 
by lymphocytes for virally infected cells. Once the pore is formed cytoplasmic granules are 
released into the target cell through the pore (Trapani and Smyth 2002). Granzyme A and 
granzyme B represent the principle components of such, both possessing serine enzyme 
protease activity (Pardo, Bosque et al. 2004). Granzyme B activates procaspase 10 and can 
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additionally cleave ICAD (Inhibitor of Caspase Activated DNAse) (Sakahira, Enari et al. 1998) 
or Bid and thus inducing cytochrome C release (Barry and Bleackley 2002; Russell, 2002) and 
can also directly activate caspase 3 thus inducing apoptosis without the requirement for 
mitochondrial disruption (Goping, Barry et al. 2003). Granzyme A however, activates 
apoptosis through caspase independent mechanisms, alternatively activating DNAse NM23-
H1, a tumor suppressor gene product (Fan, Beresford et al. 2003), which has an important 
role in preventing cancer development by apoptosis induced by immune surveillance. 
Granzyme A exhibits its effects on expression of this DNAse by inactivation of the SET 
complex (composed of; SET, Ape1, pp32, and HMG2) which ordinarily inhibits expression of 
the NM23-H1 gene, cleavage of which results in expression of this DNAse, and subsequent 
DNA degradation. The SET complex also functions in chromatin structure and DNA repair 
(Fan, Beresford et al. 2003). As such granzyme A activity exerts its pro-apoptotic effects by 
inactivation of this complex and thus blocking DNA and chromatin maintenance.  
  In contrast to extrinsic apoptosis, the intrinsic pathway is mediated by intracellular 
signals that act directly on targets within the cell and are typically mitochondrial and/or 
endoplasmic reticulum initiated events. Stimulators of intrinsic apoptosis include the 
absence of growth factors, hormones and cytokines which typically would supress cell death 
and apoptosis. As such these stimuli are known as negative regulators. Examples of positive 
regulators/stimuli include radiation, toxins, hypoxia, viral infections and free radicals. 
Ultimately however all stimuli cause mitochondrial outer membrane permeabilisation 
(MOMP), loss of mitochondrial transmembrane potential and opening of the mitochondrial 
permeability transition pore. This in turn causes the release of several pro-apoptotic 
mitochondrial constituents including; cytochrome C, Smac/DIABLO and serine proteases and 
Omi (Cai, Yang et al. 1998; Du, Fang et al. 2000; Garrido, Galluzzi et al. 2006). Once released, 
these proteins then activate the caspase dependant mitochondrial pathway of cell death. 
Cytochrome C functions by binding to Apaf-1 and procaspase 9 forming what is known as the 
apoptosome. Procaspase 9 is then activated stimulating downstream apoptotic events. 
Smac/DIABLO acts through inhibition of inhibitor of apoptosis (IAP) proteins (van Loo, van 
Gurp et al. 2002; Schimmer 2004) also stimulating pro-apoptotic downstream events. A 
second group of pro-apoptotic proteins are released from mitochondria during apoptosis 
that function independently of caspases which include; AIF, endonuclease G and CAD, but 
this is a late event that occurs when the cell is already committed to cell death. When AIF is 
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released it translocates to the nucleus causing DNA fragmentation and DNA laddering as well 
as condensation of peripheral nuclear chromatin (Joza, Susin et al. 2001) which are both 
classic signs of apoptosis. Endonuclease G, like AIF, translocates to the nucleus cleaving 
nuclear chromatin producing oligonucleosomal DNA fragments (Li, Luo et al. 2001). Finally 
CAD is released from the mitochondria which then also translocates to the nucleus leading 
to additional oligonucleosomal DNA fragmentation and the final stages of chromatin 
condensation (Enari M, Sakahira H et al. 1998). The control and regulation of these events 
has mostly been attributed to Bcl-2 protein family members themselves, regulated by the 
tumour suppressor protein p53, frequently absent or mutated in many tumours. However 
mitochondrial damage has also been suggested to occur via the Fas death receptor pathway 
and cleavage of Bid by caspase 8 (Esposti 2002; Li, Ambrosini et al. 1998) suggesting cross 
talk between death receptor and intrinsic apoptosis. 
  Ultimately both intrinsic and extrinsinc culminate in the final execution phase 
apoptosis in which execution caspases are activated which in turn activate cytoplasmic 
endonucleases which degrade nuclear material as well as proteases that degrade the nuclear 
envelope and cytoskeletal proteins. The execution caspases cleave various substrates 
including cytokeratins, PARP, the plasma membrane cytoskeletal protein alpha fodrin, the 
nuclear protein NuMA and others which ultimately causes the morphological and 
biochemical changes observed in cells undergoing apoptosis (Slee, Adrain et al. 2001). Of all 
the execution caspase, caspase 3, is considered the most important which can be activated 
by any of the initiator caspases. Caspase 3 functions in apoptosis by specific activation of the 
Ca
2+
 and Mg
2+
 dependant endonuclease CAD which is usually complexed with its inhibitor 
ICAD (Bortner, Oldenburg et al. 1995). It does this by cleaving ICAD and thus releasing CAD 
from its inhibitor (Sakahira, Enari et al. 1998). Caspase 3 also induces cytoskeletal 
reorganization and disintegration of the cell into apoptotic bodies. One of the key substrates 
identified for caspase 3 is gelsolin which is an actin binding protein which acts as a site for 
actin polymerization. Caspase 3 cleaves gelsolin and these cleaved fragments then cleave the 
actin filaments causing disruption of the cytoskeleton, signal transduction, intracellular 
transport and cell division events (Kothakota, Azuma et al. 1997). Finally, apoptotic cells are 
then consumed by surrounding cells such as macrophages by phagocytosis. It is the 
expression of cell surface markers which aids early phagocytosis which is achieved by 
movement of typically inward facing phosphatidylinositolserine of the cells lipid bilayer to 
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the outer membrane of the bilayer (Bratton, Fadok et al. 1997). Here it acts as ligand for 
phagocytes on surface of apoptotic cells. As annexin 5 interacts specifically with 
phosphatidylinositolserine it is often used an apoptotic marker utilised for analysing 
apoptosis events experimentally (Arur, Uche et al. 2003; van Engeland, Nieland et al. 1998). 
As apoptosis is such a highly regulated process of cell death with no observed inflammatory 
responses this process has been extensively researched in order to understand its role in 
health and disease, be it for apoptosis induction in diseases such as cancer or its prevention 
in neurological diseases such as Parkinson’s disease.  
Apoptosis is frequently dysregulated in cancer including melanoma. Several 
mechanisms of resistance have been proposed effecting both the induction of intrinsic and 
extrinsic apoptosis (Thompson, Scolyer et al. 2005). Intrinsic apoptosis resistance has been 
attributed to over-expression of anti-apoptotic Bcl-2 proteins including Bcl-2, Bcl-lxl and Mcl-
1. Additionally extrinsic apoptosis may result from over-expression of c-FLIP protein 
preventing caspase 8 activation and downstream apoptotic signalling stimulated by this 
initiator caspase (Xiao, Yang et al. 2005). More recently, evidence has highlighted the 
importance of the endoplasmic reticulum which may act as a potential “gatekeeper” to 
control the progression of melanoma (Denoyelle, Abou-Rjaily et al. 2006), Moreover, agents 
able to apoptosis through targeted ER stress have been shown to enhance drug induced cell 
death of melanoma both in vitro and in vivo (Lovat, Corazzari et al. 2008), including the 26S 
proteosome inhibitor, bortezomib, also know as velacde (Hill, Martin et al. 2009). 
Additionally, little to no adverse effects were observed on normal melanocytes (Fernandez, 
Verhaegen et al. 2005; Lovat, Corazzari et al. 2008). 
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Figure 1.11 Known pathways of apoptosis (Elmore 2007). Two main pathways of apoptosis have been 
determined known as the extrinsic pathway and the intrinsic pathway. An additional pathway known as the 
Perforin/Granzyme pathway has also been identified which acts through the intrinsic pathway of apoptosis. 
The extrinsic pathway is activated through extracellular death ligand interaction with death receptors causing 
disc formation and activation of capase 8. The intrinsic pathway involves intracellular mitochondrial changes, 
apoptosome formation and activation of caspase 9. The Perforin/Granzyme pathway involves the release of 
granzymes via cytotoxic T cells into target cells causing caspase 10 activation of SET complex formation and 
DNA cleavage to amplify apoptosis. Each pathway converges at the execution phase where caspase 3 is 
activated and cells are then committed to apoptotic events such as degradation of DNA, nuclear and 
cytoskeletal protein degradation and formation of apoptotic bodies.  
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Able to act as a competitive inhibitor of the 26S proteasome preventing degradation 
of many intracellular proteins, bortezomib may induce the build up of damaged proteins, 
organelles and alterations in cellular gene expression leading to the ER stress events (Attar, 
De Angelo et al. 2008; Horton, 2007; Ogawa, Tobinai et al. 2008; Papandreou, Daliani et al. 
2004; Richardson, Mitsiades et al. 2008; Yin, Zhou et al. 2005) . Bortezomib has been shown 
to induce ER stress events in a variety of cancers including glioblastoma, pancreatic cancer, 
head and neck squamous cell carcinoma (Brignole, Marimpietri et al. 2006; Fribley, Evenchik 
et al. 2006; Fribley, Zeng et al. 2004; Fribley, Zeng et al. 2004; Nawrocki, Carew et al. 2005; 
Yin, Zhou et al. 2005) and has been extensively used in the treatment of multiple myeloma 
(Jackson, Einsele et al. 2005) as well as in the treatment of metastatic melanoma in 
combination with other chemotherapeutics such as the DNA damaging agent temozolomide. 
Promising results using human melanoma mouse xenograft models revealed animals 
receiving combined bortezomib and temozolomide treatment achieved complete remission 
of palpable tumors after only 30 days of therapy revealing that the chemotherapeutic effects 
of bortezomib could be augmented using temozolomide which has subsequently led to 
phase I and phase II trials utilizing this approach (Amiri, Horton et al. 2004; Su, Amiri et al. 
2010) Additionally, more recent studies suggest the BH3 mimetic ABT-737, specifically 
targeting the anti-apoptotic Bcl-2 family proteins Bcl-2, Bcl-xl, and Bcl-w potentiates 
bortezomib-induced apoptosis of melanoma (Reuland, Goldstein et al. 2012). Interestingly 
cancer cells treated with bortezomib have also been found to induce a pro-survival 
autophagic response in order to overcome the adverse effects of proteasome inhibition 
highlighting how cancer may use autophagy to counter act apoptotic signalling (Armstrong, 
Corazzari et al. 2011). As such the implications of autophagic signalling in cancer as well as 
its potential link with apoptosis high light its potential as a therapeutic modality. 
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Figure 1.12: Bortezomib chemical structure. The 26S proteasome inhibitor Bortezomib/Velcade. 
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1.8: The Bcl-2 Family, Myeloid Cell Leukemia-1 Member (Mcl-1), and 
their Role in Autophagy 
 
The Bcl-2 oncogene was identified from an acute B-cell leukemia cell line as a gene 
locus on chromosome 18 (band q21) (Tsujimoto, Finger et al. 1984) having the ability to 
increase cellular proliferation as well as inhibiting apoptosis (McDonnell, Deane et al. 1989; 
Vaux 1988). The Bcl-2 family of proteins is composed of both pro-apoptotic members 
(namely Bax, Bak, PUMA, NOXA, BAD, BID and BIM) and anti-apoptotic members (namely 
Bcl-2, Bcl-xl, Mcl-1, Bcl-w and A1) which are usually well regulated and kept in a delicate 
balance in normal tissue homeostasis (Hocker, Singh et al. 2008). This protein family is 
divided into three groups; two pro-apoptotic groups and one anti-apoptotic group, which is 
based on their conserved regions, known as Bcl-2 homology domains (BH domains). The first 
pro-apoptotic group contains multi-domain members including Bax and Bak which have BH1, 
BH2 and BH3 domains, allowing for permeabilization of the mitochondrial membrane, but 
lack the BH4 domain. The second pro-apoptotic group contains proteins with the BH3 
domain only, which are upstream signal detectors that activate Bax and Bak upon activation 
by pro-apoptotic stimuli. The anti-apoptotic group contains proteins which have conserved 
BH1, BH2, BH3 and BH4 domains, which form a hydrophobic pocket (Muchmore, Sattler et 
al. 1996) able to bind to the BH3 domains of pro-apoptotic members (typically the BH3 only 
proteins) (Cheng, Wei et al. 2001).  
Bcl-2 family members have been implicated as one of the most crucial regulators of 
apoptosis in melanoma. Often cancers use the RAS/RAF/MEK/ERK pathway to increase 
expression of anti-apoptotic Bcl-2 family members (most notably Mcl-1, Bcl-2 and Bcl-xl) 
(Boucher, Morisset et al. 2000). As mutant BRAF
V600E
 is common in melanoma, tumours 
bearing this mutation usually exhibit high levels of ERK1/2 activity which in turn would result 
in upregulation of these ant-apoptotic members (Balmanno and Cook 2009).  Mutant 
BRAF
V600E
 signalling has also been shown to inhibit BIM (a key pro-apoptotic member) 
expression in human melanoma cells via sustained over-activation of the RAS/RAF/MEK/ERK 
signalling pathway resulting in phosphorylation of BIM, targeting this protein for degradation 
by the proteasome, which further enhances the resistance of melanoma cells to apoptosis 
(Cartlidge, Thomas et al. 2008).  
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Of particular interest is the anti-apoptotic member Mcl-1, which has been shown to 
be a critical Bcl-2 family member required for melanoma survival and is highly expressed in 
both primary and advanced disease (Tang, Tron et al. 1998). Additionally Mcl-1 expression 
has been shown to increase with increasing melanoma disease stage (Zhuang, Lee et al. 
2007). Activation of ERK1/2 stabilises Mcl-1 by phosphorylation of this protein (Domina, 
Vrana et al. 2004) and Mcl-1 over-expression in pancreatic cancer is correlated with hyper-
activation of the ERK1/2 pathway (Boucher, Morisset et al. 2000), an occurrence typically 
seen in melanoma bearing BRAF
V600E
. Resistance to a wide range of traditional and targeted 
chemotherapeutic agents has been shown to be mediated by Mcl-1 over-expression, 
possibly due to its uniquely high specificity for suppressing apoptosis induced by BAK (Zhai, 
Jin et al. 2008). Furthermore Mcl-1 has been implicated in the resistance of melanoma to 
anoikis (a form of apoptosis induced by loss of cellular adhesion or adhesion to an 
inappropriate cellular matrix), particularly in metastatic disease allowing for tumour survival 
at distant sites from the primary tumour (Boisvert-Adamo and Aplin 2008). 
More recently it has been revealed that, in addition to the role of Bcl-2 family 
members in apoptosis regulation, this protein family plays a functional role in autophagy. It 
has been known for several years that Beclin-1 is a BH3-only protein and thus is a binding 
target of Bcl-2 (Feng, Huang et al. 2007), and Erlich et al showed that Beclin-1 binds  to Bcl-2 
and Bcl-xl with a high affinity, and with a weaker interaction to Mcl-1 (Erlich, Mizrachy et al. 
2007). Therefore Bcl-2 anti-apoptotic proteins are able to inhibit Beclin-1-dependant 
autophagy, presenting a dual role for anti-apoptotic Bcl-2 members (Fig 1.9). A recent report 
by Voss et al (Voss, Senft et al. 2010) demonstrated the pan-Bcl-2 inhibitor ((-)-gossypol), is 
able to induce caspase-independent cell death in apoptosis resistant malignant glioma cells. 
As inhibition of Bcl-2 or Bcl-xL alone did not have any effect, Mcl-1 inhibition was therefore 
identified as a crucial factor mediating caspase-independent cell death in this context (Voss, 
Senft et al. 2010).  
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Figure 1.13: Schematic model of the interrelationship between Beclin-1, Bcl-2, autophagy and cancer 
initiation (Pattingre and Levine 2006). In the absence of Bcl-2 binding to the tumour suppressor Beclin-1, 
stimulation of autophagy occurs as normal, potentially resulting in the inhibition of oncogenesis. When Bcl-2 is 
bound to Beclin-1, autophagy is inhibited and thus oncogenesis may be stimulated under these conditions.  
 
The gene encoding Mcl-1 contains 3 exons encoding two splicing variants with 
opposing roles. The first variant encoded is a polypeptide of 350 amino acids in length and 
40 kDa in molecular weight, known as the long form of Mcl-1 (Mcl-1L) (Fig 1.10) which has 
35% homology with the C-terminus of Bcl-2 (Kozopas, Yang et al. 1993). The Mcl-1L protein 
possesses Bcl-2 homology domains 1-3 and transmembrane domains that are found in other 
Bcl-2 family members, as well as a unique PEST sequence (a peptide sequence rich in proline, 
glutamic acid, serine, and threonine) within its N terminus (Yang, Kozopas et al. 1995). The 
second variant is encoded when the Mcl-1 pre-mRNA undergoes alternative splicing by 
eliminating exon two resulting in the translation of a polypeptide of 271 amino acids in 
length with a molecular weight of 35 kDa, known as the short form of Mcl-1 (Mcl-1S) (Fig 
1.10) (Bingle, Craig et al. 2000). This protein has a 41 residue difference to Mcl-1L at the C-
terminus and has only a BH3 domain, much like that of the BH3-only, pro-apoptotic 
members of the Bcl-2 family. Mcl-1S is therefore able to antagonise the pro-survival role of 
Mcl-1L, promoting cells to enter apoptosis (Bae, Leo et al. 2000; Bingle, Craig et al. 2000). In 
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Basal cell carcinoma (BCC) cells it has been shown that Mcl-1L expression predominates over 
Mcl-1S, resulting in an increased ratio of Mcl-1L to Mcl-S when compared with primary 
human keratinocytes (Shieh, Liu et al. 2009). Specific targeting of Mcl-1 pre-mRNA by Mcl-1 
antisense morpholino oligonucleotides (AMOs) altered the splicing pattern and favoured 
expression of Mcl-1S mRNA (Shieh, Liu et al. 2009). This shift directly induced apoptosis in 
BCC cells as well as in a human adenocarcinoma gastric cell line. Over-expression of Mcl-1S 
has also been shown to induce apoptosis in Chinese hamster ovary (CHO) cells and 
adenocarcinoma human alveolar basal epithelial A549 cells (Bae, Leo et al. 2000; Bingle, 
Craig et al. 2000). Thus it would appear that there is a delicate balance between Mcl-1L and 
Mcl-1S which may determine the fate of many cell types. Interestingly more novel roles for 
Mcl-1 have also been observed in which a nuclear-localised proteolytic fragment of Mcl-1 
has been identified which is able to regulate cell growth by its interaction with cdk 1 (Jamil, 
Sobouti et al. 2005) in which the interaction of nuclear Mcl-1 inhibits the Cdk1 from binding 
to cyclin B1 thus preventing progression through G2 and M phases of the cell cycle (Jamil, 
Sobouti et al. 2005). These authors further suggest that inhibition of Cdk1 activity accounts 
for the inhibitory effect of Mcl-1 on cell growth (Jamil, Sobouti et al. 2005) and as such 
further highlights the potential importance of different isoforms of Mcl-1 in cancer growth 
and survival.  
An increased understanding of Bcl-2 anti-apoptotic family members in the regulation 
of autophagy, suggests these proteins play an essential role in the resistance of malignant 
cell types to both apoptosis and autophagy. The role of differing Mcl-1 splicing variants in 
malignant melanoma tumours remains poorly defined and targeting Mcl-1 may therefore be 
of therapeutic benefit. However, important questions remain regarding the ability of Mcl-1L 
to inhibit autophagy, and whether Mcl-1L inhibition would promote autophagy and tumour 
cell survival or autophagic cell death. 
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Figure 1.14: Splcing variants of Mcl-1 from the Mcl-1 gene (Shieh, Liu et al. 2009). The first variant encoded 
from Mcl-1 mRNA is known as Mcl-1L which is 350 amino acids in length and 42 kDa in molecular weight. The 
second variant is encoded when the Mcl-1 pre-mRNA undergoes alternative splicing by eliminating exon two 
resulting in the translation of Mcl-1S which is 271 amino acids in length with a molecular weight of 30 kDa. 
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1.9 Cannabinoids in Autophagy and Cancer 
 
  Cannabinoids have been used in medicine for many centuries, particularly in more 
eastern countries, however since the chemotherapeutic potential of cannabinoids was first 
suggested in 1998 (Sánchez, Galve-Roperh et al. 1998), in which anti-cancer properties of 
THC was observed in glioma, a rekindled interest for the medicinal application of 
cannabinoids for their use in the treatment of cancer has developed. The potential use of 
cannabinoids for the treatment of Glioma in particular, has recently been extensively 
researched (Duntsch, Divi et al. 2006; Salazar, Carracedo et al. 2009; Sánchez, Galve-Roperh 
et al. 1998; Sánchez, de Ceballos et al. 2001; Velasco, Carracedo et al. 2007). As such, several 
signal transduction pathways and mechanisms of action triggered by cannabinoids have 
been identified, frequently activated through stimulation of specific cannabinoid receptors 
found within the plasma membrane. Two cannabinoid receptors have been identified; 
cannabinoid receptor 1 and 2 (CB1/CBR1 and CB2/CBR2). Cannabinoid receptors are 
expressed differentially in tissues, with CB1 expression more typically observed in the central 
nervous system and CB2 expressed in the immune system (Pertwee and Ross 2002). CB 
receptor expression has however also been identified in other tissues such as lung, liver and 
the kidney (Galiègue, Mary et al. 1995; Sarafian, Montes et al. 2008). In addition, the over-
expression of both of these receptors has been found in a variety of cancers including 
Hepatocellular carcinoma (HCC), prostate, breast, lung, pancreatic and lymphoma (Sarfaraz, 
Afaq et al. 2005; Sarfaraz, Adhami et al. 2008; Xu, Liu et al. 2006). Since this discovery 
several in vivo studies have revealed the upregulation of CB2 in melanoma but not in 
surrounding tissue with further evidence for CB1 expression through its associated gene 
CNR1 (Kenessey, Bánki et al. 2012; Zhao, Yang et al. 2012). 
  Of all the identified cannabinoids two are typically used for medicinal purposes 
namely tetrahydrocannabidiol and cannabidiol (Figure 1.15). Although both these agents 
have been found to have anti-tumoural properties, the underlying mechanisms of action 
may in fact not be the same. The accumulation of a pro-apoptotic shpingolipid, ceramide, 
through CB1 activation has been suggested as the mechanism of cannabinoid-induced cell 
death and in particular in the context of THC-induced apoptosis of glioma (Gómez del Pulgar, 
Velasco et al. 2002). Additionally, strong evidence also supports a key role for autophagy 
thought to be activated by the eIF2a axis of the ER stress process and resulting in the 
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increased expression of the stress-regulated proteins p8 and TRB3, and subsequent Akt 
inhibition resulting in autophagy induction through the inhibition of mTORC1 and ultimately 
cell death (Carracedo, Gironella et al. 2006; Carracedo, Lorente et al. 2006; Salazar, 
Carracedo et al. 2009; Salazar, Carracedo et al. 2009). Unlike THC however, cannabidiol 
(CBD), used in the treatment of breast cancer and glioma does not demonstrate any 
psychoactive effects. Research into the molecular mechanisms of CBD is nevertheless limited 
and as such the mechanisms through which CBD exerts its anti-cancer activity remain to be 
fully identified. Evidence has suggested that some cannabinoids can in fact exert their 
chemotherapeutic action via an additional receptor known as the vanilloid receptor leading 
to an initial hypothesis that this receptor is crucial for CBD action (Qin, Neeper et al. 2008). 
However, CBD-induced cell death of breast cancer cells appears to be independent of both 
cannabinoid and vallinoid receptor activation (Shrivastava, Kuzontkoski et al. 2011). The lack 
of a receptor mediated mechanism for CBD is also apparent in studies of CBD-induced 
inhibition of glioma cell viability in which selective cannabinoid receptor antagonists 
SR141716 (which targets CB1) or SR144528 (which targets CB2) (Vaccani, Massi et al. 2005) 
were unable to antagonise inhibition of cell viability. Interestingly, however, both autophagy 
and apoptosis were observed by Electron microscopy following treatment of breast cancer 
cells with CBD. Additionally similar mechanisms to those observed with THC treatment such 
as induction of endoplasmic reticulum stress, Akt inhibition and mTOR inihbition have also 
been observed in breast cancer cells in response to  CBD treatment, including decreased 
levels of phosphorylated mTOR4EBP1, and cyclin D1 (Shrivastava, Kuzontkoski et al. 2011). 
Furthermore, these authors also demonstrated CBD induces several events associated with 
apoptosis including the reduction of mitochondrial membrane potential, BID translocation to 
the mitochondria, cytochrome c release into the cytosol, and the activation of the intrinsic 
apoptotic pathway. CBD also increased the generation of ROS, the inhibition of which 
blocked both apoptosis and autophagy induction (Shrivastava, Kuzontkoski et al. 2011). 
Although preliminary studies with cannabinoids have been undertaken in melanoma 
(Blázquez, Carracedo et al. 2006; Kenessey, Bánki et al. 2012; Scuderi, Cantarella et al. 2011; 
Zhao, Yang et al. 2012) there is howver, to date, limited research available as to the potential 
for THC to treat this disease or whether a similar cytotoxic process.  
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Figure 1.15: Cannabinoid chemical structures. Chemical structure of cannabinoids derived from cannabis 
sativa A) tetrahydricannabidiol and B) cannabidiol.  
   
  Observations in melanoma that both cannabinoid receptors CB1 and CB2 are 
upregulated in vitro compared to primary melanocytes lead to the hypothesis that the use of 
cannabinoids such as THC may offer therapeutic potential (Blázquez, Carracedo et al. 2006). 
Further evidence supporting this concept is given by observations that THC inhibits 
angiogenesis, tumour growth and metastasis by receptor activation as well as the induction 
apoptosis (Blázquez, Carracedo et al. 2006). Although the majority of studies revealing the 
molecular mechanisms of THC-induced cell death (and by its homologues) have been 
identified in glioma, pilot research in prostate and melanoma cancer also suggests similar 
mechanisms of action in these tumour types (Carracedo, Gironella et al. 2006; Carracedo, 
Lorente et al. 2006; Salazar, Carracedo et al. 2009). Research in both glioma and prostate 
cancer cells have highlighted the specific importance of ceramide accumulation for the anti-
tumoural effects of cannabinoids (Blázquez, González-Feria et al. 2004; Galve-Roperh, 
Sánchez et al. 2000; Gómez del Pulgar, Velasco et al. 2002; Mimeault, Pommery et al. 2003). 
The specificity of ceramide accumulation rather than its conversion to complex sphingolipids 
is also evidenced by a lack of anti-tumoural effects observed with THC treatment when 
glucosylceramide synthase (the enzyme catalysing rate limiting step of glycosphingolipid 
biosynthesis) is inhibited (Carracedo, Lorente et al. 2006). Further insights using DNA 
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microarrays have also revealed downstream signalling events resulting from ceramide 
accumulation. These include the upregulation of several stress-regulated genes including p8, 
tribbles 3 (TRB3: a mammalian homolog of Drosophila tribbles), C/EBP homologous protein 
(CHOP) and activating transcription factor 4 (ATF4) (Carracedo, Lorente et al. 2006). In this 
context the authors suggest p8 mediates THC-induced apoptosis and additionally may act as 
a co-transcription factor, regulating the expression of both CHOP and ATF4 (Carracedo, 
Gironella et al. 2006; Carracedo, Lorente et al. 2006). TRB3 expression may thus be 
regulated by ATF4 and CHOP, key markers of ER stress-induced apoptosis in several tumour 
types (Ohoka, Yoshii et al. 2005; Salazar, Carracedo et al. 2009). TRB3 overexpression has 
been shown to inhibit Akt activation in squamous cell carcinoma derived from tongue tissue 
(Zhang, Wen et al. 2011) and Akt inhibition by TRB3 has also been described in liver tissue in 
response to starvation whereby TRB3 binding to Akt prevents its kinase activity (Du, Herzig 
et al. 2003). Therefore, as Akt is an essential component of the PI3K/Akt/mTOR pathway in 
which it inhibits autophagy through activation of mTORC1, its inhibition by TRB3 
overexpression would therefore result in the induction of autophagy (Salazar, Carracedo et 
al. 2009).  
  Collectively these findings suggest that THC-induced cell death occurs as a result of 
ceramide accumulation and ER stress induction which leads to Akt inhibition and the 
induction of autophagy, ultimately resulting in cell death (Figure 6.1). The importance for 
autophagy in this pathway is further highlighted by observations in glioma showing it is 
essential for the induction of apoptosis (Salazar, Carracedo et al. 2009). Inhibition of several 
autophagy genes such as Atg1, Atg5 and Ambra-1 not only prevented the accumulation of 
autophagosomses but also inhibited THC-induced cell death revealing a novel and crucial 
role for this pathway in the ultimate induction of apoptosis (Salazar, Carracedo et al. 2009).  
Furthermore increasing evidence suggests autophagy mediated cell death by cannabinoids 
may involve the permeabilization of lysosomes (Velasco et al unpublished data) however 
whether or not this is a crucial step in THC-induced cell death remains to be determined. 
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1.10 Lysosome membrane permeabilization and cell death  
 
  Lysosomes were originally identified by De Duve et al in 1949 (Nys, Aubert et al. 
1949) who also coined their name and even in these early points of discovery that these 
organelles were implicated in cell death leading towards their description as ‘suicide bags’ 
(De Duve 1959). Since this initial observation further studies have demonstrated their 
molecular action in the cell death process revealing the requirement of lysosomal membrane 
permeabilization (LMP) (Boya and Kroemer 2008; Guicciardi, Deussing et al. 2000). LMP 
occurs when lysosomes become damaged inducing the release of many of the hydrolytic 
enzymes found within the lysosomal lumen including proteases, lipases, and nucleases (Boya 
and Kroemer 2008). Many different stimuli from differing pathways can cause lysosomal 
damage and LMP to occur which include (but is not limited to); p53, Bax, ROS, PLA2, 
caspases and bacteria and viral proteins (Figure 1.17) (Boya and Kroemer 2008). This release 
of lysosomal constitutents into the cytoplasm causes indiscriminate degradation within the 
cell which ultimately causes cell death. Depending on the degree of lysosomal damage and 
amount of LMP different modes of cell death may occur. Large scale lysosomal damage 
results in the cytoplasm becoming acidified causing necrosis, however, more typically LMP 
occurs as a partial and selective process where the released hydrolytic enzymes (particularly 
proteases) activate apoptosis through mitochondrial outer membrane permeabilization, 
cytochrome C release and subsequent activation of caspases (Guicciardi, Deussing et al. 
2000). Most enzymes found within the lysosome function maximally at an acidic pH which is 
maintained within the lysosomal lumen by vacuolar-type H+-ATPases (V-ATPases) which 
regulates pH by pumping H+ ions into the lysosome (Izumi, Torigoe et al. 2003). As such 
many of these enzymes become inactive within the relatively neutral pH conditions of the 
cytoplasm. However, certain proteases including cathepsins remain active at neutral pH 
(Emert-Sedlak, Shangary et al. 2005; Sever, Altintas et al. 2007) and as such are able to exert 
there effects within the cytoplasm. Cathespsins are a family of proteases with approximately 
a dozen members each with distinguishable characteristics such as structure, catalytic 
mechanism and their protein substrates. They are typically cysteine, serine and aspartyl 
proteinases and their expression is often associated with different diseases including cancer 
(Nomura and Katunuma 2005). Of particular interest is cathepsin B which not only remains 
active at neutral pH but also has a clear function in apoptosis induction during LMP and is 
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often linked to cancer progression due to its ability to degrade cellular matrices and aid cell 
invasion (Nomura and Katunuma 2005). Cathepsin B, once released into the cytoplasm has 
been found to induce cytochrome C release and apoptosis (Guicciardi, Deussing et al. 2000). 
Interestingly it has been found that not all lysosomes are permeabilized at the same time 
(Ono, Kim et al. 2003) (although the reasons for this remain unknown) and cancer cells are 
more prone to LMP than normal cells. Conditions within these cells often result in large 
amounts of reactive oxygen species (ROS) being produced and it is these ROS which are able 
to induce LMP (Figure 1.17). However this effect is only able to occur in subcellular regions 
such as near the mitochondria due to the spatially limited range of action of ROS. Another 
mechanism particularly relevant to cancer cells including melanoma is due to the presence 
of iron within the lysosomes. Lysosomes are the main reservoir of chelatable iron within the 
cell which typically accumulates within these compartments upon the degradation of iron-
containing proteins such as ferritin and cytochromes. It is iron which catalyses fenton 
reactions within lysosomes and this produces highly reactive pro-oxidants which may result 
in damage to the lysosomal membrane particularly if the levels of iron are too great (Link, 
Pinson et al. 1993; Mak and Weglicki 1985) (Figure 1.17). As a further point of interest, THC 
may also induce fenton reactions which can increase cell death in glioma cells as a result of 
oxidative stress (Goncharov, Weiner et al. 2005). Moreover, a link between melanoma and 
iron-containing proteins has been demonstrated through the increased expression of ferritin 
in melanoma cell compared to normal melanocytes, in which increased expression is 
associated with tumour progression through reduced sensitivity to oxidative stress (Baldi, 
Lombardi et al. 2005).  
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1.11 Aims of the Studies 
 
  With increasing evidence emerging linking autophagy and apoptosis, including 
interactions between anti-apoptotic Bcl-2 proteins Beclin-1, as well as both pro-survival and 
pro-death functions of this pathway in cancer, the importance of autophagy as a potential 
chemotherapeutic target is becoming ever more apparent. The principle aim of this study 
was therefore to determine how autophagy modulation in metastatic melanoma may be 
harnessed for clinical benefit.  
  
To this the specific objectives were to:  
 
 Determine the influence of oncogenic BRAF on Mcl-1 splice variant expression in 
melanoma and the effect of modulating Mcl-1 expression on drug-induced autophagy and 
cell death 
 Decipher the contribution of autophagy to THC-induced cell death in comparison to 
canonical autophagy induction in response to bortezomib. 
 Identify further potential molecular targets through the utilization of data mining software 
to determine possible underlying molecular events both upstream and downstream of 
autophagy induction.  
 Determine the contribution of molecular targets identified through data mining software 
to identify potential molecular links between THC-induced autophagy and cell death. 
 Decipher whether THC treatment causes the permeabilization of lysosomes as a 
mechanism of melanoma cell death and whether autophagy plays a role in this process. 
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2.1: Growth and maintenance of melanoma cell lines 
 
  Human A375, SKMEL-23, SKMEL-28, CHL-1 and G361 melanoma cell lines were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich Co; Poole, UK) 
supplemented with 10% foetal calf serum (FCS; Sigma-Aldrich) culture medium and 
maintained in a humidified atmosphere of 5% CO2 in air at 37°C. Each cell line was cultured 
continuously for up to 50 passages. A375 and CHL-1 cells stably expressing RFP-GFP-LC3 or 
A375 cells overexpressing Ambra 1 or β-Gal were cultured as above but only cultured for a 
maximum of 5 passages. 
  A375 cells stably transfected using short hairpin Ambra 1 RNA or with a short 
hairpin Ctrl RNAi (Kindly provided by Dr Marco Corazzari (University of Rome ‘Tor Vergata’, 
Italy) were maintained under selection with puromycin (2.5 µM) in Dulbecco’s modified 
Eagle’s medium (DMEM; Sigma-Aldrich Co; Poole, UK) supplemented with 10% foetal calf 
serum (FCS; Sigma-Aldrich). Frozen stocks of replacement cell lines were stored in liquid 
nitrogen in 10% dimethyl sulfoxide (DMSO, Fisher Scientific; New Jersey, USA) and 90% FCS. 
  Human primary melanocytes supplied by Professor Reynolds and colleagues were 
cultured in Medium 254 supplemented with Human Melanocyte Growth Supplement (Life 
Technologies; Invitrogen; Paisley, UK). 
2.2: Treatment of melanoma cells with chemical agents 
 
  Prioir to all drug treatments, cells were seeded in 6 well plates (Helena Biosciences) 
at a density of 1.8 x 10
5
 (A375) and 1.5 x 10
5 
(CHL-1) cells per well, 12 well plates at a density 
of 0.71 x 10
5
 (A375) and 0.5 x 10
5 
(CHL-1) cells per well, or 96 well plates a density of 0.5 x 
10
4
 cells per well (A375, CHL-1). Cells treated with THC were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM; Sigma-Aldrich) supplemented with 0.5% foetal calf serum (FCS; 
Sigma-Aldrich) (THC culture medium) and allowed to attach overnight. For all other 
treatments conditions cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
Sigma-Aldrich) supplemented with 10% foetal calf serum (FCS; Sigma-Aldrich) and allowed to 
attach overnight. 
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  MEK inhibitor U0126 (Promega; Southampton, UK) was dissolved in DMSO at a 
concentration of 10 mM, stored at -20°C for 7 days and added to cell cultures at a final 
concentration of 10 µM (for 1 or 3 days; Helena Biosciences; Gateshead, UK) to cells seeded 
at a density of 1.05 x 10
6
 cells per flask, with an equal volume of vehicle added to control 
cells.  
  Tetrahydrocannabinol (THC) (Kindly provided by Dr Guillermo Velasco; 
Complutense University, Madrid, Spain) was dissolved in DMSO at a concentration of 100 
mM, stored at -20°C and added to cell cultures at 1-10 µM for initial optimisations and at 
final optimised concentrations of 4.5 µM or 5 µM (for 24 hours).  
  Bortezomib (Promega; Southampton, UK) initially dissolved in DMSO at a 
concentration of 10 mM and stored at -80°C was added to cell cultures at final 
concentrations of 10, 50 and 100nM (for 24 hours). Chloroquine (CQ; Sigma-Aldrich) was 
dissolved in nanopure H2O at a concentration of 10 mM, stored under light protected 
conditions at room temperature and added to cell cultures at a final concentration of 10 µM 
(for 2 or 24 hours).  
  Cathepsin B inhibitor (CAO74-me) (Promega; Southampton, UK) was dissolved in 
DMSO at a concentration of 10 mM, stored at -20°C and added to cell cultures at a final 
concentration of 10 µM (for 24 hours).  
  Ceramide synthetase inhibitor (ISP-1) (Enzo life sciences (UK) Ltd, Exeter, UK) was 
dissolved in DMSO at a concentration of 10 mM, stored at -20°C and added to cell cultures at 
a final concentration of 5 µM (for 24 hours).  
  Bafimoycin (Sigma-Aldrich) was dissolved in DMSO at a concentration of 100 mM, 
stored at -20°C and added to cells cultured at a final concentration of 10 nM (for 24 hours).  
  The mTOR inhibitor Rapamycin (Sigma-Aldrich) was dissolved in DMSO at a 
concentration of 100 mM and added to cells cultured at a final concentration of 1 µM (for 24 
hours).  
  The pan caspase inhibitor ZVAD-fmk (benzyloxycarbonyl-V-A-D(OMe)-
fluoromethylketone) (Tocris Bioscience, Bristol, UK) was dissolved in DMSO at a 
concentration of 2 mM, stored at -20°C and added to cell cultures at a final concentration of 
20 µM (for 24 hours).  
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2.3: Reverse-transcriptase polymerase chain reaction 
 
  Total RNA was isolated from melanoma cell lines using an RNAeasy Mini Kit 
according to manufacturer’s specifications with included DNase digestion (Qiagen; Hilden, 
Germany). Reverse transcriptase polymerase chain reaction (RT-PCR) was performed using 
the Access RT-PCR system (Promega; Madison, USA) using primers for Mcl-1 (5’-
GGACACAAAGCCAATGGGCAGGT-3’ forward primer, 3’-GCAAAAGCCAGCAGCACATTCCTGA-5’ 
reverse primer) (Gautrey and Tyson-Capper 2012) TRB3 (5’-GGACACAAAGCCAATGGGCAGGT-
3’ forward primer, 3’-GCAAAAGCCAGCAGCACATTCCTGA-5’ reverse primer) or ß-actin 
(Armstrong, Ruiz et al. 2005). 0.15µg of RNA (for Mcl-1 amplification) 0.1µg (for TRB3 
amplification) or 10ng (for ß-actin amplification) was used in each reaction. 35 cycles of PCR 
were performed for Mcl-1 and TRB3 under the conditions 95°C, 30s; 60°C, 1 minute, 72°C, 2 
minutes and a final extension at 72°C, 7 minutes. 40 cycles of PCR were performed for ß-
actin under the following conditions 95°C, 30s; 65°C, 1 minute; 72°C, 2 minutes; and a final 
extension at 72°C, 7 minutes. Control reactions (no RNA, no reverse transcriptase and 
positive control RNA (Promega)) were included in each experiment using the manufacturer’s 
recommended specifications. PCR products were separated on a 2% (w/v) agarose gel and 
visualised by UV light upon ethidium bromide staining (10mg/ml) (Sigma, UK).  
2.4: Immunohistochemistry for Mcl-1 expression in formalin-fixed 
paraffin-embedded (FFPE) melanoma cell lines 
 
  Melanoma cell line pellets were mixed with agar and then fixed in formalin and 
embedded in paraffin, prior to sectioning onto glass slides (performed by Cellular Pathology, 
Royal Victoria Infirmary, Newcastle Upon Tyne). 4 µM sections were subsequently de-
paraffinised in Histoclear (AGTC Bioproducts; Hessle, UK) for 20 minutes before being 
rehydrated in 100%, 75% and 50% ethanol prior to distilled water for 5 seconds each. 
Antigen retrieval was achieved by microwaving in 10 mM sodium citrate (pH 6.0) (Mcl-1L/S 
antibody, Santa Cruz Biotechnology Inc; Delaware Avenue, USA; sc-819), or for optimisation 
of an Mcl-1L specific antibody (Abcam; Cambridge, UK; ab 25955) in 10 mM sodium citrate, 
10 mM Tris-HCL (pH 7.6), 10 mM Tris-HCL (pH 9.0) or 10 mM citric acid (pH 6.0). Slides were 
then allowed to cool at room temperature for 20 minutes before washing for 3 minutes in 
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phosphate buffered saline (PBS; Sigma-Aldrich) containing 0.05% Tween-20 (T; Fisher 
Scientific). Slides were then incubated in 0.2% Triton X-100 in PBS/T for 10 minutes at room 
temperature, and washed in PBS/T prior to blocking endogenous peroxidase with 3% 
hydrogen peroxide (Vector Laboratories, Ltd; Peterborough, UK) in water. After a further 3 
washes with PBS/T, sections were incubated in 2% serum in PBS/T (provided in a Vectastain 
Elite kit (Vector Laboratories, Ltd) for 20 minutes at room temperature. Sections were then 
incubated with primary antibodies to Mcl-1L/S (diluted 1:1000) or Mcl-1L (Abcam) (diluted 
1:1000; 1:2000; 1:5000) diluted in PBS containing 2% bovine serum albumin (BSA) (Alpha 
Diagnostics; San Antonio, Texas, USA) for 1 hour at room temperature. After washing 3 times 
with PBS/T, sections were incubated for 30 minutes with biotinylated secondary antibodies 
(diluted 1:200 in 2% serum/PBS/T) (supplied with Vectorstain Elite kit) before washing 3 
times in PBS/T. Sections were then incubated with Vectorstain Elite ABC reagent for 30 
minutes at room temperature, washed 3 times with PBS/T, and incubated with VIP solution 
(Vector Laboratories, Ltd) for 10 minutes before rinsing in tap water for 5 minutes 
rehydrating in 75% and 100% ethanol for 5 seconds and  finally cleaned in Histoclear for 2 
minutes before mounting in di-n-butylPhthalate (DPX; Sigma-Aldrich Co). Mcl-1 and Mcl-1L 
staining was visualised by light microscopy using a Leica DFC310 FX microscope (Leica 
Microsystems; Milton Keynes, UK) and images captured with Leica QWin software.   
2.5: Immunohistochemistry for Mcl-1 and Beclin-1 expression in 
formalin-fixed paraffin-embedded (FFPE) primary tissue  
 
  Immunohistochemical analysis of Beclin-1 and Mcl-1 in benign neavi or primary 
melanoma tissue was performed in formalin-fixed paraffin-embedded sections (prepared by 
Cellular Pathology, Royal Victoria Infirmary, Newcastle Upon Tyne). 5-6 µm sections were 
baked at 56°C overnight onto X-tra microscope slides (Leica Microsystems, Milton Keynes, 
UK). Sections were de-paraffinised in Histoclear (AGTC Bioproducts; Hessle, UK) for 20 
minutes before being rehydrated in 100%, 75% and 50% ethanol prior to distilled water for 5 
seconds each. Antigen retrieval was achieved by microwaving in 10 mM sodium citrate (pH 
6.0) (Mcl-1L/S antibody, Santa Cruz Biotechnology Inc; Delaware Avenue, USA; sc-819; 
Beclin-1 antibody) for 12 minutes. Slides were then allowed to cool at room temperature for 
20 minutes before washing for 3 minutes in phosphate buffered saline (PBS; Sigma-Aldrich) 
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containing 0.05% Tween-20 (T; Fisher Scientific). Slides were then incubated in 0.2% Triton 
X-100 in PBS/T for 10 minutes at room temperature, and washed in PBS/T prior to blocking 
endogenous peroxidase with 3% hydrogen peroxide (Vector Laboratories, Ltd; Peterborough, 
UK) in water. Endogenous Avidin was then blocked using Avidin solution of an Avidin/Biotin 
Blocking kit (Vector Laboratories Inc., Burlingame, USA) for 15 minutes, and then washed 
with PBS/T. Sections were then incubated with Biotin for 15 minutes and then washed with 
PBS/T. Protein was blocked by incubating sections in 2% blocking serum from an animal 
specific Vectastain Elite kit (Vector Laboratories Inc., Burlingame, USA) (Mouse for Beclin-1, 
Rabbit for Mcl-1) for 20 minutes at room temperature. Sections were then incubated with 
primary antibodies to Mcl-1L/S (diluted 1:1000) or Beclin-1 (BD transduction Lab, Oxford, 
UK; 612112) (diluted 1:100) diluted in PBS containing 2% bovine serum albumin (BSA) (Alpha 
Diagnostics; San Antonio, Texas, USA) for 1 hour at room temperature. After washing 3 times 
with PBS/T, sections were incubated for 30 minutes with animal specific biotinylated 
secondary antibodies (diluted 1:200 in 2% serum/PBS/T) (supplied with Vectorstain Elite kit) 
before washing 3 times in PBS/T. Sections were then incubated with Vectorstain Elite ABC 
reagent for 30 minutes at room temperature, washed 3 times with PBS/T, and incubated 
with VIP solution (Vector Laboratories, Ltd) for 10 minutes. Slides were rinsed in tap water 
for 5 minutes and counter stained with haematoxylin (Sigma Diagnostics, St.Louis, USA) for 2 
minutes. After counter staining, slides were washed for 10 minutes in tap water with 
frequent changes. Slides were finally dehydrated using 75% and then 100% ethanol for 5 
seconds and sections were cleaned for 2 minutes in histoclear. Slides were allowed to dry 
and coverslips were mounted with DPX mountant (VWR International Ltd., Poole, UK).  Mcl-1 
and Beclin-1 staining was visualised by light microscopy using a Zeiss Axioimager II (Carl Zeiss 
Microscopy, LLC, United States; 490022-0011-000) and images captured with Axioimager 
software. 
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2.6: Western blotting  
 
  Protein was extracted from melanoma cell lines into cell lysis buffer (0.1 M Tris-HCl 
(pH7.4), 25 mM NaF, 0.1 M NaCl, 2 mM EDTA (pH8), 1 mM benzamidine, 0.1 mM sodium 
orthoVanadate, 0.1% Triton-X100) (all supplied by Sigma-Aldrich Co) containing complete 
mini EDTA-free protease inhibitor cocktail (Roche, Manheim, Germany). Cell lysates were 
incubated on ice for 20 minutes and then probe sonicated for 3 X 5 seconds at 6 microns 
(Soniprep150, MSE, UK). Protein concentration was quantified using a commercial Bradford 
assay using Coomassie reagent (Pierce Biotech, Rockford, IL, USA) according to 
manufacturer’s specifications in a 96-well flat bottomed plate (Helena Biosciences) and 
absorbance measured at 595nm using a SpectraMAX 250 plate reader (Molecular Devices 
Ltd; Wokingham, UK). Proteins were denatured in 4x sample buffer (0.25 M Tris-HCl (pH8.0), 
8% sodium dodecyl sulphate (SDS), 40% Glycerol, bromophenol blue, 100 µl/ml ß-
mercaptoethanol) (all supplied by Sigma-Aldrich) and separated by gel electrophoresis in 4-
20% Tris-Glycine pre-cast gels (Life Technologies; Invitrogen) with Tris-Glycine (0.25M Tris 
Base; 1.92M Glycine) running buffer containing 1% SDS. Protein was then transferred onto 
Hybond-P transfer membrane (GE healthcare; Little Chalfont, UK) in Tris-Glycine buffer with 
10% methanol (Fisher Scientific; Loughborough, UK). Membranes were subsequemtly 
washed in Tris buffered saline (TBS) containing 5% milk (OXOID; Basingstoke, Hertfordshire, 
UK) to block exposed hydrophobic sites. Membranes were then incubated with primary 
antibodies to Mcl-1L/S (1:4000; sc-819, Santa Cruz, Mcl-1L 40 kDa, Mcl-1S 35 kDa), BRAF 
(1:100,000; sc-5284, Santa Cruz, 86 kDa), phosphorylated ERK1/2 (P-ERK,  1:4000; 4377S, Cell 
Signalling/NEB (Hitchin, Hertfordshire), 42/44 kDa), ERK1/2 (1:4000; 9102, Cell 
Signalling/NEB, 42/44 kDa) Beclin-1 (1:2000;  BD transduction Lab, 62 kDa), Atg7 (1:1000; sc-
8668, Santa Cruz, 60kDa) Cleaved Caspase 3 (1:1000; 9661, Cell Signalling, 19/17 kDa), LC3-
I/II (1:5000; 2775, Cell signalling, 18/16 kDa), Ambra 1 (1:1000; 26190002, Novus Biologicals 
(Cambridge, UK), 139 kDa) and ß-actin as a loading control (1:40,000; AC-74 Sigma Aldrich, 
45 kDa), diluted in TBS / 5% non-fat milk (Mcl-1, BRAF, Beclin-1, Atg7, Ambra 1, ß-actin) or 
5% BSA (Alpha Diagnostic Intl, Inc; San Antonio, Texas, USA) (P-ERK, ERK, LC3-I/II, Cleaved 
Caspase 3). To detect proteins, membranes were incubated with horseradish peroxidase-
conjugated secondary antibodies (Vector Laboratories, Ltd, Burlingame, CA, USA) diluted 
1:4000 (Mcl-1L/S, P-ERK and ERK), 1:100,000 (BRAF), 1:1000 (Atg7, Ambra 1, Cleaved 
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Caspase 3), 1:2000 (Beclin-1) 1:5000 (LC3-I/II) or 1:40,000 (ß-actin), and visualised using the 
ECL-plus system (GE healthcare) and photographic film using a developer (MINIMED90 X-
RAY film processor; photon imaging systems, AFP imaging corp., Elmsford, NY, USA). 
Densitometric quantification of signal intensity was performed using FluorcChem software 
(Alpha Inntoech; San Leandro, CA, USA) and quantified as described in section 2.13 
2.7: Plasmid preparation and restriction enzyme digestion  
 
  The expression vectors pEFm-BRAF
wt
 and pEFm-BRAF
V600E
 (provided by Professor 
Richard Marais, Institute of Cancer Research, London), pcDNA4 or pcDNA3.1-Mcl-1S (Fig. 3.1, 
provided by Dr Jeng-Jer Shieh, National Hsing University Taichung, Taiwan) were 
transformed into competent E.coli (OneShot TOP10 chemically competent E.coli, Life 
Technologies; Invitrogen) using a standard heat shock procedure (according to supplier 
protocol), and selected by ampicillin (50µg/ml and isolated using a HiSpeed plasmid Maxi kit 
(Qiagen) according to manufacturer’s instructions.  pcDNA3.1-Mcl-1S was subsequently 
digested using HindIII (Roche; Hertfordshire, UK) and EcoRV (Fermentas; St. Leon-Rot, 
Germany ) using SuRE Cut buffer B (Roche) for 2 hours at 37°C and analysed by agarose gel 
electrophoresis (0.8% agarose). 
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Figure 2.1: pcDNA3.1Mcl-1S plasmid map  
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2.8: Transient transfection of BRAFV600E and Mcl-1S in human 
melanoma cells 
 
  For over-expression of BRAF
wt
 or BRAF
V600E
, CHL-1 melanoma cells were seeded in 
25 cm
2
 tissue culture flasks (Helena Biosciences) at a density of 1 x 10
6
 and allowed to 
adhere overnight. Cells were then washed with PBS and the medium replaced with 5 ml of 
OPTIMEM (Life Technologies; Invitrogen) transfection medium prior to transfection for 6 
hours with 5 µg pEFm-BRAF
wt
 and pEFm-BRAF
V600E
 and 15 µl lipofectamine 2000 (Life 
Technologies; Invitrogen) in accordance with the manufacturer’s instructions. Transfection 
was terminated by replacing the OPTIMEM with culture medium. Cells were re-seeded 20 
hours later at a density of 0.5 x 10
6 
cells/25 cm
2
 flask and harvested after a further 48 hour. 
BRAF over-expression and downstream activation of ERK was verified by Western blot 
analysis.  
  For over-expression of Mcl-1S, A375 cells were seeded in 6-well tissue culture 
plates (Helena Biosciences) at a density of 4 x 10
5
 cells/well and allowed to adhere 
overnight. Cells were then washed with PBS and the medium replaced with 2 ml of 
OPTIMEM prior to transfection for 6 hours with 0-5 µg pcDNA3.1-Mcl-1S and 0-8 µl 
lipofectamine 2000 (Life Technologies; Invitrogen) in accordance with the manufacturers 
instructions. Cells were re-seeded 20 hours later at a density of 2 x 10
5 
cells/well and 
harvested after a further 48 hour. Mcl-1S over-expression was verified by Western blot 
analysis.  
2.9: Transient RNAi-mediated knockdown of Mcl-1, Beclin-1, Atg7 
and TRB3 in melanoma cell lines using reverse transfection. 
 
A375 or CHL-1 cells were transfected using siRNAs; Mcl-1 (M-004501-08-0005) 
(Thermo Scientific, Loughborough, UK), Beclin-1 (HSS112741, HSS112742) (Life Technologies; 
Invitrogen, Paisley, UK), Atg7 (HSS116182, HSS173705) (Life Technologies; Invitrogen, 
Paisley, UK), TRB3 (sc-44426) (Santa Cruz) and validated using negative control siRNA 
(Qiagen AllStars Negative Control siRNA/Life Technologies; Invitrogen Negative Control Low 
GC Duplex siRNA); at the point of seeding in a volume of 2 ml culture medium in 6 well 
plates or 0.8ml culture medium to achieve a desired cell density of 50-80%, which 
corresponds approximately to 1.5 x 10
5
 cells per well for CHL-1 cells and 1.8 x 10
5
 cells per 
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well for A375 cells. For transient transfection, siRNA was transfected using lipofectamine 
RNAiMAX according to the manufacturers’ specifications in 0.5ml (6 well plate) or 0.2ml (12 
well plate) serum-free Opti-MEM growth medium (Life Technologies; Invitrogen Ltd) to given 
final concentrations of 2-4 nM siRNA. The siRNA containing Opti-MEM was then added to 
2ml (6 well plates) or 0.8ml (12 well plates) of complete culture medium with the 
appropriate cell concentrations to a final volume of 2.5ml (6well plates) or 1ml (12 well 
plates) and incubation was continued overnight before knockdown of the target gene was 
verified by Western blot analysis 24 hours after transfection or subsequent cell viability, 
death or autophagy assays performed.  
2.10 Cell Viability Assays 
 
  MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) or MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assays 
were used as ameasure of celll viability For MTT assays, SK-MEL-28 or A375 cells were 
seeded at 0.71x10
5
 cells/well and CHL-1 cells seeded at 0.5 x10
5
 cells/well into 12 flat well 
tissue culture plates (Corning Inc, Corning, NY) in a volume of 1 ml of culture medium and
 
allowed to adhere overnight.  Cells were treated using THC in the presence or absence of CQ, 
CathBi, Bafilomycin, ZVAD or ISP (see 2.2) or following RNAi-mediated knockdown studies 
(see 2.9). Cell viability was assessed by the addition of 100µl of Thiazolylbluetetrazolium at a 
concentration of 5mg/ml and incubation for 4hours with the absorbance measured at 
570nm using a SpectraMAX 250 plate reader.  
  For MTS assays SK-MEL-28, A375, or CHL-1 cells were seeded at 0.5x10
4
 cells/well 
and
 
cultured in 100µl complete media in a 96 well plate (Corning Inc) and allowed to adhere 
overnight. Following drug treatment, cell viability, was assessed by the addition of 20 µl of 
MTS to each well and incubation continued for a further 4hours before absorbance was 
measured at 490nm using a SpectraMAX 250 plate reader. 
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2.11 Immunofluorescence 
  
  Melanoma cell lines were seeded in 12 well plates (Helena Biosicnces) on sterile 
glass cover slips at a density of 0.71 x 10
5
 (A375, SKMEL-28) or 0.5 x 10
5 
(CHL-1) cells per well 
in a volume of 1ml media and allowed to attach for 24 hours prior to chosen treatment 
conditions. After treatment, cells were fixed in 100% ice cold methanol for 10 minutes and 
subsequently washed three times with 1ml PBS for 1 minute. Cells were stored at 4°C for up 
to two weeks for immunofluorescence analysis.  
  Analysis of Cyctochourome C release as well as Mcl-1 expression levels in BRAF
V600E
 
mutated overexpressing CHL-1 cells was performed using the following immunefluorescence 
protocol. After permeabilisation for 10 min with 0.2% Triton-X100 (Sigma-Aldrich) in 
phosphate buffered saline (PBS) and two washes with 1ml PBS containing 0.05% Tween 20 
(PBS/T; Sigma-Aldrich) cells were immersed in 10% goat serum in 1ml PBS/T for 10 min to 
minimise non-specific binding before treatment with primary antibodies to BRAF (Santa 
Cruz), Mcl-1 (Santa Cruz) or Cytochourome C (BD Biosciences). BRAF, and Cytochourome C 
staining was detected with a secondary Oregon green-conjugated goat anti-rabbit secondary 
antibody (Life Technologies; Invitrogen Ltd) diluted 1:200 in PBS/T containing 2% bovine 
serum albumin (BSA; Sigma-Aldrich), Mcl-1 was detected with secondary 633-conjugated 
goat anti-mouse secondary antibody (Alexfluor,) and cytochrome C staining was detected 
with a secondary goat anti-rabbit secondary antibody (Life Technologies; Invitrogen Ltd) 
diluted 1:200 in PBS/T containing 2% bovine serum albumin (BSA; Sigma-Aldrich) for 1 hour 
at room temperature. Stained sections were mounted in Vector Shield containing DAPI 
(Vector Laboratories; Peterborough, UK). For Cytochourome C staining RNase was was 
added for 20 minutes after three 2 minute washes in 1ml PBS-T post secondary antibody 
incubation before counterstaining nuclei for 15 min with TOTO-3 iodide (Life Technologies; 
Invitrogen Ltd) diluted 1:7,000 in PBS/T containing 2% BSA. All slides were analysed by 
confocal microscopy using a Leica TCS SP II laser scanning confocal microscope with images 
captured and processed using LCS Lite 2.61 software (Leica Microsystems; Heidelberg, 
Germany). 
  Analysis of cathepsin B release and co-localisation with lysosomal associated 
membrane protein 2 (LAMP2) was performed using Immunofluorescence double staining 
approach for primary antibodies raised from the same species (Mouse). Cells fixed to cover 
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slips were washed two times with 1ml PBS containing 0.05% Tween 20 (PBS/T; Sigma-
Aldrich). The first serum blocking step was performed by immersing fixed cells with 2% goat 
serum/2% BSA in PBS for 30 minutes to minimise non-specific binding before treatment with 
mouse anti-cathepsin B antibody (Calbiochem; IM27L) diluted 1:200 in 2% goat 
serum/2%BSA in PBS for 1 hour at room temperature. After three 2 minute washes with 1ml 
PBS/T, Cathepsin B staining was detected using Oregon green-conjugated goat anti-mouse 
secondary antibody (Life Technologies; Invitrogen Ltd) diluted 1:200 in PBS. The second 
serum blocking was performed by incubating fixed cells for 1 hour using MOM (Mouse on 
Mouse) reagent (MKB-2213) (Vector Laboratories; Peterborough, UK) (2 drops in 5ml PBS) to 
block free binding sites of the anti-mouse immunoglobulin. Additional blocking was 
performed by immersing fixed cells in 2% goat serum/2% BSA in PBS for 30 minutes to 
further minimise non-specific binding before addition of the second primary antibody mouse 
antibody LAMP2 (BD; (Oxford, UK) 555803) which was added to the fixed cells diluted 1:200 
in 1% goat serum/1% BSA in PBS for 1 hour at room temperature. LAMP2 staining was 
detected with secondary 633-conjugated goat anti-mouse secondary antibody (Life 
Technologies; Invitrogen, A-21052) diluted 1:200 for 1 hour at room temperature. Stained 
cells were washed and dehydrated in 100% ethanol before mounting cover slips onto slides 
with in Vector Shield containing DAPI (Vector Laboratories) to counterstain cell nuclei. Cells 
were analysed by confocal microscopy using a Leica TCS SP II laser scanning confocal 
microscope with images captured and processed using LCS Lite 2.61 software (Leica 
Microsystems; Heidelberg, Germany). 
2.12: Analysis of autophagic flux in dual tagged mRFP-GFP-LC3 
melanoma cells 
 
  Human A375 and CHL-1 melanoma cell lines stably expressing LC3 fluorescently 
tagged with red fluorescent protein (RFP) and green fluorescent protein (GFP) (mRFP-GFP-
LC3) were kindly provided Dr Marco Corazzari and seeded in 12 well plates at a density of 
0.71 x 10
5
 (A375) and 0.5 x 10
5 
(CHL-1) cells per well on cover slips prior to treatment with 
THC at optimised concentrations (section 2.2) for 18 hours and fixation for 10 minutes with 
10% paraformaldehyde. Cells on cover slips were mounted in Vector Shield containing DAPI 
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(Vector Laboratories). Cellular mRFP-GFP-LC3 fluorescence was visualised using Zeiss 
AxioImager II (Carl Zeiss Microscopy, LLC, United States; 490022-0011-000) and images 
captured using the supplied Axioimager software. Autophagy induction was assessed by the 
puntal staining patterns observed for degradation of LC3-GFP signal and increased LC3-RFP 
signal. This assay allows for measurement of autophagic flux by pH changes occurring during 
autophagy in which autophagosomse/lysosome fusion occurs which eliminates signals 
emitted by GFP resulting in RFP signals alone.  
2.13: Molecular visualisation software for Beclin-1 protein-protein 
interactions 
 
  Beclin-1 protein-protein interactions were pooled and identified from several 
articles using the cytoscpae plugin provided by Biological General Repository for Interaction 
Datasets (BioGRID) and the data downloaded directly from the BioGRID website for 
visualisation (http://thebiogrid.org/). Beclin-1 protein-protein interactions were visualised 
and organised into cellular processes of relevance to the project using an open source 
bioinformatics software platform Cytoscape (http://www.cytoscape.org/). 
2.14: Statistical analysis 
 
  Protein expression data were analysed by cell line (CHL-1, SKMEL-23, A375,G361) or 
transfection type (Control (non-transfected), BRAF
WT
, BRAF
V600E
) with the use of one-way 
ANOVA and Dunnett’s post-hoc correction, using SPSS Release 15 (SPSS Inc.). For Mcl-1L 
expression analysis, Mcl-1 band intensity was normalised to ß-actin band intensity (Mcl-1/ß-
actin) for each cell line and expressed relative to the mean Mcl-1/ß-actin value (across all cell 
lines) for each individual experiment.  
  Autophagy induction was determined and statistically analysed using LC3-II In vitro 
protein expression data normalised to ß-actin band intensity (LC3-II/ß-actin) for each cell line 
expressed relative to the mean LC3-II/ß-actin value (across all cell lines) for each individual 
experiment. Variation in expression levels were analysed between RNAi-mediated 
knockdown and treatment conditions in A375 and CHL-1 melanoma cell lines with the use of 
one-way ANOVA and Dunnett’s post-hoc correction, using SPSS Release 15 (SPSS Inc.). 
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  Statistical analysis of all MTT/MTS proliferation data was undertaken using 
GraphPad Prism 5 (GraphPad Software; San Diego, USA) software and all representative 
graphs were created using this software. Significance is indicated as P values of p < 0.05 *, p 
< 0.01 **, p < 0.001 *** thouroughout based on a minimum of 3 replicates with the use of 
one-way ANOVA and Dunnett or Bonferonni post-hoc correction.   
  Mcl-1 In vitro expression levels analysed by immunocytochemistry were 
determined using Image J analysis software (National Institute of Health; Bethesda, 
Maryland, USA) and variation in expression levels was established using one-way ANOVA 
with Dunnett’s post-test correction. 
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3.1 Introduction 
 
Current research suggests tumour cell resistance to chemotherapy-induced apoptosis 
may be overcome by manipulation of the autophagy pathway (Armstrong, Corazzari et al. 
2011; Degtyarev, De Mazière et al. 2008; Salazar, Carracedo et al. 2009; Shrivastava, 
Kuzontkoski et al. 2011). Additionally recent reports have implicated anti-apoptotic 
members of the Bcl-2 family of proteins (crucial to the regulation of apoptosis) in the 
regulation of autophagy (Feng, Huang et al. 2007), thereby presenting potential therapeutic 
targets involved in both processes. The anti-apoptotic Bcl-2 family member Mcl-1 is of 
particular interest as it is highly expressed in both primary and advanced melanoma and has 
previously been shown to be essential for melanoma survival (Tang, Tron et al. 1998). The 
gene encoding Mcl-1 contains 3 exons encoding two splicing variants, Mcl-1L and Mcl-1S, 
with opposing roles. Mcl-1L is a polypeptide of 350 amino acids in length and 40 kDa in 
molecular weight (Kozopas, Yang et al. 1993) which possesses Bcl-2 homology domains 1-3 
and transmembrane domains that are found in other Bcl-2 family members, as well as a 
unique PEST sequence (a peptide sequence rich in proline, glutamic acid, serine, and 
threonine) within its N terminus (Yang, Kozopas et al. 1995). Mcl-1S is encoded by 
alternative splicing of Mcl-1 pre-mRNA which eliminates the second exon resulting in the 
translation of a polypeptide of 271 amino acids in length with a molecular weight of 35 kDa 
(Bingle, Craig et al. 2000). Mcl-1S protein has a 41 residue difference to Mcl-1L at the C-
terminus and only has a BH3 domain, similar to pro-apoptotic BH3-only members of the Bcl-
2 family. Mcl-1S is thought therefore to antagonise the pro-survival role of Mcl-1L, 
promoting cells to enter apoptosis (Bae, Leo et al. 2000; Bingle, Craig et al. 2000). To date, 
however, the differential expression of each Mcl-1 splice variant in melanoma has remained 
undefined, and which may be important in terms of mitogen activated protein kinase 
(MAPK) signalling (Huang, Huang et al. 2000), a pathway frequently constitutively activated 
in melanoma through hyperactivating mutations in the BRAF protein kinase and which 
contribute to apoptotic resistance and tumour progression (Davies, Bignell et al. 2002; Dong, 
Phelps et al. 2003; Uong and Zon 2009). Activation of ERK1/2 stabilises Mcl-1 by 
phosphorylation of the protein and Mcl-1 over-expression has been shown to correlate with 
hyper-activation of ERK1/2 signalling (Boucher, Morisset et al. 2000). Additionally Mcl-1L has 
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been shown to interact directly with Beclin-1 (a BH3 only Bcl-2 family member involved in 
the nucleation step of autophagy) suggesting a potential role for Mcl-1 in autophagy 
regulation (Feng, Huang et al. 2007). 
The aim of this chapter was therefore to characterise the expression levels of Mcl-1 
and its splice variants in metastatic melanoma cells in vitro and in vivo and establish whether 
there is a relationship between differing splice variant expression and constitutive activation 
of MAPK signalling, as well as to investigate the effect of manipulating Mcl-1 expression on 
drug-induced autophagy and cell death in response to the autophagy-inducing therapeutic 
agents, bortezomib and Tetrahydrocannabinol (THC). 
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3.2: Results 
 
3.2.1: Mcl-1 mRNA is increased in metastatic melanoma cells compared to expression in 
primary melanocytes in vitro. 
 
 
  Reverse transcription PCR (RT-PCR) was performed in order to analyse the 
differential expression of Mcl-1L and Mcl-1S in primary human melanocytes as well as in 
metastatic melanoma cell lines with differing BRAF mutational status, specifically BRAF
V600E 
mutated metastatic A375, G361 and BRAF
WT
 CHL-1 and SKMEL-23 cells. A significant increase 
in Mcl-1L, but not Mcl-1S, mRNA expression was seen in melanoma cell lines compared to 
primary melanocytes, with the highest expression of Mcl-1L observed in BRAF
V600E
 mutated 
cells (Figure 3.1 B&C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Mcl-1L mRNA expression in metastatic melanoma cell lines and primary melanocytes. (A) RT-PCR 
of Mcl-1L, Mcl-1S and β-actin mRNA expression in primary melanocytes (1° Mel samples 1-3), BRAF
WT
 CHL-1 
and SKMEL-23 or BRAF mutated A375 and G361 human metastatic melanoma cell lines. Each bar represents (B) 
Mcl-1L and (C) Mcl-1S band intensity normalised to β-Actin loading control (mean +/- SEM, n=3). Statistics were 
acquired using one way ANOVA with Dunnet’s post-hoc test * p< 0.05, *** p<0.001 comparing Mcl-1 
expression levels in melanoma cell lines to Mcl-1 expression in primary melanocytes.  
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3.2.2: Mcl-1 protein expression is increased in BRAF mutated compared BRAF wild-type 
metastatic melanoma cell lines.  
 
Analysis of total Mcl-1 protein expression by immunocytochemistry of formalin-fixed 
and paraffin-embedded (FFPE) cell pellets derived from metastatic melanoma cell lines 
revealed increased expression of Mcl-1 in BRAF
V600E
 mutated G361 cells compared to 
expression in BRAF
WT 
CHL-1 cells (Figure 3.2).  
 
 
 
  
 
 
 
 
Figure 3.2: Mcl-1 expression is increased in BRAF mutated metastatic melanoma cells. Immunoctyochemical 
analysis of Mcl-1 expression in BRAF
WT
 CHL-1 and BRAF
V600E
 mutated G361 metastatic melanoma cell lines.  
 
As it was not possible to measure Mcl-1 splice variant expression by 
immunohistochemistry using a currently available antibody for Mcl-1L splice variant 
detection (data not shown), protein was isolated from human metastatic melanoma cell 
lines CHL-1, SKMEL-23, A375 and G361 and expression of both Mcl-1L and Mcl-1S 
determined by Western blotting using an antibody able to detect both splice variants. 
 
 
 
 
 
 
 
CHL-1                                 G361
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Results demonstrated significantly increased expression of Mcl-1L in BRAF
V600E
 A375 
and G361 cells compared with expression in BRAF
WT
 cell lines, CHL-1 and SKMEL-23 (Figure 
3.3B). Additionally, membranes derived from the Western blot analysis of Mcl-1L were over 
exposed in order to detect Mcl-1S protein. Results demonstrated Mcl-1S expression was 
detectable in BRAF
V600E
 mutated A375 and G361 cells while little or no expression was 
evident in BRAF
WT
 CHL-1 or SKMEL-23 cells (Figure 3.3A). 
 
 
 
 
 
                                                               
 
 
 
 
 
 
 
 
 
Figure 3.3: Mcl-1L expression is increased in BRAF mutated metastatic melanoma cell lines. (A) Western blot 
of Mcl-1L, Mcl-1S and β- actin expression in BRAF
WT
 CHL-1 and SKMEL-23 cells and BRAF
V600E 
mutated A375 and 
G361 cells. (B) Each bar represents Mcl-1L band intensity normalised to β-actin and expressed relative to Mcl-
1L expression in CHL-1 cells (mean ± SD, n=3). Statistical analysis was performed using one-way ANOVA, with 
Dunnett’s post-hoc test, ** p < 0.01 comparing Mcl-1 expression levels in BRAF
V600E
 melanoma cell lines to 
expression in BRAF
WT 
melanoma cell lines. 
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3.2.3: Oncogenic BRAF signalling increases Mcl-1L expression 
 
In order to further assess the influence of hyperactivated BRAF signalling on the 
differential expression of Mcl-1L and Mcl-1S, BRAF
WT
 or BRAF
V600E
 were transiently 
transfected into BRAF
WT
 CHL-1 cells and levels of Mcl-1L and Mcl-1S expression levels 
determined by Western blotting. Over-expression of both BRAF
WT
 and BRAF
V600E
 was 
confirmed by the increased expression of BRAF (Figure 3.4A). Activation of BRAF signalling 
was confirmed by increased phosphorylation of ERK for BRAF
WT 
and BRAF
V600E
 over-
expressing cells, with higher levels of ERK phosphorylation observed in cells over-expressing 
BRAF
V600E
 (Figure 3.4A). Results demonstrated Mcl-1L expression was increased following 
over-expression of either BRAF
V600E
 or BRAF
WT
, and was significantly increased by over 
expression of BRAF
V600E
 relative to levels in control untransfected CHL-1 cells p < 0.05, 
(Figure 3.4B). Additionally Mcl-1S was also increased following over-expression of either 
BRAF
V600E
 or BRAF
WT
, and further increased by over-expression of BRAF
V600E
, relative to levels 
in control untransfected cells. 
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Figure 3.4: Oncogenic BRAF increases Mcl-1L/S expression. (A) Western blot for Mcl-1L/S, BRAF, 
phosphorylated ERK 1/2 (P-ERK 1/2), ERK 1/2 and β-actin expression in BRAF wild-type CHL-1 cells or in CHL-1 
cells transiently transfected for 3 days with BRAF
WT
 or BRAF
V600E
. (B) Each bar is relative to Mcl-1L expression 
levels in non-transfected control CHL-1 cells (mean ± SEM, n=3). Statistics were acquired using one way ANOVA 
with Dunnett post-hoc test, * p< 0.05, ns - not significant comparing BRAF
V600E
 and BRAF
WT
 transfected CHL-1 
cells to control un-transfected CHL-1 cells. 
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The ability of oncogenic BRAF signalling to increase Mcl-1 expression was also 
confirmed by immunofluorescence (IF) studies. Results demonstrated transfection of BRAF
WT
 
CHL-1 cells with BRAF
V600E
 induced a small but significant increase in the expression of Mcl-1, 
compared to cells transfected with BRAF
WT 
(Figure 3.5). Mcl-1 Nuclear localisation was also 
observed in cells transfected with BRAF
V600E
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 3.5: Oncogenic BRAF increases Mcl-1 expression compared to wild-type BRAF. (A) Immunofluorescence 
for Mcl-1 (Red) and BRAF (Green) expression in BRAF wild-type in CHL-1 cells transiently transfected for 3 days 
with BRAF
WT
 or BRAF
V600E
. (B) Relative Mcl-1 expression in CHL-1 cells transiently transfected for 3 days with 
BRAF
WT
 or BRAF
V600E
. Each bar is a representative of 54 and 52 transfected cells. Statistics were acquired by t-
test analysis, *** p< 0.001 comparing BRAF
V600E
 transfected CHL-1 cells to BRAF
WT
 transfected control CHL-1 
cells.  
 74 
 
3.2.4 Expression of Mcl-1L/S in metastatic melanoma tumours in vivo 
 
To assess Mcl-1 splice variant expression levels in vivo, protein was isolated from 
metastatic melanoma tumour samples derived from 8 patients with advanced stage 
melanoma and the expression of Mcl-1L or S evaluated by Western blotting.  Each tumour 
sample was also genotyped by SNP analysis of the most common BRAF (V600E and V600D) 
and NRAS mutations (Q61K and Q61R) as previuously described (Hiscutt, Hill et al. 2010). 
 
Results demonstrated differential expression of both Mcl-1L and Mcl-1S in melanoma 
tumours derived from patients however, no correlation with BRAF/NRAS mutational status 
was observed (Figure 3.6). As the data derived was from a panel of only 8 tumours it remains 
unclear as to whether or not Mcl-1 expression definitively correlates with BRAF/NRAS 
mutational status in melanoma in vivo. 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Expression of Mcl-1 splice variants in 8 metastatic melanoma tumours. Western blot for Mcl-1L, 
Mcl-1S and ß-actin in a small panel of BRAF/NRAS wild-type (WT), BRAF mutated (V600E) or NRAS mutated 
(Q61K) (Q61R) metastatic melanoma tumours. 
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3.2.5: RNAi-mediated knockdown of Mcl-1 increases THC and bortezomib-induced 
autophagy and cell death 
 
As activating mutations in BRAF increases the expression of both Mcl-1L and Mcl-1S 
in vitro, identification of a functional role for Mcl-1 in the regulation of autophagy and cell 
death was undertaken. This was achieved by modulation of Mcl-1 expression either through 
RNAi-mediated knockdown or through transient over-expression of Mcl-1S, prior to 
determining the effect on drug-induced autophagy and apoptosis in response to bortezomib 
or Tetrahydrocannabinol (THC). RNAi-mediated knockdown of Mcl-1 was achieved by 
reverse transfection and autophagy was induced by incubating cells with THC or bortezomib 
in the presence or absence of chloroquine (CQ). Initial dose response studies of THC-induced 
inhibition of cell viability were performed in order to find an optimal dose in which THC 
induces approximately 50% inhibition of cell viability at 24 hours. Treatment of A375 cells 
with increasing concentrations of THC demonstrated THC-induced approximately 50% 
inhibition of cell viability between concentrations of 4 and 5 µM (Figure 3.7), and hence this 
concentration range was adopted for use in all subsequent experiments. RNAi-mediated 
knockdown of Mcl-1 resulted in enhanced THC-induced inhibition of A375 cell viability which 
was prevented by combined treatment with chloroquine (Figure 3.8).  
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Figure 3.7: THC induces dose-dependent inhibition of A375 cell viability. MTT proliferation assay for cell 
viability (absorbance 570nm) of A375 cells treated for 24 hours with a dose range of THC (0, 3, 4, 5, 6, 7, 8, 10 
µM) or with vehicle control (DMSO). Each bar is the mean +/-SD, n=3. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: RNAi-mediated knockdown of Mcl-1 enhances THC-induced inhibition of A375 cell viability, which 
is prevented by combined treatment with chloroquine. Relative viability A375 cells following transfection with 
control siRNA (Ctrl siRNA) or Mcl-1 siRNA for 24 hours and subsequent treatment  for 24 hrs with 4.5 µM or 5 
µM THC either alone or in combination with 10µM CQ. Each bar is relative to untreated melanoma cells for 
each siRNA condition (mean +/- SEM, n=3). Statistics were acquired using one way ANOVA with Dunnett post-
hoc test, * p< 0.05, ** p< 0.01, *** p<0.001 comparing drug treatments shown to untreated melanoma cells 
for each siRNA condition alone. 
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To confirm THC activated autophagy beyond basal levels in A375 cells, conversion of 
LC3-I to LC3-II (a standard marker of autophagy) was analysed by Western blotting. 
Combined treatment with chloroquine for the final 2 hours of treatment was used to 
prevent degradation of LC3-II in the latter stages of autophagy to provide a more accurate 
indication of autophgaic flux. Results demonstrated THC at concentrations of 4.5 µM or 5 
µM induced increased levels of LC3-II in the presence of chloroquine compared to cells 
treated with either THC or chloroquine alone, demonstrating that THC is able to activate 
autophagy  (Figure 3.9). Furthermore, RNAi-mediated knockdown of Mcl-1 in A375 cells 
enhanced THC-induced LC3-II levels in the presence of chloroquine compared to the same 
treatment in cells transfected with ctrl siRNA (Figure 3.9 B). To confirm THC treatment 
resulted in apoptosis in A375 cells, the levels of caspase 3 cleavage (a downstream marker of 
both extrinsic and intrinsic apoptosis) were analysed by Western blotting. Results 
demonstrated THC at concentrations of 4.5 µM or 5 µM induced a modest increase in 
cleavage of caspase 3 compared to untreated cells in all cases (Figure 3.9). Additionally, 
RNAi-mediated knockdown of Mcl-1 in A375 cells resulted in substantially increased levels of 
Cleaved Caspase 3 which were further increased by THC treatment suggesting increased 
sensitivity of A375 cell to THC in the absence of Mcl-1. 
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Figure 3.9: RNAi-mediated knockdown of Mcl-1 enhances THC-induced autophagy. (A) Western blot for Mcl-1, 
LC3-I/LC3-II, Cleaved Caspase 3 and ß-actin in A375 cells treated with THC for 24 hours in the presence or 
absence of CQ for the final 2 hours of treatment (B) Each bar represents LC3-II band intensity normalised to β-
actin band intensity (LC3-II/β-actin) for each treatment condition, and expressed relative to the mean of each 
individual experiment across multiple experiments (mean ± SD, n=3). Statistics were acquired using one way 
ANOVA with Dunnett post-hoc test, * p< 0.05 comparing drug treatments shown relative to untreated 
melanoma cells for each siRNA condition alone. 
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To further assess the underlying effects of pro-death induced autophagy with THC 
after Mcl-1 knockdown in A375 cells, the pro-survival autophagy inducing agent bortezomib 
was used to evaluate its effect on the inhibition of cell viability, and the induction of caspase 
3 cleavage and LC3-II induction. In line with THC treatment, results also demonstrated 
treatment of cells with bortezomib for 24 hours inhibited A375 cell viability, which was 
further enhanced by RNAi-mediated knockdown of Mcl-1 (Figure 3.10). However, in contrast 
to THC, bortezomib-induced inhibition of cell viability was not prevented by the combined 
treatment with chloroquine (Figure 3.10). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: RNAi-mediated knockdown of Mcl-1 enhances bortezomib-induced-inhibition of A375 cell 
viability, which is not prevented by combined treatment with chloroquine. Relative viability of A375 cells 
following transfection with control siRNA (Ctrl siRNA) or Mcl-1 siRNA for 24 hr and subsequent treatment for 24 
hours with 10 or 50nM Bort either alone or in combination with 10µM CQ. Each bar is relative to untreated 
melanoma cells for each siRNA condition (mean +/- SEM, n=3). Statistics were acquired using one way ANOVA 
with Dunnett post-hoc test, * p< 0.05, ** p< 0.01, *** p<0.001 comparing drug treatments shown relative to 
untreated melanoma cells for each siRNA condition alone. 
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Western blotting also confirmed bortezomib treatment resulted in increased LC3-II 
expression; however, this was not further enhanced by knockdown of Mcl-1. Increased 
apoptosis was also observed in response to bortezomib treatment and this was enhanced by 
RNAi-mediated knockdown of Mcl-1. Treatment with bortezomib also resulted in an increase 
in Mcl-1 levels in both Ctrl siRNA and Mcl-1 siRNA transfected cells (Figure 3.11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              
 
 
 
 
 
 
 
Figure 3.11: Bortezomib treatment induces autophagy which is not enhanced by RNAi-mediated knockdown 
of Mcl-1. (A) Western Mcl-1, LC3-I/LC3-II, Cleaved Caspase 3 and ß-actin in A375 cells treated with Bort for 8 
hours in the presence or absence of CQ for the final 2 hours of treatment. (B) Each bar represents 3 replicates 
of LC3-II band intensity normalised to β-actin band intensity (LC3-II/β-actin) for each treatment condition, 
expressed relative to the mean of each individual experiment across multiple experiments (mean ± SD, n = 3).  
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3.2.6: Effect of Mcl-1S over-expression on A375 induced inhibition of cell viability and 
induction of autophagy   
 
In order to determine whether inhibition of total Mcl-1 or just Mcl-1L alone is able to 
promote cell death and autophagy as well as enhance the observed effects of THC on these 
processes, expression of Mcl-1S was modulated in BRAF mutated A375 melanoma cells. 
Approximately 50% inhibition of A375 cell viability was observed with over-expression of 
Mcl-1S alone (data not shown) and although THC significantly inhibited the viability of A375 
cells transfected with both control pcDNA4 and Mcl-1S, there was however, no overall 
increased effect of Mcl-1S over expression on THC-induced inhibition of cell viability (Figure 
3.12). Results also demonstrated combined treatment of THC with CQ for 24 hours 
prevented reduction of cell viability (Figure 3.12).  
 
 
 
  
 
 
 
 
 
 
 
Figure 3.12: THC-induced inhibition of A375 cell viability is not enhanced by Overexpression of Mcl-1S. 
Relative viability of A375 cells transfected for 24 hrs with pcDNA4 empty vector or pcDNA 3.1-Mcl-1Ss and 
treated subsequently with 4.5 µM or 5 µM THC either alone or in combination with 10 µM CQ. Each bar is 
relative to untreated melanoma cells for each siRNA condition (mean +/- SEM, n=3). Statistics were acquired 
using one way ANOVA with Dunnett post-hoc test, * p < 0.05, ** p < 0.01, *** p <0.001 comparing drug 
treatments shown relative to untreated melanoma cells for each DNA transfection condition alone.  
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Interestingly unlike the effects derived by RNAi-mediated knockdown of Mcl-1, over-
expression of Mcl-1 S did not increase THC-induced LC3-II expression (Figure 3.13). In fact 
the data suggests over-expression of Mcl-1S blocked induction of autophagy in response to 
THC indicating an inhibitory role for Mcl-1S in THC-induced autophagy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: Overexpression of Mcl-1S does not enhance THC-induced autophagy. Western blot for Mcl-1L, 
Mcl-1S, LC3-I/LC3-II, Cleaved Caspase 3 and ß-actin in A375 cells transfected for 24 hrs with pcDNA4 empty 
vector or pcDNA 3.1-Mcl-1S and treated subsequently with THC (4.5 µM or 5 µM) for 24 hours in the presence 
or absence of CQ (10 µM) for the final 2 hours of treatment. 
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3.3: Discussion  
 
Results from this chapter suggest that activating mutations in BRAF result in 
increased expression of anti-apoptotic Mcl-1L and pro-apoptotic Mcl-1S in vitro. RT-PCR of 
the gene encoding Mcl-1 revealed a significant increase in Mcl-1L, but not Mcl-1S, mRNA 
expression in melanoma cell lines compared to primary melanocytes, with the highest 
expression of Mcl-1L observed in melanoma cells bearing mutant BRAF
V600E
.  
Immunocytochemistry of FFPE melanoma cells confirmed total Mcl-1 protein expression was 
greater in melanoma cells bearing a BRAF
V600E
 mutation compared to expression in BRAF
WT
 
cells however, this approach was not suitable for the detection of splice variant expression. 
Furthermore no correlation was identified in a small panel of patient tumours with 
BRAF/NRAS mutated or BRAF wild-type tumours.  
Western blotting using an antibody to detect both Mcl-1L and Mcl-1S showed a 
significantly higher level of Mcl-1L expression in BRAF mutated melanoma cell lines 
compared to expression in BRAF wild-type cells supporting the increased mRNA levels found 
by RT-PCR for Mcl-1L. Increased expression of Mcl-1S protein was also detected, however 
this was only detectable in BRAF mutated cell lines. Mcl-1 has a relatively short half-life and 
is tightly regulated by the proteasome, however it has been suggested that the stability of 
Mcl-1 protein is potentially increased by ERK-dependent phosphorylation of the Mcl-1 PEST 
domain at site Threonine
163
 which could account for the resulting increased expression of 
both Mcl-1L and Mcl-1S protein observed (Domina, Vrana et al. 2004). These data support 
previous observations (Zhai, Jin et al. 2008) suggesting that high expression of anti-apoptotic 
Mcl-1 in advanced melanoma promotes resistance to chemotherapy-induced apoptosis. 
Wild-type CHL-1 cells over-expressing BRAF
V600E
 also showed a significant increase in the 
expression of Mcl-1L (as well as an increase in Mcl-1S) compared to those over-expressing 
BRAF
WT
 or untransfected CHL-1 cells. Immunofluorescence also demonstrated a small but 
significant increase in the expression of Mcl-1 following over-expression of BRAF
V600E
 
compared to CHL-1 cells over-expressing BRAF
WT
 providing further evidence for a role of 
mutant BRAF in Mcl-1 expression levels. Interestingly, nuclear expression of Mcl-1 was 
observed in this study which is consistent with previous reports which identified localisation 
of a proteolytic fragment of Mcl-1 to the nucleus resulting in growth inhibition, likely due to 
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an inhibitory interaction with cdk 1 (Jamil, Sobouti et al. 2005). However, whether nuclear 
Mcl-1 has any functional impact in melanoma has yet to be defined. 
RNAi-mediated knockdown of Mcl-1 alone resulted in decreased viability in A375 
cells. This effect was not surprising since previous reports have shown that Mcl-1 is essential 
for melanoma survival, particularly in advanced stage disease (Tang, Tron et al. 1998). 
However, this also presented a weakness in this study as complete knockdown of the Mcl-1 
gene could not be achieved without causing excessive cell death, thereby preventing 
subsequent studies. However despite this limitation, interesting and useful data were 
generated from these findings. Studies using THC and bortezomib revealed both agents 
induced apoptosis as indicated by an increase in Cleaved Caspase 3. Interestingly, treatment 
with bortezomib also increased the levels of Mcl-1 in both Ctrl siRNA and Mcl-1 siRNA 
transfected cells. This is most likely due to inhibition of the proteasome by bortezomib thus 
preventing proteasomal degradation of Mcl-1. Furthermore, results confirmed both THC and 
bortezomib-induced autophagy as indicated by increased LC3-I/LC3-II conversion. RNAi-
mediated knockdown of Mcl-1 resulted in a significant increase in THC and bortezomib-
induced inhibition of A375 viability and interestingly combined treatment of THC with 
chloroquine prevented any loss of THC-induced inhibition of cell viability suggesting 
autophagy is involved in cell death induced by this agent. These data support previous 
findings in glioma and pancreatic cancer which also suggest autophagy is crucial to THC-
induced apoptosis in these cancers (Salazar, Carracedo et al. 2009). No change in the 
reduction of viability was evident in response to dual treatment with bortezomib and 
chloroquine suggesting, in contrast to THC, that autophagy induced by bortezomib is not 
required for bortezomib-induced cell death. Indeed these findings are partially in line with 
previous findings demonstrating a pro-survival function of bortezomib-induced autophagy in 
melanoma, however these studies demonstrated knockdown of key autophagy genes 
(Beclin-1 or Atg7) sensitized BRAF
WT
 cells to bortezomib-induced cell death (Armstrong, 
Corazzari et al. 2011) therefore one would expect a similar effect with dual treatment with 
chloroquine. It is possible that the time course of treatment and the method chosen to 
assess viability changes is not a sensitive enough approach to therefore demonstrate 
sensitisation of melanoma cells to bortezomib-induced cell death in combination with 
chloroquine. Additionally, more recent studies suggesting chloroquine promotes apoptosis 
in melanoma cells through inhibiting the degradation of BH3-only protein p53 upregulated 
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modulators of apoptosis (ie: PUMA) which required far greater concentrations of 
chloroquine (50µM) to impact on the viability of melanoma cells (Lakhter, Sahu et al. 2013). 
However this effect was likely directly through stimulation of pro-apoptosis rather than 
solely through inhibition of pro-survival autophagy. Furthermore, the fact that metastatic 
melanoma A375 cells harbour mutated BRAF
V600E
 may also prevent sensitisation of this cell 
line to bortezomib when used in combination with chloroquine, in line with previous 
observations demonstrating autophagy inhibition is only beneficial in BRAF
WT
 cells 
(Armstrong, Corazzari et al. 2011).  
Studies of Mcl-1 expression demonstrated over-expression of Mcl-1S alone reduced 
viability of A375 melanoma cells to a similar extent to that observed by RNAi-mediated 
knockdown of Mcl-1. Over-expression of Mcl-1S has also been shown to induce apoptosis in 
Chinese hamster ovary (CHO) cells and adenocarcinoma human alveolar basal epithelial 
A549 cells (Bae, Leo et al. 2000, Bingle, Craig et al. 2000) supporting data derived from the 
present study and a pro-apoptotic role for Mcl-1S. It would appear that over-expression of 
Mcl-1S directly induces apoptosis of melanoma, in keeping with findings reported in basal 
carcimona cells in which targeting Mcl-1 pre-mRNA with Mcl-1 antisense morpholino 
oligonucleotides (AMOs) shifted expression towards Mcl-1S and directly induced apoptosis 
(Shieh, Liu et al. 2009). It is therefore most likely that the resulting apoptosis observed 
following Mcl-1S over-expression was due to the antagonising role of Mcl-1S on Mcl-1L, 
which acts in a similar manner to other BH3-only proteins thus inhibiting the anti-apoptotic 
function of Mcl-1 (Bae, Leo et al. 2000; Bingle, Craig et al. 2000). However in contrast to 
RNAi-mediated knockdown of Mcl-1, data reported in this chapter for over-expression of 
Mcl-1S did not show any significant increase in the sensitivity of A375 cells to treatment with 
THC. Additionally Mcl-1S over-expression did not enhance autophagy and in fact appeared to 
prevent autophagy induction by THC in this case. How Mcl-1S prevents THC-induced 
autophagy and still results in cell death in response to this agent (despite autophagy being 
required for THC-induced cell death) remains to be seen, however these data suggest the 
functional effect of total Mcl-1 knockdown may be via loss of Mcl-1L rather than total Mcl-1. 
Although the basis of autophagy abrogation remains unclear it is possible Mcl-1S is able to 
interact with key members of the autophagy pathway perhaps by displacement of Beclin-1 
from its identified binding partners such as Mcl-1L by Mcl-1S. Again however, the 
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mechanisms of this effect have yet to be determined with limited published data on Mcl-1 
splice variants available. 
In summary, data derived from this chapter suggests that activating mutations in 
BRAF result in increased expression of anti-apoptotic Mcl-1L and also Mcl-1S. Additionally, 
these data suggest Mcl-1 is able to inhibit autophagy to some extent, thus supporting the 
hypothesis that Mcl-1 amplification, in addition to prevention of apoptosis, may contribute 
to oncogenesis stimulated by the inhibition of Beclin-1-depedant autophagy. This effect 
could potentially function in addition to other potential cancer promoting functions, such as 
a recently reported role for localisation of an amino-terminally truncated isoform of Mcl-1 
into the mitochondrial matrix to facilitate mitochondrial fusion, ATP production, membrane 
potential, respiration and potentially control survival of cancer cells (Perciavalle, Stewart et 
al. 2012). Enhanced sensitivity of melanoma cells with Mcl-1 knockdown in these findings 
suggest specifically targeting Mcl-1 (with more specific BH3 mimetics for example) may 
represent an alternative therapeutic approach in combination with novel therapeutics 
shown to induce both cytotoxic autophagy and apoptosis like THC as well as pro-survival 
autophagy induced bortezomib. Furthermore, targeting Mcl-1 pre-mRNA with Mcl-1 
antisense morpholino oligonucleotides (AMOs) or other alternative splicing inducing agents 
may also present an alternative approach to apoptosis induction as a further mechanism to 
exploit for the therapeutic benefit of advanced stage melanoma. 
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3.4: Summary 
  
 
• Mcl-1L but not Mcl-1S mRNA expression is increased in melanoma cells compared to primary 
melanocytes. 
• Mcl-1L but not Mcl-1S mRNA expression is further increased in BRAF
V600E
 mutant melanoma 
cells compared to BRAF
WT 
melanoma cells. 
• Activating mutations in BRAF increase the expression of both Mcl-1L and Mcl-1S in vitro 
• No correlation was identified in a small panel of patient tumours for BRAF/NRAS mutated 
tumours and BRAF wild-type tumours. 
• Mcl-1L is required for the maintenance of melanoma cell viability 
• Mcl-1L expression reduced autophagy and cell death in melanoma cells in response to 
cytotoxic agents THC and bortezomib.  
• Over-expression of pro-apoptotic Mcl-1S alone reduced viability of A375 melanoma but did 
not enhance autophagy or cell death in response to THC.  
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4.1: Introduction 
 
  The use of cannabinoids in medicine has been applied for many centuries however, 
since the chemotherapeutic potential of cannabinoids was first suggested in glioma in 1998 
(Sánchez, Galve-Roperh et al. 1998) extensive research into the medicinal application of 
these agents has sparked rekindled interest for their use in the treatment of cancer. 
Arguably the tumour type which has undergone the most intensive research for the 
chemotherapeutic action of cannabinoids is glioma (Duntsch, Divi et al. 2006; Sánchez, de 
Ceballos et al. 2001; Sánchez, Galve-Roperh et al. 1998; Velasco, Carracedo et al. 2007), 
revealing several signal transduction pathways triggered by cannabinoids which are 
activated through stimulation of specific cannabinoid receptors. The accumulation of 
ceramide through CB1 has been suggested as the likely contender responsible for cell death 
induced by cannabinoids, particularly THC, in glioma (Gómez del Pulgar, Velasco et al. 2002). 
Additionally, strong evidence exists for autophagy being a key player in this process, thought 
to be activated by the eIF2α axis of the ER stress process and increased expression of the 
stress-regulated protein p8 and TRB3, and Akt inhibition resulting in autophagy induction 
through mTOR inhibition and ultimately cell death (Carracedo, Gironella et al. 2006; 
Carracedo, Lorente et al. 2006; Salazar, Carracedo et al. 2009; Salazar, Carracedo et al. 
2009). However, although preliminary studies with cannabinoids have been undertaken in 
melanoma (Blázquez, Carracedo et al. 2006; Kenessey, Bánki et al. 2012; Scuderi, Cantarella 
et al. 2011; Zhao, Yang et al. 2012) there are limited research available as to the potential for 
THC to treat this disease or whether a similar cytotoxic process occurs.  
  The potential for cannabinoid action in melanoma was first speculated by the 
observation that both cannabinoid receptors CB1 and CB2 are up-regulated in melanoma in 
vitro compared to primary melanocytes (Blázquez, Carracedo et al. 2006). Activation of these 
receptors inhibited tumour growth, angiogenesis, and metastasis as well as promoting the 
induction of apoptosis, suggesting that CB activation by a cannabinoid such as THC could 
have similar effects (Blázquez, Carracedo et al. 2006). Prevention of angiogenesis with 
cannabinoids has also been further assessed in the context of cannabinoids (Blázquez, 
Casanova et al. 2003; Casanova, Blázquez et al. 2003). Several mechanisms suggest 
angiogenesis prevention including, inhibition of vascular endothelial cell migration and 
impacts on cell survival, as shown by altered blood vessel morphology and decreased 
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expression of pro-angiogenic factors (vascular endothelial growth factor (VEGF and 
angiopoietin-2) as well as the expression of matrix metalloproteinase-2 in melanoma 
tumours further supporting the potential therapeutic efficacy for THC and other 
cannabinoids for melanoma (Blázquez, Casanova et al. 2003; Casanova, Blázquez et al. 
2003).  CB receptors are usually expressed differentially with CB1 being expressed more 
typically in the central nervous system and CB2 expressed in the immune system (Galiègue, 
Mary et al. 1995; Sarafian, Montes et al. 2008)) with increased expression of both receptors 
reported in a variety of cancers (Sarfaraz, Afaq et al. 2005; Sarfaraz, Adhami et al. 2008; Xu, 
Liu et al. 2006), including melanoma   
Results from the previous chapter revealed that treatment of A375 metastatic 
melanoma cells with THC results in autophagy induction and cell death. The importance of 
autophagy in THC-induced cell death in glioma is clear as abrogation of this pathway 
completely prevents cell death in response to THC (Salazar, Carracedo et al. 2009). 
Interestingly studies in glioma have found the autophagy induced in response to THC is via a 
non-canonical autophagic pathway which is independent of Beclin-1 activity (Salazar, 
Carracedo et al. 2009). The aims of this chapter were therefore to; verify autophagy 
induction in response to THC in a panel of metastatic melanoma cell lines; determine the 
contribution of autophagy to THC-induced cell death as well as identify the molecular 
pathway responsible for cell death; identify similarities and differences between THC-
induced molecular events in melanoma with those reported in glioma; and finally, to 
compare the role of autophagy in THC-induced cell death with that of canonical autophagy 
induced in response to bortezomib.  
 
 
 
 
 
 
 
 
 92 
 
4.2: Results 
 
4.2.1: THC induces autophagy in melanoma cells in vitro 
  
  Observations from the previous chapter revealed induction of autophagy in 
response to THC in A375 cells. In order to confirm THC-induced autophagy in melanoma cells 
in vitro, conversion of LC3-I to LC3-II was analysed by Western blotting in a panel of 
metastatic melanoma cell lines (A375, CHL-1 and SKMEL-28) (Figure 4.1 A, B, C respectively), 
and following combined treatment with chloroquine to prevent LC3-II degradation in the 
latter stages of autophagy, hence providing a more accurate indication of LC3-II conversion 
levels. The induction of autophagy by THC treatment was confirmed in all tested cell lines at 
optimised concentrations of 4.5 µM or 5 µM respectively by the observation of increased 
LC3-II levels compared to control untreated cells. Additionally autophagy induction was 
assessed by fluorescence microscopy in A375 or CHL-1 cells stably expressing mRFP-GFP-LC3. 
Autophagy induction and flux is indicated by the presence of autophagosomes represented 
as distinct green/yellow puncta and autolysosomes represented as red puncta. Results 
clearly demonstrated THC-induced autophgaic flux in this context in both A375 and CHL-1 
cells compared to control untreated cells (Figure 4.1 D, E). 
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Figure 4.1: THC induces autophagy in melanoma cells in vitro. Western blot for LC3-I/LC3-II and ß-actin in (A) 
A375, (B) SKMEL-28 and (C) CHL-1 cells treated with 4.5 or 5 µM THC for 24 hours in the presence or absence of 
10 µM CQ for the final 2 hours of treatment. Densitometric analysis representing LC3-II expression relative to 
β-actin loading control is given above each treatment condition. The data expressed are a combination of LC3-
II/β-actin normalised relative to the mean of one experiment. Representative fluorescence microscopy from 3 
replicate experiments for autophagosome (green/yellow) and autolysosome (red) mRFP-GFP-LC3 puncta in (D) 
A375 and (E) CHL-1 cells treated with 5 µM THC for 18 hours (scale bar represents a length of 20 µm). 
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4.2.2: THC-induced cell death is prevented when autophagy is deficient  
 
Previous studies have shown that autophagy is required for cell death in response to 
THC in other cancer types (Salazar, Carracedo et al. 2009; Shrivastava, Kuzontkoski et al. 
2011). As such, in order to ascertain whether the autophagy induced by THC is crucial for the 
induction of cell death in melanoma, RNAi-mediated knockdown of Atg7 (an essential 
autophagy gene) was achieved by reverse transfection. Treatment with THC for 24 hours 
reduced viability of metastatic melanoma cell lines (A375, CHL-1), which was prevented by 
Atg7 knockdown or treatment with chloroquine (Fig 4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: RNAi-mediated knockdown of Atg7 prevents THC-induced inhibition of melanoma cell viability. 
Relative viability of melanoma cell lines (A) A375 and (B) CHL-1 following transfection with control siRNA (Ctrl 
siRNA) or Atg7 siRNA for 24 hours and subsequent treatment for 24 hours with 4.5 µM or 5 µM THC in the 
presence or absence of 10 µM CQ. Each bar is relative to untreated melanoma cells for each siRNA condition 
(mean +/- SEM, n=3). Statistics were acquired using one way ANOVA with Dunnett post-hoc test, ** p< 0.01 
*** p< 0.001 comparing drug treatments relative to untreated melanoma cells for each siRNA condition.  
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To confirm THC-induced autophagy was prevented by either Atg7 knockdown or co-
treatment with chloroquine, conversion of LC3-I to LC3-II was analysed by Western blotting. 
The induction of autophagy by THC treatment was confirmed in both A375 and CHL-1 cells 
transfected with Ctrl siRNA by the increased LC3-II levels observed compared to control 
untreated cells (Figure 4.3 A and 4.4 A), which was significant following treatment with 5 µM 
THC in combination with chloroquine in both A375 and CHL-1 cells compared to cells treated 
with chloroquine alone. Although some LC3-II accumulated in untreated Atg7 knockdown 
cells compared to untreated Ctrl siRNA cells, RNAi-mediated knockdown of Atg7 prevented 
significant autophagy induction by THC as shown by the non-significant increase in the levels 
of LC3-II after treatment with THC compared to control untreated cells and the equal levels 
of LC3-II observed in response to combined treatment with chloroquine (Figure 4.3 B).  
To determine whether autophagy deficiency prevented THC-induced cell death and if 
the cell death observed was apoptosis, levels of Cleaved Caspase 3 were analysed by 
Western blotting. THC treatment resulted in increased Cleaved Caspase 3 in both A375 and 
CHL-1 cells following treatment with 4.5 µM or 5 µM concentrations compared to little or no 
expression in untreated cells this indicating increased apoptosis in response to THC (Figures 
4.3 and 4.4). While RNAi-mediated knockdown of Atg7 in CHL-1 cells resulted in increased 
caspase 3 cleavage, THC treatment did not however, promote caspase 3 cleavage in the 
absence of Atg7 knockdown in either cell line (Figure 4.4). 
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Figure 4.3: RNAi-mediated knockdown of Atg7 prevents autophagy and apoptosis induced by THC. (A) 
Western blot for Atg7, LC3-I/LC3-II, Cleaved Caspase 3 and ß-actin in A375 cells treated with 4.5 or 5 µM  THC 
for 24 hours in the presence or absence of 10 µM CQ for the final 2 hours of treatment following transfection 
with control siRNA (Ctrl siRNA) or Atg7 siRNA for 24 hours. (B) Each bar represents 3 replicates of LC3-II band 
intensity normalised to β-actin band intensity (LC3-II/β-actin) for each treatment condition, and expressed 
relative to the mean of each individual experiment (mean ± SD, n = 3). Statistics were acquired using one way 
ANOVA with Dunnett’s post-hoc test, * p< 0.05 comparing drug treatments to either control DMSO or 
combined treatment with CQ for each siRNA condition.  
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Figure 4.4: RNAi-mediated knockdown of Atg7 prevents autophagy and apoptosis induced by THC. (A) 
Western blot for Atg7, LC3-I/LC3-II, Cleaved Caspase 3 and ß-actin in CHL-1 cells treated with 4.5 or 5 µM THC 
for 24 hours in the presence or absence of 10 µM CQ for the final 2 hours of treatment following transfection 
with control siRNA (Ctrl siRNA) or Atg7 siRNA for 24 hours. (B) Each bar represents 3 replicates of LC3-II band 
intensity normalised to β-actin band intensity (LC3-II/β-actin) for each treatment condition, and expressed 
relative to the mean of each individual experiment (mean ± SD, n = 3). Statistics were acquired using one way 
ANOVA with Dunnett’s post-hoc test, * p< 0.05 comparing drug treatments to either control DMSO or 
combined treatment with CQ for each siRNA condition.   
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  The effect of Atg7 knockdown on bortezomib-induced inhibition of cell viability, 
caspase 3 cleavage and LC3-II induction was also evaluated in A375 and CHL-1 metastatic 
melanoma cells in order to compare pro-survival autophagy induced by bortezomib with 
pro-death autophagy activated by THC. In line with THC treatment, results demonstrated 
treatment of cells with bortezomib for 24 hours inhibited melanoma cell viability. RNAi-
mediated knockdown of Atg7 or treatment with chloroquine, in contrast to THC, however, 
did not effect the inhibition of cell viability in response to bortezomib (Figure 4.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Bortezomib-induced inhibition of melanoma cell viability, is not prevented by Atg7 knockdown or 
combined treatment with Chloroquine. Relative viability of melanoma cell lines (A) A375 and (B) CHL-1 
following transfection with control siRNA (Ctrl siRNA) or Atg7 siRNA for 24 hours and subsequent treatment for 
24 hours with 10 or 50 nM bortezomib either alone or in combination with 10 µM CQ. Each bar is relative to 
untreated melanoma cells for each siRNA condition (mean +/- SEM, n=3).Statistics were acquired using one 
way ANOVA with Dunnett post-hoc test, ** p< 0.01, *** p< 0.001 comparing drug treatments to untreated 
melanoma cells for each siRNA condition. 
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Western blotting also confirmed bortezomib treatment resulted in increased LC3-II 
expression in both A375 and CHL-1 cells which was partially prevented by Atg7 knockdown, 
however these data did not reach statistical significance. RNAi-mediated knockdown of Atg7 
also increased bortezomib-induced apoptosis, as indicated by increased expression of 
Cleaved Caspase 3 (Figures 4.6 and 4.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Bortezomib-induced autophagy and apoptosis is not prevented by RNAi-mediated knockdown of 
Atg7 in A375 cells. (A) Western blot for Atg7, LC3-I/LC3-II , Cleaved Caspase 3 and ß-actin in A375 cells treated 
with 10 or 50 nM Bortezomib (Bort) for 8 hours in the presence or absence of 10 µM CQ for the final 2 hours of 
treatment following transfection with control siRNA (Ctrl siRNA) or Atg7 siRNA for 24 hours. (B) Each bar 
represents 3 replicates of LC3-II band intensity normalised to β-actin band intensity (LC3-II/β-actin) for each 
treatment condition, and expressed relative to the mean of each individual experiment (mean ± SD, n = 3).   
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Figure 4.7: Bortezomib-induced autophagy and apoptosis is not prevented by RNAi-mediated knockdown of 
Atg7 in CHL-1 Cells. (A) Western blot for Atg7, LC3-I/LC3-II , Cleaved Caspase 3 and ß-actin in CHL-1 cells 
treated with 10 or 50 nM Bortezomib (Bort) for 8 hours in the presence or absence of 10 µM CQ for the final 2 
hours of treatment following transfection with control siRNA (Ctrl siRNA) or Atg7 siRNA for 24 hours. (B) Each 
bar represents 3 replicates of LC3-II band intensity normalised to β-actin band intensity (LC3-II/β-actin) for each 
treatment condition, and expressed relative to the mean of each individual experiment (mean ± SD, n = 3).   
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4.2.3: THC-induced cell death is dependent on a class III PI3K, Beclin-1 
 
It has been previously reported that the presence of functional Beclin-1 is not  
essential for THC to activate autophagy and cell death (Salazar, Carracedo et al. 2009). To 
determine whether this is the case in melanoma and to also provide further evidence for the 
role of autophagy in THC-induced cell death, RNAi-mediated knockdown of Beclin-1 was 
achieved by reverse transfection. Treatment with THC for 24 hours reduced viability of A375 
and CHL-1 cells, however, unlike in studies of glioma Beclin-1 knockdown prevented THC-
induced inhibition of cell viability as did treatment with chloroquine (Fig 4.8).  
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Figure 4.8: RNAi-mediated knockdown of Beclin-1 prevents THC-induced inhibition of melanoma cell viability. 
Relative viability of melanoma cell lines (A) A375 and (B) CHL-1 following transfection with control siRNA (Ctrl 
siRNA) or Beclin-1 siRNA for 24 hour and subsequent treatment  for 24 hours with 4.5 µM or 5 µM THC in the 
presence or absence of 10 µM CQ. Each bar is relative to untreated melanoma cells for each siRNA condition 
(mean +/- SEM, n=3). Statistics were acquired using one way ANOVA with Dunnett post-hoc test, * p< 0.05 *** 
p< 0.001 comparing drug treatments shown relative to untreated melanoma cells for each siRNA condition. 
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THC-induced autophagy was confirmed in each cell line following transfection with Ctrl 
siRNA which were subsequently treated with 4.5 or 5 µM THC, as evidenced by increased 
LC3-II levels compared to control untreated cells (Figures 4.9 and 4.10). Furthermore, the 
increased levels of LC3-II were significant for A375 cells treated with 4.5 µM and 5 µM THC in 
combination with chloroquine compared to A375 cells treated with chloroquine alone. 
Interestingly, although RNAi-mediated knockdown of Beclin-1 prevented THC-induced 
autophagy in CHL-1 cells (Figure 4.10), this effect was only apparent in A375 cells in response 
to treatment with THC at 5 µM concentrations (Figure 4.9).  
To further verify autophagy deficiency prevented THC-induced cell death caspase 3 
cleavage was analysed by Western blotting. THC treatment (with 4.5 or 5 µM 
concentrations) resulted in increased expression of Cleaved Caspase 3 in both A375 and CHL-
1 compared to untreated cells indicating increased apoptosis (Figures 4.9 and 4.10). Similarly 
to Atg7 knockdown, RNAi-mediated knockdown of Beclin-1 in CHL-1 cells resulted in 
increased caspase 3 cleavage however this was not increased by THC treatment in either 
CHl-1 or A375 cells in the presence of Beclin-1 knockdown (Figure 4.10).  
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Figure 4.9: RNAi-mediated knockdown of Beclin-1 prevents apoptosis but not autophagy induced by THC. (A) 
Western blot for Beclin-1, LC3-I/LC3-II, Cleaved Caspase 3 and ß-actin in A375 cells treated with 4.5 or 5 µM  
THC for 24 hours in the presence or absence of 10 µM CQ for the final 2 hours of treatment following 
transfection with control siRNA (Ctrl siRNA) or Beclin-1 siRNA for 24 hours. (B) Densitometric analysis 
representing LC3-II expression relative to β-actin loading control. Each bar represents 3 replicates of LC3-II 
band intensity normalised to β-actin band intensity (LC3-II/β-actin) for each treatment condition, and 
expressed relative to the mean of each individual experiment (mean ± SD, n = 3). Statistics were acquired using 
one way ANOVA with Dunnett post-hoc test, * p< 0.05, ** p< 0.01, *** p< 0.001 comparing drug treatments 
shown to either control DMSO or combined treatment with CQ for each siRNA condition.  
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Figure 4.10: RNAi-mediated knockdown of Beclin-1 prevents autophagy and apoptosis induced by THC. (A) 
Western blot for Beclin-1, LC3-I/LC3-II, Cleaved Caspase 3 and ß-actin in CHl-1 cells treated with 4.5 or 5 µM  
THC for 24 hours in the presence or absence of 10 µM CQ for the final 2 hours of treatment following 
transfection with control siRNA (Ctrl siRNA) or Beclin-1 siRNA for 24 hours. (B) Each bar represents 3 replicates 
of LC3-II band intensity normalised to β-actin band intensity (LC3-II/β-actin) for each treatment condition, and 
expressed relative to the mean of each individual experiment (mean ± SD, n = 3). Statistics were acquired using 
one way ANOVA with Dunnett post-hoc test, * p< 0.5 comparing drug treatments shown to either control 
DMSO or combined treatment with CQ for each siRNA condition.  
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The effect of Beclin-1 knockdown on bortezomib-induced inhibition of cell viability, 
caspase 3 cleavage and LC3-II induction was again evaluated in metastatic melanoma cell 
lines A375 and CHL-1 to compare pro-survival autophagy induced by bortezomib with THC-
induced autophagy. In line with THC treatment, results also demonstrated treatment of cells 
with bortezomib for 24 hours inhibited cell viability of both cell lines. RNAi-mediated 
knockdown of Beclin-1, in contrast to THC, did not however, prevent bortezomib-induced 
inhibition of cell viability (Figure 4.11). Additionally, combined treatment with chloroquine 
did not effect bortezomib-induced inhibition of cell viability with or without knockdown of 
Beclin-1 (Figure 4.11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: bortezomib-induced inhibition of melanoma cell viability, is not prevented by Beclin-1 
knockdown or combined treatment with Chloroquine.  Relative viability of melanoma cell lines (A) A375 and 
(B) CHL-1 following transfection with control siRNA (Ctrl siRNA) or Beclin-1 siRNA for 24 hours and subsequent 
treatment for 24 hours with 10 or 50 nM bortezomib either alone or in combination with 10 µM CQ. Each bar is 
relative to untreated melanoma cells for each siRNA condition (mean +/- SEM, n=3). Statistics were acquired 
using one way ANOVA with Dunnett post-hoc test, * p< 0.05, ** p< 0.01, *** p< 0.001 comparing drug 
treatments shown to untreated melanoma cells for each siRNA condition. 
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  Western blotting also confirmed bortezomib treatment resulted in increased LC3-II 
expression in both A375 and CHL-1 cells (although not to significant levels in CHL-1 cells) 
while Beclin-1 knockdown had no inhibitory effects on LC3-II expression (Figures 4.12 and 
4.13). Increased apoptosis indicated by the levels of Cleaved Caspase 3 was also observed in 
response to bortezomib treatment of both cell lines, and was noticeably enhanced by RNAi-
mediated knockdown of Beclin-1 in A375 cells followed by treatment with 10nM bortezomib 
(Figures 4.12 and 4.13). Additionally RNAi-mediated knockdown of Beclin-1 alone induced 
increased levels of Cleaved Caspase 3 (Figures 4.12 and 4.13).  
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Figure 4.12: Bortezomib treatment induces autophagy and apoptosis in melanoma cells which is not 
prevented by RNAi-mediated knockdown of Beclin-1. (A) Western blot for Beclin-1, LC3-I/LC3-II , Cleaved 
Caspase 3 and ß-actin in A375 cells treated with 10 or 50 nM Bortezomib (Bort) for 8 hours in the presence or 
absence of 10 µM CQ for the final 2 hours of treatment following transfection with control siRNA (Ctrl siRNA) or 
Beclin-1 siRNA for 24 hours. (B) Each bar represents 3 replicates of LC3-II band intensity normalised to β-actin 
band intensity (LC3-II/β-actin) for each treatment condition, and expressed relative to the mean of each 
individual experiment (mean ± SD, n = 3). Statistics were acquired using one way ANOVA with Dunnett post-hoc 
test ** p< 0.01 *** p< 0.001 comparing drug treatments shown to either control DMSO or combined treatment 
with CQ for each siRNA condition.  
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Figure 4.13: Bortezomib treatment induces autophagy and apoptosis in melanoma cells which is not 
prevented by RNAi-mediated knockdown of Beclin-1. (A) Western blot for Beclin-1, LC3-I/LC3-II , Cleaved 
Caspase 3 and ß-actin in CHL-1 cells treated with 10 or 50 nM Bortezomib (Bort) for 8 hours in the presence or 
absence of 10 µM CQ for the final 2 hours of treatment following transfection with control siRNA (Ctrl siRNA) or 
Beclin-1 siRNA for 24 hours. (B) Each bar represents 3 replicates of LC3-II band intensity normalised to β-actin 
band intensity (LC3-II/β-actin) for each treatment condition, and expressed relative to the mean of each 
individual experiment (mean ± SD, n = 3). 
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4.2.4: Validation for the role of Beclin-1 in canonical autophagy in melanoma cell lines 
 
In normal tissues, Beclin-1 is required for canonical/starvation induced autophagy 
(Liang, Jackson et al. 1999; Pattingre, Tassa et al. 2005). However results from these studies 
reveal autophagy induction in A375 cells in response to both THC and bortezomib even in 
the absence of this protein. The reasons for this are unclear, however the chosen siRNA’s 
may have off target effects which may have resulted in the unexpected findings observed. In 
order to confirm the role of Beclin-1 in canonical autophagy, cells were treated with the 
mTOR inhibitor rapamycin (Li, Wu et al. 2013) for 24 hours following Beclin-1 knockdown . 
Combined treatment with chloroquine was again used in the final two hours of treatment to 
provide a more accurate indication of LC3-II conversion levels for each treatment condition. 
Rapamycin treatment resulted in the induction of LC3-II in A375 cells following transfection 
with either control or Beclin-1 siRNA (Figure 4.14), suggesting autophagy induction is stil 
occurring even in the absence of Beclin-1 expression. 
 
 
 
 
 
 
 
 
 
 
 
 111 
 
 
Figure 4.14: RNAi-mediated knockdown of Beclin-1 prevents Rapamycin induced autophagy. Western blot for 
Beclin-1, LC3-I/LC3-II, and ß-actin in (A i) A375 cells  (B i) CHL-1 cells treated with 100 nM Rapamycin (Rap) for 
24 hours in the presence or absence of 10 µM CQ for the final 2 hours of treatment following transfection with 
control siRNA (Ctrl siRNA) or Beclin-1 siRNA for 24 hours. (A ii, B ii) Each bar represents LC3-II band intensity 
normalised to β-actin band intensity (LC3-II/β-actin) for each treatment condition, and expressed relative to the 
mean of an individual experiment. 
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4.2.5: Beclin-1 expression in patient tumours  
  
  Results from these studies suggest the requirement of Beclin-1 for the induction of 
cell death in response to THC. Therefore the expression of Beclin-1 was determined in a 
panel of primary melanomas in order to determine the potential efficacy of THC treatment 
in vivo. An immunohistochemical assay was optimised to determine Beclin-1 protein 
expression in formalin-fixed and paraffin-embedded (FFPE) cell pellets derived from 
metastatic the melanoma cell line CHL-1 or in CHL-1 cells stably overexpressing Beclin-1 
(Figure 4.15). Results confirmed increased levels of Beclin-1 in CHL-1 cells overexpressing 
Beclin-1 compared to control CHL-1 cells.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15: Optimisation of Beclin-1 immunohistochemistry. Immunohistochemical analysis of Beclin-1 
expression in formalin-fixed paraffin-embedded cell blocks of untransfected control CHL-1 cells and CHL-1 cells 
over-expressing Beclin-1 (scale bar represents a length of 100 µm). 
 
Primary melanomas derived from 20 patients were subsequently analyzed for the 
expression of Beclin-1 and scored according to the intensity of staining observed where 0 
represents no expression, 1 represents low expression, and 2 represents high expression of 
Beclin-1 (Figure 4.16). Results showed medium to high expression of Beclin-1 in advanced 
melanomas while little or no expression was observed in, two out of three early stage 
tumours. Beclin-1 expression also varied in the analysed normal nevi and no correlation was 
identified between expression in NRAS/BRAF wild-type and mutant tumours (Table 4.1).  
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Figure 4.16: Scoring of Beclin-1 expression in patient tissues. Representative images for scoring of 
immunohistochemical analysis of Beclin-1 expression in formalin-fixed paraffin-embedded patient tissues. 0 
represents no expression (example tumour; MO57) 1 represents low expression (example tumour; MO110) and 
2 represents high expression (example tumour; MO43) (scale bar represents a length of 100 µm). 
 
Table 4.1: Beclin-1 expression in vivo. Analysis of patient derived tissue: 10 naevi (white), 3 early stage 
melanomas (yellow) and 7 advanced stage melanomas (red). Expression of Beclin-1 is indicated as no 
expression, low expression and high expression scored as 0, 1, 2 respectively.  
 
Tumour Beclin-1  
Score 
Disease 
Stage: 
Diagnosis 
Disease Stage: 
Final 
BRAF 
Mutational 
status 
M004 2 Naevus Naevus V600E 
M049 0 Naevus Naevus WT 
M108 0 Naevus Naevus V600E 
M109 1 Naevus Naevus V600E 
M110 1 Naevus Naevus V600E 
M208 0 Naevus Naevus V600E 
M219 2 Naevus Naevus WT 
M220 0 Naevus Naevus V600E 
M222 0 Naevus Naevus V600E 
M053 1 Naevus Naevus V600E 
M057 0 I I WT 
M237 0 I I V600E 
M130 2 I I WT 
M043 2 II III WT 
M074 2 II II WT 
M077 1 II IV V600E 
M137 1 II III WT 
M147 1 II II V600E 
M155 2 II IV V600E 
M060 2 II III V600E 
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4.2.6: THC is less cytotoxic to primary melanocytes compared to melanoma cells 
 
  It has been suggested that THC causes little cytotoxic effect in normal tissue 
revealing specificity for anti-tumour activity with relatively harmless potential side effects for 
surrounding tissues (Chan, Sills et al. 1996; Iversen 2005). As melanoma cells are derived 
from melanocytes the effect of THC on the viability of primary melanocytes was compared 
with the effects on metastatic melanoma cell lines THC-induced Inhibition of cell viability 
was observed in A375 and CHL-1 cells in response to treatment for 24 hrs with 
concentrations of > 4 µM with complete inhibition observed using 7 µM or above, whereas 
concentrations of > 7 µM were required to inhibit the viability of primary melanocytes 
(Figure 4.17).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17: Effect of THC on normal melanocyte cell viability. Relative viability of normal melanocytes 
compared to metastatic melanoma cell lines (A375, CHL-1) in response to 24 hour treatment with increasing 
doses of THC (0,3,4,5,6,7,8,10 µM) or with vehicle control (DMSO). Each bar is the mean +/- SD, n=2. 
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4.2.7: THC-induced cell death of metastatic melanoma cell lines is dependent on the 
activity of caspases   
 
  Data from this chapter demonstrates THC induces cleavage of caspase 3 in A375 
and CHL-1 cells. However, whether the resulting inhibition of cell viability and observed cell 
death is due entirely to the activity of caspases required confirmation. Therefore, in order to 
determine whether THC-induced cell death was caspase-dependant, A375 and CHL-1 cells 
were treated with the pan caspase inhibitor ZVAD-fmk either alone or in combination with 
THC. As shown by Figure 4.18, the combined treatment with THC and ZVAD-fmk prevented 
the significant inhibition of cell viability observed by treatment with THC alone in both 
melanoma cell lines (Figure 4.18), thereby confirming THC-induced inhibition of cell viability 
is caspase-dependent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18: THC-induced apoptosis is caspase-dependent. Relative viability of melanoma cells (A) A375 and (B) 
CHL-1) following treatment for 24 hours with 5 µM THC in the presence or absence of 20 µM ZVAD-fmk (ZVAD). 
Each bar is relative to vehicle-treated control melanoma cells (mean +/- SEM, n=3). Statistics were acquired 
using one way ANOVA with Dunnett’s post-hoc test, ** p< 0.01 *** p< 0.001 comparing all treatment 
conditions to untreated cells. 
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4.3: Discussion 
 
Results from this chapter demonstrate THC induces autophagy in a panel of 
melanoma cell lines bearing both mutatant and wild-type BRAF, as confirmed by Western 
blot analysis of LC3-I/II conversion and analysis of autophagic flux by fluorescence 
microscopy. Strong evidence in the literature suggests THC activates autophagy via inhibition 
of PI3K/Akt/mTOR signalling and activation of the elF2α pathway in glioma (Salazar, 
Carracedo et al. 2009), with data from this chapter showing for the first time that THC 
causes autophagy induction in melanoma and leading to the speculation of a similar process 
of autophagy induction to that identified in glioma. Additionally, studies in glioma highlight 
the requirement of autophagy for the cytotoxic effect of THC (Salazar, Carracedo et al. 
2009), and suggest that THC essentially hijacks the autophagy process to promote a cell 
death outcome. Again, results from this chapter confirm similar effects in melanoma cells as 
evidenced by observations in which RNAi-mediated knockdown of  both Atg7 and Beclin-1 
prevented THC-induced inhibition of cell viability and further verified by combined 
treatment wit the lysosomal inhibitor chloroquine (Egger, Huang et al. 2013; Shen, Wang et 
al. 2013). Interestingly increased LC3-I levels were observed in A375 cells transfected with 
Atg 7 siRNA compared to cells transfected Ctrl siRNA however Atg7 knockdown nevertheless 
prevented significant autophagy induction by THC. It is likely that the knockdown of Atg7 has 
resulted in the inhibition of autophagy and therefore prevented autophagic flux and LC3 
degradation, which could also explain why the addition of chloroquine had no effect on LC3 
levels in cells in which Atg7 had been knocked down. Additionally the cell death observed in 
response to THC was likely via apoptosis, as indicated by increased levels of Cleaved Caspase 
3 and the ability of the caspase inhibitor to abrogate THC-induced loss of cell viability.  
In studies of glioma, Beclin-1 was not required for THC-induced cell death leading the 
authors to suggest a non-canonical pro-death autophagic response (Salazar, Carracedo et al. 
2009). Non-canonical autophagic signalling has also been mentioned demonstrated in breast 
cancer in which treatment with resveratrol not only induced cell death but also required a 
Beclin-1-independent autophagy process (Scarlatti, Maffei et al. 2008). However the 
requirement for Beclin-1 in THC-induced cell death in this study reveals noticeable 
differences for the possible underlying molecular events in melanoma cells treated with THC 
compared with studies in glioma. Increasing evidence in the literature supports the induction 
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of intrinsic apoptosis in response to a range of natural and synthetic cannabinoids in which 
several mechanisms are suggested to be involved. There is evidence for multiple cell 
signalling events occurring in different cancer types in response to cannabinoids such as 
increased phosphorylation of BAD, Akt inhibition, increased phosphorylation of ERK and lipid 
raft signalling events (Galve-Roperh, Sánchez et al. 2000; Greenhough, Patsos et al. 2007; 
Salazar, Carracedo et al. 2009; Scuderi, Cantarella et al. 2011) so it is entirely possible for the 
underlying molecular events in melanoma to be specific to this tumour type. However, the 
ultimate outcome in many of these cancers appears to be definitive in that THC ultimately 
induces cell death at clinically achievable doses. It should be noted cell viability assays 
involving analysis of formazan dye products (i.e. MTT/XTT/MTS assays) have several 
limitations when assessing cell death responses to drugs due to underestimations in findings 
attributed, for example, to the presence of cellular superoxides  (Wang, Henning et al. 2010; 
Wang, Yu et al. 2011). As THC has been shown to generate reactive oxygen species in cancer 
cells (Shrivastava, Kuzontkoski et al. 2011) this could result in increased formazan dye 
products being produced indicating the cells are more viable than they are in reality. 
However the supporting Western data indicating increased apoptosis upon THC treatment 
support the findings observed using these assays.  
As further evidence for the requirement of autophagy for THC-induced cell death in 
melanoma, RNAi-mediated knockdown of both Atg7 and Beclin-1 prevented THC-induced 
caspase 3 cleavage in A375 and CHL-1 cells. Two interesting observations occurred from this 
study however. Firstly, knockdown of either Beclin-1 or Atg7 alone in BRAF
WT
 CHL-1 cells 
resulted in a markedly increased level of Cleaved Caspase 3 despite preventing any 
enhancement in response to THC. As autophagy is typically required as a pro-survival 
response in many normal tissues and tumour types including melanoma (Armstrong, 
Corazzari et al. 2011; Wright, McKee et al. 2013; Del Bello, Toscano et al. 2013; Greene, 
Nolan et al. 2013; Periyasamy-Thandavan, Jiang et al. 2008) and basal autophagy levels are 
noticeably lower in BRAF
WT
 compared with BRAF mutated melanoma cell lines (Armstrong, 
Corazzari et al. 2011), this may account for the death observed following knockdown of Atg7 
or Beclin-1 as autophagy may be more essential to CHL-1 cell survival. Secondly, knockdown 
of Beclin-1 in A375 cells did not prevent THC-induced autophagy despite preventing cell 
death in response to THC. The reasons for this observation remain unclear, however 
increasing evidence for alternative roles of Beclin-1 that are independent of autophagy 
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which may account for this effect (a point addressed and described in greater detail in 
proceeding chapters). One possibility could have been a lack of siRNA specificity for the 
Beclin-1 siRNA. As such studies were undertaken in an attempt to validate the role of Beclin-
1 in canonical autophagy in melanoma cell lines using the mTOR inhibitor rapamycin, known 
to require Beclin-1 for autophagy induction (Armstrong, Corazzari et al. 2011; Li, Wu et al. 
2013). Results demonstrated rapamycin induced autophagy beyond basal levels in A375 and 
CHL-1 cells transfected with control siRNA. However, rapamycin was also able to induce 
autophagy in cells transfected with Beclin-1 siRNA. Ultimately these data are hence difficult 
to interpret in terms of Beclin-1’s function in autophagy within these cells in addition to the 
limited number of experiments performed (n=1) however, combined with observations that 
THC and bortezomib can still induce autophagy in the absence of Beclin-1 questions the 
function of this protein in autophagy in A375 and CHL-1 cells.  
Although the increased levels of Cleaved Caspase 3 identified in these studies is a 
reasonable indication for the induction of intrinsic apoptosis in response to THC treatment, 
the possibility of caspase-independent cell death or necrosis (a process suggested to occur 
by cannabinoid treatment (Gustafsson, Wallenius et al. 2013)) could not be ruled out. In 
order to determine whether caspase cleavage is essential for THC-induced cell death use of 
the irreversible pan caspase inhibitor ZVAD-fmk was employed to test its ability to inhibit 
THC-induced inhibition of cell viability. Treatment with ZVAD-fmk partially prevented THC-
induced inhibition of cell viability suggesting the observed cell death is caspase-dependent 
and providing further evidence for intrinsic apoptosis. As THC has also been shown to induce 
anti-proliferative effects through its effects on the cell cycle and which ZVAD-fmk can not 
prevent (Blázquez, Casanova et al. 2003; Blázquez, Carracedo et al. 2006), this  possibility 
can also not be ruled out.  
Although these studies demonstrate the clear cytotoxic effects of THC on melanoma 
cells in vitro, cytotoxicity is nevertheless a matter of concern for many chemotherapeutics 
resulting in limitations including achievable clinical doses which exert a similar effect in vivo 
as to that seen in vitro as well as potentially harmful side effects. Interestingly however, 
cannabinoids display a particularly good drug safety profile in both animal models and 
humans with no observed cytotoxic effects on normal tissues (Chan, Sills et al. 1996; 
Grotenhermen 2003; Iversen 2005). In line with these findings treatment with increasing 
concentrations of THC did not reduce the cell viability of primary melanocytes in response to 
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doses of THC which were shown to significantly inhibit viability of both A375 and CHL-1 cells. 
These observations support previous findings comparing stable melanocyte cell lines melan-
c and Hermes 2b with melanoma cell lines B16 and A375 in which inhibition of melanoma 
cell viability was observed in response to cannabinoids (THC and WIN-55,212-2) but for 
which no significant cytotoxic effect was observed in melanocytes (Blázquez, Carracedo et al. 
2006), albiet using low 1 µM concentrations, far below the maximal dose used in the current 
studies of 10 µM. It was once written by the proclaimed father of toxicology, Paracelsus, 
"Everything is poison. Only the dose makes a thing not a poison" this could therefore be 
adapted in this case in which such a high dose of THC (far beyond that required to induce cell 
death in cancer cells) would ultimately result in non-tumour cell cytotoxic effects.  
As previously discussed, the possibility of tumour cell death induced by autophagy is 
an uncommon and novel occurrence as cancer cells typically induce autophagy as a pro-
survival response to chemotherapies. In order to determine the difference in pro-death 
autophagy induced by THC with a more typical pro-survival autophagic response, 
bortezomib treatment of melanoma cells was compared with the effects of THC on the 
induction of both autophagy and apoptosis. Bortezomib acts through inhibition of the 26S 
proteasome and it is reported to induce apoptosis through ER stress of melanoma cells 
(Corazzari, Lovat et al. 2007; Hill, Martin et al. 2009). Additionally, bortezomib has little to no 
adverse effects on normal melanocytes (Fernandez, Verhaegen et al. 2005; Lovat, Corazzari 
et al. 2008). However, induction of unfolded protein response (UPR) as well as the induction 
of pro-survival autophagy may overcome the cellular stress conditions caused by bortezomib 
(Armstrong, Corazzari et al. 2011). Results from the present study demonstrate bortezomib-
induced inhibition of cell viability is neither abrogated nor enhanced in combination with 
chloroquine suggesting that this event is autophagy independant. Additionally, in contrast to 
previous reports demonstrating Beclin-1 or Atg7 knockdown sensitized BRAF
WT
 cells 
to bortezomib-induced cell death (Armstrong, Corazzari et al. 2011), knockdown of Atg7 and 
Beclin-1 in CHL-1 cells did not enhance inhibition of cell viability in these studies. However, 
knockdown of autophagy genes in CHL-1 cells (particularly Beclin-1) resulted in cell death 
and high levels of Cleaved Caspase 3 levels of which were further increased in response to 
bortezomib supporting the previous suggestion of a pro-survival function of autophagy in 
this cell line. It is possible that limitations in the MTS assay used to assess cell viability meant 
this method was not sensitive enough to determine the differences in cell viability in 
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response to abrogated autophagy. However, it is clear that autophagy is not required for cell 
death in response to bortezomib and confirms the differing role autophagy plays in response 
to different chemotherapeutics.  
It should be noted that, although the underlying molecular events for the 
contribution of Beclin-1 to THC-induced cell death in melanoma have yet to be determined, 
the requirement for Beclin-1 for THC to cause cell death is more conclusive. As such, if 
similar findings were to be found in vivo the expression of Beclin-1 in patient tumours may 
potentially determine the stratification of particular patients for treatment with THC. In 
order to determine this, Beclin-1 expression was assessed in a small cohort of nevi and 
primary melanomas. However, during the timescale of this research results have since been 
published which demonstrate a biphasic expression pattern in melanoma (Sivridis, 
Koukourakis et al. 2011). In essence low expression of Beclin-1 in tumours was associated 
with high breslow depth, ulceration , and increased angiogenesis, whereas high expression 
of Beclin-1 resulted in increased rate of early deaths and metastatic disease (Sivridis, 
Koukourakis et al. 2011). Although the panel studied in this chapter is relatively small, initial 
observations indicate similar findings where expression of Beclin-1 is lost in earlier stage 
disease and some naevi while expression is maintained in more advanced tumours, thus 
supporting the paradoxical role of autophagy in cancer  (Mathew, Karp et al. 2009; White 
and DiPaola 2009; Wu, Coffelt et al. 2012). As such one could speculate maintained Beclin-1 
expression may predict THC responsiveness in vivo. Nevertheless it should be noted that 
expression of Beclin-1 does not necessarily confer functional activity. In summary, data 
derived from this chapter demonstrates THC-induced apoptosis of melanoma cells likely 
depends on autophagy. However a definitive link between autophagy and apoptosis remains 
elusive and further studies are required to discern this link which is the focus of studies in 
subsequent chapters. With promising data derived from clinical trials of sativex (a mixture of 
THC and canibidol) in glioma this research nevertheless enhance our understanding of how 
to exploit autophagy for the clinical benefit of melanoma and the potential use of  
cannabinoids to promote effective cell death.  
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4.4: Summary 
 
• THC induces autophagy in melanoma cells in vitro. 
• THC-induced autophagy is required for cell death.  
• THC-induced cell death is likely mediated via intrinsic apoptosis requiring the activity of 
caspases. 
• Bortezomib-induced cell death is independent of autophagy.  
• Expression of Beclin-1 in a small panel of patient tumours indicates increased expression in 
advanced stage compared to earlier disease stages. 
• THC is relatively in toxic to primary melanocytes.  
 
Table 4.2 Summary for the observed effects of THC and bortezomib treatment on autophagy induction, 
caspase 3 cleavage and inhibition of cell viability in A375 and CHL-1 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell line Treatment Process Dependent 
on Atg7?
Dependent 
on Beclin-1?
A375 THC Autophagy induction Yes No
Caspase 3 cleavage Yes Yes
Inhibition of cell viability Yes Yes
* Bort Autophagy ? partially No
Caspase 3 cleavage
Inhibition of cell viability No No
CHL-1 THC autophagy Yes Yes
Caspase 3 cleavage Yes ?
Loss of viability Yes Yes
* Bort Autophagy induction ? Partially ?
Caspase 3 cleavage
Inhibition of cell viability No No
* Bortezomib induces pro-survival autophagy
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5.1: Introduction 
 
  Results from the previous chapter demonstrated autophagy is apparently required 
for THC-induced cell death of metastatic melanoma cells in vitro, verified both by the 
knockdown of two essential autophagy genes (Beclin-1 and Atg7) and treatment with 
chloroquine. Conversely, bortezomib-induced autophagy in metaststic melanoma cells is pro 
survival. However despite the observed data following knockdown of Atg7, knockdown of 
Beclin-1 did not prevent THC-induced autophagy despite preventing cell death. Beclin-1 
siRNA target specificity was verified using rapamycin thus suggesting an alternative 
mechanism for Beclin-1 in determining the fate of metastatic melanoma cell lines treated 
with THC. As such, investigations of known interactions of Beclin-1 were undertaken to 
further elaborate on potential molecular mechanisms induced by THC involving Beclin-1. 
  In recent years several publications have revealed interacting partners for many 
members of the autophagy pathway including Beclin-1. A vast wealth of information 
revealing potentially crucial protein-protein interactions is readily available in the current 
literature, however pooling of this data can prove taxing by conventional approaches. 
Several bioinformatics tools have become available over the years which allow for accurate 
data mining approaches. One such tool is Cytoscape, an open source bioinformatics software 
platform used for visualizing molecular interaction networks which has multiple functions 
enhanced by the use of specific plugins designed by the scientific community (Shannon, 
Markiel et al. 2003; Yeung, Cline et al. 2008). In essence a plugin is a set of software 
components that adds specific abilities to a larger software application for which several are 
available for the Cytoscape software to advance upon its analytical capabilities (Shannon, 
Markiel et al. 2003). One such plugin used for the visualisation of known protein-protein 
interactions for a protein of interest has been designed by Biological General Repository for 
Interaction Datasets (BioGRID) which gathers constantly updated interaction data for several 
organisms (Homo sapiens included) from several databases; Saccharomyces Genome 
Database, Flybase, GeneDB, TAIR, and Entrez Gene (Chatr-Aryamontri, Breitkreutz et al. 
2013). The data provides several useful pieces of information in addition to the identified 
genetic and protein-protein interactions such as the source of the information, listed by 
publication, as well as the techniques used to obtain the results allowing for further in depth 
analysis of each identified interaction. 
 125 
 
  The overall aim of this chapter was therefore to utilize such software to gain further 
insight into protein-protein interactions for Beclin-1. This information was then further 
advanced by categorising identified interacting proteins into key cellular pathways of 
relevance to the central focus of this thesis, namely autophagy, apoptosis and the cell cycle. 
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5.2: Results 
 
5.2.1: Protein-protein interactions of Beclin-1  
 
Several publications in recent years have revealed the many genetic and protein 
interactions for several key members of the autophagy pathway (Behrends, Sowa et al. 
2010). Beclin-1 is one of such member for which interacting partners have been extensively 
researched (Chang, Nguyen et al. 2010; Chen, Gao et al. 2010; Criollo, Niso-Santano et al. 
2011; Kim, Bennett et al. 2011; Liang, Kleeman et al. 1998; Platta, Abrahamsen et al. 2012; 
Shi and Kehrl 2010; Wagner, Beli et al. 2011; Xu, Liu et al. 2011; Yue, Horton et al. 2002). The 
data mining tool cytoscape was hence used in combination with a plug-in provided by 
BioGRID in order to identify known protein-protein interactions of Beclin-1 and combine all 
known published data of these interactions. A total of 34 known protein-protein interactions 
were identified for Beclin-1 (Figure 5.1). 
 
Figure 5.1: Known protein-protein interactions for Beclin-1. The plot shown represents all direct protein-
protein interactions identified using BioGRID and visualised in cytoscape. 
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5.2.2: Categorization of identified protein-protein interactions of Beclin-1  
 
In order to further evaluate initial findings for known Beclin-1 interacting proteins, all 
identified Beclin-1 protein-protein interactions were categorised according to their biological 
function and subcategorised according to whether they have a positive or negative 
regulatory role in these cellular pathways. Many of the proteins identified fit into categories 
for biological processes relevant to the theme of this thesis, namely those involved in 
autophagy, the cell cycle and apoptosis (Figure 5.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Regulatory functions of known Beclin-1 interacting proteins. Proteins are grouped according to 
their regulatory roles positive (Green) or negative (Red) in several intracellular pathways; Autophagy (Circles), 
Apoptosis (Hexagons), Cell cycle (Squares), Miscellaneous (Misc, Diamonds). 
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Seven identified Beclin-1 interacting proteins were found to have a crucial regulatory 
role in the autophagy pathway. Of these, seven were found to have a positive role in 
autophagy regulation; Ambra 1, PIK3R4, UVRAG, PIK3C3, Atg14 while two were found to 
have a negative role; KIAA0226 (also known as Rubicon) and KIAA0226L (Figure 5.3). 
Individual functions for Beclin-1 interactors key to the regulation of autophagy are outlined 
in Table 5.1. 
 
 
 
 
 
 
Figure 5.3: Autophagy regulatory proteins which interact with Beclin-1. Proteins are grouped according to 
their regulatory roles positive (Green) or negative (Red). 
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Table 5.1: Beclin-1 interacting proteins involved in autophagy regulation 
Identified 
member 
Regulatory 
role 
Function 
Ambra 1 Positive Ambra 1 is a positive regulator of Beclin-1-dependent autophagy (Fimia, 
Stoykova et al. 2007). ULK1 activity releases Ambra 1 from dynein which 
then localizes to the ER and primes autophagosome formation and 
nucleation (Di Bartolomeo, Corazzari et al. 2010). Additionally under normal 
conditions, a pool of Ambra 1 is bound to Bcl-2 at the mitochondria 
preventing its role in autophagy however after autophagy is induced, this 
mitochondrial bound Ambra 1 separates from Bcl-2 and binds to Beclin-1 
further enhancing the induction of autophagy. (Strappazzon, Vietri-Rudan et 
al. 2011) 
Atg14 Positive Atg14 is a specific substrate of the Beclin-1 complex which functions in the 
targeting of this complex to the site of autophagosome formation. Atg14 C 
terminus contains an Barkor/Atg14(L) autophagosome-targeting sequence 
(BATS) domain which preferentially binds to curved membranes containing 
PI(3)P and targets the Beclin-1 complex to the isolation membrane. (Obara 
and Ohsumi 2011) 
KIAA0226 
(Rubicon) 
Negative Rubicon binds to a subpopulation of UVRAG complexes separate to Atg14L 
forming a different Beclin-1 complex (Sun Q 2010). Rubicon was localized at 
the endosome/lysosome and knockdown of Rubicon caused enhancement 
of autophagy, especially at the maturation step, as well as enhancement of 
endocytic trafficking. These data suggest that the Beclin-1-hVps34 complex 
functions in two different steps of autophagy by altering the subunit 
composition. (Matsunaga, Saitoh et al. 2009; Zhong, Wang et al. 2009). 
KIAA0226L  
(RubiconL) 
Negative Functions in the same manner as Rubicon. 
 
 
PIK3C3 Positive Regulatory subunit of the PI3K complex also known as Vps34. Vps34 may 
also regulate membrane trafficking late in the endocytic pathway (Johnson, 
Overmeyer et al. 2006). This protein belongs to the protein kinase Ser/Thr 
protein kinase superfamily. This subunit, part of a complex composed of 
regulatory and catalytic subunits, associates with the phosphatidylinositol 3-
kinase type 3 (PIK3C3) (Zhou, Takatoh et al. 2011). 
PIK3R4 Positive Catalytic subunit of the PI3K complex which is involved in the transport of 
lysosomal enzyme precursors to lysosomes. Belongs to the PI3/PI4-kinase 
family and forms a complex with Ambra 1 and Beclin-1. PIK3C3 is also critical 
for the formation of pre-autophagosomes which are important for 
degradation of large protein aggregates and organelles (Petiot, Ogier-Denis 
et al. 2000). Finally, PIK3C3 is shown to be required for nutrient/amino acid 
mediated activation of mTOR signaling in cultured cells (Zhou, Takatoh et al. 
2011). 
UVRAG Positive Originally identified as a protein related to UV resistance, this protein 
promotes autophagy by activation of the Beclin-1-PI(3)KC3 complex and 
suppresses the proliferation of human colon cancer cells (Liang, Feng et al. 
2007; Iida, Emi et al. 2000). Additionally UVRAG has been found to have a 
role in the maintenance of chromosome stability independent of autophagy 
where it localizes at centrosomes and physically associates with CEP63 
(Knævelsrud H, Ahlquist T et al. 2010; Zhao, Oh et al. 2012). Chromosomal 
aberrations involving this gene are associated with left-right axis 
malformation and mutations in this gene have been associated with colon 
cancer (Iida, Emi et al. 2000). 
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Five identified Beclin-1 interacting proteins were found to have a crucial regulatory 
role in the apoptosis pathway. Of these five, two were found to have a positive role in 
apoptosis regulation; ITCH and TP53P2 and three were found to have a negative role; Bcl-2, 
Bcl-2L1, TNFAIP3 (Figure 5.4). Each of these proteins has been extensively studied and has a 
crucial role in apoptosis regulation for which their individual functions are outlined in Table 
5.2. 
 
 
 
 
 
Figure 5.4: Apoptosis regulatory proteins known to interact with Beclin-1. Proteins are grouped according to 
their regulatory roles positive (Green) or negative (Red) 
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Table 5.2: Beclin-1 interacting proteins involved in apoptosis regulation 
Identified 
member 
Regulatory 
role 
Function 
Bcl-2 Negative The proteins encoded by the Bcl-2 gene family are located at the outer 
mitochondrial membrane, and have been shown to regulate outer 
mitochondrial membrane channel (VDAC) opening. VDAC regulates 
mitochondrial membrane potential, and thus controls the production of 
reactive oxygen species (ROS) and release of cytochrome C by mitochondria, 
both of which are the potent inducers of cell apoptosis. (Tsujimoto and 
Shimizu 2000) 
Bcl-2L1 Negative Same function as Bcl-2. 
ITCH Negative Itch selectively binds and ubiquitinates p73 but not p53; this results in the 
rapid proteasome-dependent degradation of p73. P73 is a member of the 
p53 family of transcription factors and is up-regulated in response to DNA 
damage thus inducing cell cycle arrest and apoptosis (Rossi M 2005). 
TNFAIP3 Positive This gene was identified as a gene whose expression is rapidly induced by 
the tumour necrosis factor (TNF). The protein encoded by this gene is a zinc 
finger protein and ubiquitin-editing enzyme, and has been shown to inhibit 
NF-kappa B activation as well as TNF-mediated apoptosis (Li, Soetandyo et 
al. 2009). The encoded protein, which has both ubiquitin ligase and 
deubiquitinase activities, is involved in the cytokine-mediated immune and 
inflammatory responses. (Li, Soetandyo et al. 2009) 
TP53P2 Positive This gene encodes a member of the ASPP (apoptosis-stimulating protein of 
p53) family of p53 interacting proteins. The protein contains four ankyrin 
repeats and an SH3 domain involved in protein-protein interactions. It is 
localized to the perinuclear region of the cytoplasm, and regulates apoptosis 
and cell growth through interactions with other regulatory molecules 
including members of the p53 family thus acting as a tumour suppressor 
(Nakagawa, Koyama et al 2000; Samuels-Lev, O'Connor et al 2001). 
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Six identified Beclin-1 interacting proteins were found to have a crucial regulatory 
role in the cell cycle pathway. Of these six, five were found to have a positive role in cell 
cycle regulation; PTOV1, SMC3, SEH1L, SMC1A, ZWINT and one was found to have a negative 
role; GSPT1 (Figure 5.5). Each of these proteins is key to the regulation of the cell cycle for 
which their individual functions are outlined in table 5.3. 
 
 
 
 
 
Figure 5.5: Cell cycle regulatory proteins known to interact with Beclin-1. Proteins are grouped according to 
their regulatory roles positive (Green) or negative (Red) 
 
 
 
 
 
 
 
 
 
 
 133 
 
Table 5.3: Beclin-1 interacting proteins involved in cell cycle regulation 
Identified 
member 
Regulatory 
role 
Function 
GSPT1 Negative The GTP protein encoded by this gene belongs to the GTP-binding 
elongation factor family and was first identified from the cDNA library of 
human KB cells (Hoshino, Miyazawa et al. 1989). It is Involved in 
translation termination in response to the termination codons UAA, UAG 
and UGA. Additionally it stimulates the activity of ERF1 and is Involved in 
regulation of mammalian cell growth. (Hoshino, Miyazawa et al. 1989) 
PTOV1 Positive PTOV1 has been shown to promote cell proliferation and as well as 
stimulate entry into the S phase of the cell cycle (Santamaría, Fernández 
et al. 2003). 
SEH1L Positive The protein encoded by this gene is part of a nuclear pore complex, 
Nup107-160. This protein contains WD repeats and shares 34% amino 
acid identity with yeast SEH1. All constituents of the Nup107-160 
complex, including this protein, specifically localize to kinetochores in 
mitosis. (Glavy, 2007). 
SMC1A Positive The protein encoded by this gene is part structural maintenance of 
chromosomes (SMC) protein family. These act as part of the cohesin 
multiprotein complex which is needed for sister chromatid cohesion 
(Losada and Hirano 2005). Cohesion of sister chromatids is required for 
the correct segregation of chromosomes during cell division. The 
cohesion multiprotein complex is composed partly of two SMC proteins, 
SMC3 and either SMC1L2 and SMC1A (Anderson DE 2002). Most of the 
cohesin complexes dissociate from the chromosomes before mitosis, 
however the complexes at the kinetochore remain. As such SMC1A is 
thought to be an important part of functional kinetochores (Haering CH 
2004). In addition, this protein has been shown to be required for 
growth of several cancer types (Ma Z 2013; Zhang YF 2013). 
SMC3 Positive This gene belongs to the SMC3 subfamily of SMC proteins. The encoded 
protein occurs in certain cell types as either an intracellular, nuclear 
protein or a secreted protein. The nuclear form, known as structural 
maintenance of chromosomes 3, is a component of the multimeric 
cohesin complex that holds together sister chromatids during mitosis, 
enabling proper chromosome segregation (Losada and Hirano 2005). 
ZWINT Positive ZWINT-1 is involved in kinetochore function as It interacts with ZW10, 
another kinetochore protein, recruiting It for attachment to unattached 
kinetochores (Wang, Hu et al. 2004; Kops, Kim et al. 2005). The encoded 
protein localizes to prophase kinetochores before ZW10 does and it 
remains detectable on the kinetochore until late anaphase. It has a 
uniform distribution in the cytoplasm of interphase cells. 
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5.3: Discussion  
 
Results from this chapter identified 34 known Beclin-1 protein-protein interactors 
using a freely available plugin tool provided by The Biological General Repository for 
Interaction Datasets (BioGRID). Cytoscape, was used to visualize molecular interaction 
networks. Investigation of individual functions for each of the 34 identified proteins resulted 
in the categorization of several interactors into three molecular processes relevant to the 
underlying research focus of this thesis, ie) Autophagy (seven members identified), 
Apoptosis (five members identified) and the cell cycle (six members identified). Members 
identified within each biological process were further subdivided into whether they have a 
positive or negative regulatory role for each of these processes revealing the potential 
effects an interaction with Beclin-1 may ensue. 
Data suggests that core members and conformation of the Beclin-1 complex may 
both positively and negatively impact on a multitude of cellular pathways. The identification 
of at least three different PI(3)K complexes in autophagy further supports the possibility of 
differing roles for Beclin-1 depending on what it is complexed to (Matsunaga, Saitoh et al. 
2009) although the physiological function of several of the above interactions have yet to be 
defined. Interestingly a recent article highlighted the importance of Beclin-1 in cell cycle 
regulation where it is required for chromosome congression and proper outer kinetochore 
assembly (Frémont S 2013) thus revealing an important role for Beclin-1, independent of 
autophagy. Several interactions of Beclin-1 with key members of cell cycle regulation were 
identified in this chapter which are particularly important during mitosis and kinetochore 
assembly including; SEH1L, SMC3, ZWINT (Glavy, 2007; Kops, Kim et al. 2005; Losada and 
Hirano 2005; Wang, Hu et al. 2004) further highliting a role for Beclin-1 in cell cycle 
regulation. Additionally, recent observations show under certain conditions Beclin-1 may be 
cleaved by caspases thus preventing its pro-autophagic activity (Wirawan, Vande Walle et al. 
2010). Interestingly further studies have found the C-terminal fragment produced as a result 
of this cleavage event has a function of its own in which it amplifies mitochondrial mediated 
apoptosis suggesting cross talk between apoptosis and autophagy (Djavaheri-Mergny, Maiuri 
et al. 2010). Thus, caspase activation (an event shown to occur during treatment with THC) 
could further drive cells to a point of no return and their entry into apoptosis. As a further 
point linking cross talk between autophagy and apoptosis, the interaction of Beclin-1 with 
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the apoptosis-stimulating protein of p53 tumour suppressor family member tumor protein 
53-induced nuclear protein 2 (TP53P2, also known as ASPP2) was also highlighted in these 
studies. TP53P2 is typically found in the perinuclear region of the cytoplasm and its key 
responsibilities within the cell are the regulation of apoptotsis and cell growth via a 
multitude of interactions including TP53 and has been shown to enhance DNA binding of 
TP53 on the promoters of proapoptotic genes in vivo (Nakagawa, Koyama et al 2000; 
Samuels-Lev, O'Connor et al 2001). Another member of this protein family, TP53P1 
(otherwise known as TP53INIP1) has not only been shown to induce apoptosis in pancreatic 
cancer cells but also promotes autophagy-dependent cell death, highlighting the importance 
of this protein family as a tumour suppressor mechanism (Gironella, Seux et al. 2007; 
Gommeaux, Cano et al. 2007; Seillier, Peuget et al. 2012). Seillier et al showed knockdown of 
key autophagy genes Beclin-1 and Atg5 as well as inhibition of caspase activity prevented cell 
death induced by TP53INIP1 suggesting a cross link between autophagy and apoptosis and 
implicating the requirement of both processes (Seillier, Peuget et al. 2012). Additionally 
TP53INP1 has also been shown to interact with Atg8-family proteins as well as LC3 to induce 
autophagy-dependent cell death. Hence, the interaction of Beclin-1 with members of this 
protein family may also have important implications in this context which are yet to be 
defined. As such, future insights into the physiological relevance of Beclin-1 and its recently 
identified protein-protein interactions will undoubtedly help to define further cellular 
functions in which Beclin-1 is implicated.  
Ambra 1 (or activating molecule in Beclin-1 regulated autophagy protein 1) was one 
of the key autophagy proteins identified as an interactor of beclin-1 and several reports 
support the role for this protein as a positive regulator of autophagy and a component of the 
Beclin-1/VPS34 complex (Fimia, Di Bartolomeo et al. 2011; Fimia, Stoykova et al. 2007; Roy 
and Debnath 2010). Ambra 1 is a WD40-containing protein allowing it to function as a 
protein-protein interacting platform (Fimia, Corazzari et al. 2012) where its key role in 
autophagy is in the nucleation phase where it associates with additional members of the 
Beclin-1 complex such as Atg14 and UVRAG (Di Bartolomeo, Corazzari et al. 2010; Fimia, Di 
Bartolomeo et al. 2011; Fimia, Stoykova et al. 2007; Itakura and Mizushima 2010; Roy and 
Debnath 2010). However, other interactions with Ambra 1 have been identified which are 
independent of autophagy and linked to apoptosis. A recent report demonstrated 
mitochondrial Bcl-2 interacts directly with Ambra 1 independently of Beclin-1; an event 
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which is disrupted by the induction of either autophagy of apoptosis (Strappazzon, Vietri-
Rudan et al. 2011). Interestingly Ambra 1 and Bcl-2 bind to Beclin-1 at the same site and so it 
is suggested that Ambra 1 competes with the binding of Bcl-2 to Beclin-1 (Strappazzon, 
Vietri-Rudan et al. 2011). As Bcl-2 family members are often highly expressed in melanoma 
this interaction may be critical to both the regulation of both autophagy and apoptosis in 
this cancer type. Furthermore, in a similar manner to caspase cleavage of Beclin-1 , Ambra 1 
may be irreversibly cleaved and degraded by the activity of caspases and calpains (Corazzari, 
Fimia et al. 2012), key to the promotion of cell death over a pro-survival autophagic 
response in which the switch is regulated by caspases. 
Due to its interaction with Beclin-1, its known role in autophgay (Di Bartolomeo, 
Corazzari et al. 2010; Fimia, Stoykova et al. 2007; Itakura, Kishi et al. 2008; Simonsen and 
Tooze 2009; Roy and Debnath 2010) and links with apoptosis (Corazzari, Fimia et al. 2012), 
Ambra 1 was therefore identified as a key protein to further evaluates and in particular the 
evaluation of its contribution to THC-induced autophagy and cell death in melanoma.  
Previous studies in glioma have shown that Ambra 1 is essential for THC-induced autophagy 
and cell death (Salazar, Carracedo et al. 2009) and that this process did not require Beclin-1 
(personal communication with Guillermo Velasco). Therefore further studies were also 
undertaken to determine the role of Ambra 1 in THC-induced autophagy and cell death in 
melanoma in a cell survival versus cell death context. 
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5.4: Summary  
 
• A total of 34 known Beclin-1 protein-protein interactions were identified using The BioGRID 
plugin for cytoscape. 
• 7/34 identified proteins were key to autophagy of which 5 displayed a positive and 2 a 
negative regulatory role.  
• 5/34 identified 34 proteins were key to apoptosis of which 2 displayed a positive and 3 a 
negative regulatory role. 
• 6/34 identified proteins were key to the cell cycle of which 5 displayed a positive and 1 a 
negative regulatory role. 
• Identified interactions revealed alternative roles for Beclin-1, both dependent and 
independent of autophagy. 
• Ambra 1 was identified as a key interactor of Beclin-1. 
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6.1: Introduction  
 
  Since the chemotherapeutic potential of THC was first suggested extensive research 
has been undertaken to identify its underlying mechanisms of action in a variety of cancers. 
While the majority of identified mechanisms induced by THC have predominately been 
identified in glioma, recent research in prostate and melanoma have also been carried out 
(Carracedo, Gironella et al. 2006; Carracedo, Lorente et al. 2006; Salazar, Carracedo et al. 
2009). Studies in glioma and prostate tumour cells suggest that the anti-tumoural effect of 
cannabis is due in part to the accumulation of ceramide, a pro-apoptotic sphingolipid 
(Blázquez, González-Feria et al. 2004; Galve-Roperh, Sánchez et al. 2000; Gómez del Pulgar, 
Velasco et al. 2002; Mimeault, Pommery et al. 2003). Interestingly the conversion of 
ceramide to complex sphingolipids was not found to be a key event in THC-induced 
apoptosis evidenced by inhibition of glucosylceramide synthase (the enzyme catalysing rate 
limiting step of glycosphingolipid biosynthesis) having no preventative effects on THC 
treatment suggesting it is the accumulation of ceramide itself which exerts the effects 
observed in response to THC treatment (Carracedo, Lorente et al. 2006). In light of these 
observations, DNA microarrays identified the upregulation of several stress-regulated genes 
in response to cannabinoid induced ceramide accumulation including p8, tribbles 3 (TRB3: a 
mammalian homolog of Drosophila tribbles), C/EBP homologous protein (CHOP) and 
activating transcription factor 4 (ATF4) (Carracedo, Lorente et al. 2006). Identification of 
each of these genes revealed that the stress regulated protein p8 mediates THC-induced 
apoptosis and may act as a co-transcription factor to regulate the expression of ATF4, CHOP 
(Carracedo, Gironella et al. 2006; Carracedo, Lorente et al. 2006). ATF4 and CHOP in turn 
have been found to regulate expression of TRB3 in response to ER stress events in tumour 
cells (Ohoka, Yoshii et al. 2005). The overexpression of TRB3 often occurs in response to 
endoplasmic reticulum stress events (Salazar, Carracedo et al. 2009) and has been shown to 
inhibit Akt activation in squamous cell carcinoma derived from tongue tissue (Zhang, Wen et 
al. 2011). The link between TRB3 and Akt inhibition was first identified in liver tissue in which 
insulin resistance was attributed to TRB3 expression induced during fasting conditions in 
which TRB3 disrupts insulin signalling by binding directly to Akt preventing its kinase activity 
and suggesting Akt inhibition by overexpression of TRB3 may be a universal mechanism (Du, 
Herzig et al. 2003). TRB3 inhibition of Akt would then prevent activation of mTORC1 through 
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the PI2K/Akt/mTOR pathway and thus result in the induction of autophagy (Salazar, 
Carracedo et al. 2009). As such the following molecular pathway has been suggested for 
THC-induced autophagy in which THC binds to cannabinoid receptors causing the 
accumulation of ceramide which then leads to activation of the elF2α axis of the ER stress 
pathway. These events result in the increased expression of p8 and TRB3 that in turn inhibits 
the Akt/mTOR pathway causing the induction of autophagy which is required for THC-
induced cell death (Figure 6.1). 
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 As a result of such findings we are now beginning to understand some of the 
pathways induced by THC which lie upstream of autophagy. The requirement of autophagy 
for THC-induced cell death is also becoming clearer (Salazar, Carracedo et al. 2009). 
However, although several mechanisms of cell death have been identified in response to 
THC including mitochondrial outer membrane permeabilization (MOMP) and caspase 3 
activation (Casanova, Blázquez et al. 2003; Carracedo, Gironella et al. 2006; Galve-Roperh, 
Sánchez et al. 2000; Ruiz, Miguel et al. 1999; Sánchez, Galve-Roperh et al. 1998; Sarfaraz, 
Afaq et al. 2005), the link between THC-induced ER stress, autophagy and apoptosis has yet 
to be identified. One suggestion is that treatment with THC results in permeabilization of 
lysosomal membranes in cancer cells (personal communication, G Velasco). Lysosome 
membrane permabilization (LMP) is an event resulting from damage to lysosomes resulting 
in the release of several hydrolytic enzymes including proteases, lipases, nucleases and 
more. Typically most of these enzymes function maximally at acidic pH however certain 
proteases known as cathepsins (or more specifically cathespin B, D and L) remain active at 
neutral pH (Emert-Sedlak, Shangary et al. 2005; Sever, Altintas et al. 2007). The release of 
lysosomal contents into the cytoplasm causes indiscriminate degradation ultimately 
resulting in cell death. Depending on the degree of lysosomal damage and LMP different 
outcomes may ultimately occur as large scale damage may result in acidification of the 
cytoplasm leading to necrosis of the cell. However, more typically partial and selective LMP 
occurs in which the proteases activate apoptosis and controlled cell death through MOMP, 
cytochrome C release and caspase activation (Guicciardi, Deussing et al. 2000). The 
convergence of autophagic pathway with lysosomes in addition to identified ceramide 
accumulation makes LMP an interesting potential missing link in the understanding of 
mechanisms of THC-induced apoptosis downstream of autophagy.  
  As a further point of interest, results from the previous chapter identified Ambra 1 
as a key Beclin-1 interacting protein with a positive regulatory role in autophagy. 
Interestingly Ambra 1 was found to be essential for THC-induced cell death and autophagy in 
glioma (Salazar, Carracedo et al. 2009) which is believed to be independent of Beclin-1 
(personal communication with Guillermo Velasco). However, to date, the molecular function 
of this protein in melanoma or even the requirement of Ambra 1 in autophagy induced by 
chemotherapeutic agents including THC and bortezomib remains unknown.  
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  Results from previous chapters determined the requirement for autophagy 
induction by THC in order to induce apoptosis suggesting similar modes of action to those 
discussed here may be occur in metastatic melanoma cells. Therefore, the aim of this 
chapter was to firstly asses the requirements for Ambra 1 in THC-induced autophagy and cell 
death and secondly to verify the underlying molecular events occurring in melanoma which 
lie both upstream and downstream of autophagy in order to identify a potential link 
between THC-induced autophagy and cell death in melanoma. 
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6.2: Results 
  
6.2.1: The role of identified Beclin-1 interacting protein, Ambra 1 during cytotoxic and pro-
survival autophagy 
 
  Ambra 1 was identified in the previous chapter as a key Beclin-1 interacting protein 
chosen for both its involvement in autophagy and its previous implication in THC-induced 
cell death in glioma (Salazar, Carracedo et al. 2009). As such, in order to ascertain the 
importance of Ambra 1 for autophagy and cell death induced by THC in melanoma, the 
effect of THC on autophagy and apoptsos induction was determined following modulation of 
Ambra 1 expression in A375 cells. A375 cell stably overexpressing Ambra 1 (rAmbra 1 cells) 
or stably transfected with a lentiviral shAmbra 1 construct (shAmbra 1 cells) were kindly 
provided in collaboration with  Dr Marco Corazzari, University of Rome, Tor  Vergata) 
together with A375 cells transfected with appropriate control vectors (rβGal, shCtrl). Results 
demonstrated treatment with THC for 24 hours reduced viability of all transfected A375 
cells, which was not affected by the presence or absence of Ambra 1. Treatment with 
chloroquine also prevented inhibition of cell viability (Figure 6.2).  
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Figure 6.2: THC-induced inhibition of melanoma cell viability is independent of Ambra 1. Relative viability of 
melanoma cell line A375 stably (A) overexpressing Ambra 1 or (B) knocked down for Ambra 1 after subsequent 
treatment for 24 hours with 5 µM THC in the presence or absence of 10 µM CQ. Each bar is relative to 
untreated melanoma cells for each shRNA condition (mean +/- SEM, n=3). Statistics were acquired using one 
way ANOVA with Dunnett post-hoc test, ** p< 0.01 *** p< 0.001 comparing drug treatments shown to 
untreated melanoma cells for each shRNA or overexpression condition alone. 
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  To identify whether Ambra 1 was required for THC-induced autophagy, conversion 
of LC3-I to LC3-II was analysed by Western blotting in rAmbra 1 and shAmbra 1 A375 cells. 
Combined treatment with chloroquine was included in the final two hours of treatment in 
order to prevent LC3-II degradation in the latter stages of autophagy. The induction of 
autophagy by THC treatment was confirmed at optimised concentrations of 4.5 µM or 5 µM 
respectively by increased LC3-II levels compared to control untreated cells (Figure 6.3). 
Overexpression and knockdown of Ambra 1 was confirmed by Western blotting and THC-
induced autophagy was maintained in these conditions (Figure 6.3). 
  To assess whether the presence or absence of Ambra 1 expression was required for 
THC-induced cell death the level of Cleaved Caspase 3 was analysed by Western blotting. 
THC treatment resulted in increased Cleaved Caspase 3 in all tested cell lines in response to 
treatment with concentrations of 4.5 µM or 5 µM compared to untreated cells, indicating 
increased apoptosis (Figure 6.3). Neither overexpression nor knockdown of Ambra 1 
prevented THC-induced apoptosis. As a further point of interest THC treatment alone also 
appeared to down-regulate the expression of Ambra 1 (Figure 6.3).  
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Figure 6.3: THC-induced autophagy and apoptosis are independent of Ambra 1. Western blot for  Ambra 1, 
LC3-I/LC3-II, Cleaved Caspase 3 and ß-actin in A375 cells stably (A) overexpressing Ambra 1 or (B) knocked 
down for Ambra 1 treated with 5 µM THC for 24 hours in the presence or absence of 10 µM CQ for the final 2 
hours of treatment. 
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  The role of Ambra 1 in bortezomib-induced inhibition of cell viability, caspase 3 
cleavage and LC3-II induction was also evaluated in rAmbra 1 and shAmbra 1 melanoma cells 
In line with THC treatment, results also confirmed treatment of cells with bortezomib for 24 
hours inhibited melanoma cell viability. Inhibition of cell viability was partially enhanced in 
shAmbra 1 cells treated with bortezomib compared with shCtrl Cells (45% viability on 
average compared with 55% viability respectively) while bortezomib treatment of rAmbra 1 
over expressing cells resulted in partially reduced inhibition of cell viability compared with 
rβGal cells (66% viability on average compared with 50% viability respectively) (Figure 6.4). 
Ultimately however, this difference was not significant and bortezomib-induced inhibition of 
viability appeared to be independent of Ambra 1. Additionally, combined treatment with 
chloroquine did not alter any effect of bortezomib on inhibition of cell viability (Figure 6.4). 
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Figure 6.4:  Bortezomib-induced inhibition of melanoma cell viability is independent of Ambra 1. Relative 
viability of melanoma cell line A375 stably (A) overexpressing Ambra 1 or (B) knocked down for Ambra 1 after 
subsequent treatment for 24 hours with 100nM Bort in the presence or absence of 10µM CQ. Each bar is 
relative to untreated melanoma cells for each shRNA condition (mean +/- SEM, n=3). Statistics were acquired 
using one way ANOVA with Dunnett post-hoc test, ** p< 0.01 *** p< 0.001 comparing drug treatments shown 
to untreated melanoma cells for each shRNA or overexpression condition alone. 
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  Western blotting also confirmed bortezomib-induced LC3-II expression in all tested 
melanoma cells which was neither prevented by Ambra 1 knockdown nor enhanced by 
Ambra 1 overexpression. Increased apoptosis was observed with bortezomib treatment as 
indicated by increased levels of Cleaved Caspase 3. This effect was further enhanced by 
Ambra 1 knockdown but Ambra 1 overexpression had no observed effects on the levels of 
Cleaved Caspase 3 (Figures 6.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5: Ambra 1 is not required for enhancement of autophagy and apoptosis induced by bortezomib. 
Western blot for Ambra 1, LC3-I/LC3-II, Cleaved Caspase 3 and ß-actin in A375 cells stably (A) overexpressing 
Ambra 1 or (B) knocked down for Ambra 1 treated with 100 nM Bort for 24 hours in the presence or absence of 
10 µM CQ for the final 2 hours of treatment. 
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6.2.2: THC-induced events upstream of autophagy induction 
  
  The accumulation of ceramide is suggested as an early event after THC treatment 
and has been verified in glioma by use of the serine palmitoyl transferase-1 inhibitor ISP-1 
(also known as myriocin) (Gómez del Pulgar, Velasco et al. 2002; Salazar, Carracedo et al. 
2009). As such combined treatment of THC with ISP-1 can be used in an attempt to prevent 
THC-induced inhibition of cell viability by preventing ceramide accumulation and thus 
subsequent downstream events. Although in the present study less reduction in viability was 
observed in response to the combined treatment of A375 cells with THC and ISP-1 (5 µM) 
(Figure 6.6 A) no significant difference was found between treatment conditions comparing 
6 µM THC alone with 6 µM THC combined with ISP-1 (Figure 6.6 B). As such ISP-1 at 5 µM did 
not prevent THC-induced loss of viability (Figure 6.6) in A375 melanoma cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: Inhibtion of melanoma cell viability with THC is independent of Ceramide accumulation. Relative 
viability of A375 melanoma cell lines treatment for 24 hrs with 5 or 6 µM THC either alone or in combination 
with 5 µM ISP. Each bar is relative to melanoma cells untreated with THC for either control DMSO or combined 
with ISP (mean +/- SEM n=3). (A) Statistics were acquired using one way ANOVA with Dunnett post-hoc test or 
one way ANOVA  * p< 0.05, *** p< 0.001 comparing treatment with THC relative to untreated melanoma cells 
for control DMSO or treatment with ISP alone. (B) Statistics were acquired using one way ANOVA with 
Bonferroni post-hoc test * p< 0.05, ns – non-significant comparing drug treatments shown relative to untreated 
melanoma cells for control DMSO .  
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  TRB3 has is also upregulated in glioma in response to THC resulting in TRB3-
dependent autophagy induction and thus cell death in this tumour type (Salazar, Carracedo 
et al. 2009; Salazar, Carracedo et al. 2009). Therefore in order to define mechanisms 
upstream of autophagy crucial for THC-induced cell death, RNAi-mediated knockdown of 
TRB3 was achieved by reverse transfection. Knockdown was confirmed by RT-PCR and 
optimal conditions determined by using 2nM TRB3 siRNA (Fig 6.7 A). Treatment with THC for 
24 hours reduced viability of A375 cells which was prevented by transient knockdown of 
TRB3. (Fig 6.7 B)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: RNAi-mediated knockdown of TRB3 prevents THC-induced inhibition of melanoma cell viability. A) 
mRNA expression levels of TRB3 for ctrl siRNA transfectd A375 cells or cells transfected with 2 nM TRB3 siRNA 
B) Relative viability of melanoma cell lines (A375) following transfection with control siRNA (Ctrl siRNA) or TRB3 
siRNA for 24 hours and subsequent treatment for 24 hours with 5 µM or 6 µM THC. Each bar is relative to 
untreated melanoma cells for each siRNA condition (mean +/- SEM, n=3). Statistics were acquired using one 
way ANOVA with Dunnett post-hoc test, * p<0.05 comparing drug treatments shown relative to untreated 
melanoma cells for each siRNA condition. 
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6.2.3: THC-induced events downstream of autophagy 
 
  Although THC has been shown to induce apoptosis in a variety of cancers and 
autophagy is emerging as a crucial event in this process, the molecular events downstream 
of autophagy which may result in apoptosis are yet to be fully defined in melanoma. One 
suggested mechanism for THC-induced apoptosis is the permeabilization of lysosomes 
resulting in the release of apoptosis inducing proteins such as cathepsins (Velasco et al 
unpublished data). As such to assess the underlying mechanisms for THC-induced apoptosis 
which lie downstream of autophagy, lysosome membrane permeabilization was assessed by 
analysing cathepsin B release. Cathepsin B release from lysosomes was confirmed by dual 
staining of melanoma cells to determine cathepsin B (Green) co-localisation with lysosomal 
associated membrane protein 2 (LAMP2; Red) and visualised using immunofluorescence and 
confocal microscopy. Control untreated melanoma cells exhibited a granular fluorescence 
pattern representing intracellular lysosomes which co-localised with cathepsin B. Treatment 
with THC resulted in large swollen lysosomal structures. Results also demonstrated 
cathepsin B release from lysosomes into the cytoplasm as determined by a reduction in co-
localisation (yellow) in melanoma cells treated with THC at concentrations high enough to 
induce apoptosis (Figure 6.8).   
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Figure 6.8: THC induces LMP and cathepsin B release from lysosomes. Immunofluorescence for cathepsin B 
(Green) and LAMP2 (Red) co-localisation in A375 melanoma cells treated with control DMSO or with 5 µM THC 
for 18 hours (scale bar represents a length of 20 µm). 
   
  Bafilomycin should prevent release of cathepsins from the lysosomal lumen as it 
has been shown to prevent LMP by acting as both an inhibitor of lysosomal acidification and 
lysosome-autophagosome fusion by inhibition of vacuolar H+ ATPase (V-ATPase) 
(Yamamoto, Tagawa et al. 1998). As such combined treatment with bafilomycin was used in 
an attempt to prevent THC-induced apoptosis by inhibition of lysosome membrane 
permeabilization. Treatment with bafilomycin alone did not result in cathepsin B release 
unlike treatment with THC; however, combined treatment with THC and bafilomycin 
prevented the release of cathepsin B from lysosomes and the granular staining pattern 
observed in control untreated cells was retained (Figure 6.9 B). Additionally, combined 
treatment with THC and bafilomycin prevented THC-induced loss of viability suggesting LMP 
is involved in cell death (Figure 6.9 A).  
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Figure 6.9: Bafilomycin prevents THC-induced cell death and prevention of cathepsin B release from 
lysosomes. (A) Relative viability of melanoma cell lines (A375) following treatment for 24 hours with 5 µM THC 
in the presence or absence of 10 nM bafilomycin (Baf). Each bar is relative to melanoma cells untreated with 
THC using control DMSO (mean +/- SEM, n=3). Statistics were acquired using one way ANOVA with Dunnett 
post-hoc test, *** p<0.001 comparing drug treatments shown relative to untreated melanoma cells for control 
DMSO or combined treatment conditions. (B) Immunofluorescence for cathepsin B (Green) and LAMP2 (Red) 
co-localisation with lysosomes in A375 melanoma cells treated for 18 hours individually or in combination with 
THC and bafilomycin (scale bar represents a length of 20 µm). 
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6.2.4: Lysosome membrane permeabilization and THC-induced apoptosis in metastatic 
melanoma 
 
  The release of cathepsins from lysosomes has been shown to disrupt mitochondrial 
integrity leading to an event known as mitochondrial outer membrane permeabilization 
(MOMP). This in turn results in distinct changes in intracellular mitochondrial staining 
patterns observed and cytochrome C release (Guicciardi, Deussing et al. 2000). In order to 
determine whether THC-induced apoptosis occurs as a result of MOMP, cytochrome C 
staining was analysed by immunofluorescence in A375 cells. Control untreated melanoma 
cells revealed a distinct mitochondrial staining pattern similar to those observed using 
mitochondrial imagining techniques (Mitra and Lippincott-Schwartz 2010) (Figure 6.10). 
Treatment with THC resulted in a diffuse staining pattern representing cytochrome C release 
into the cytoplasm (an early event in intrinsic apoptosis) as well as morphological changes 
such as cellular shrivelling and damaged nuclei. Additionally nuclear localisation of 
cytochrome C was also observed (Figure 6.10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10: THC induces cytochrome C release in A375 melanoma cells. Representative immunofluorescence 
from 3 replicate experiments for cytochrome C expression in A375 cells treated with (A) DMSO vehicle control 
or (B) 5 µM THC for 24 hours (Original magnification is 63x, scale bar represents a length of 20 µm). 
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  In order to determine whether cathespsin B was essential for cytochrome C release 
and subsequent cell death, combined treatment of THC with a cathepsin B inhibitor (CAO74-
me) was assessed for its effect on THC-induced inhibition of cell viability and induction of 
cytochorme C release. Combined treatment of THC with the cathepsin B inhibitor (CAO74-
me) partially prevented THC-induced loss of cell viability when THC was used at a 
concentration of 6 µM (Figure 6.11 A). Treatment with the cathepsin B inhibitor alone 
however, did not reduce cell viability (Figure 6.11 A) or result in cytochrome C release 
(Figure 6.10 B). Interestingly combined treatment with  THC and  the cathepsin B inhibitor 
for 24 hours revealed a mixed pattern of loss of mitochondrial integrity and cytochrome C 
release (as observed for cells treated with THC alone) as well as stable mitochondrial staining 
patterns (as observed in both untreated and cathepsin B inhibitor alone treated cells) (Figure 
6.11 B).  
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Figure 6.11: Inhibition of cathepsin B activity prevents THC-induced cell death and cytochrome C release. (A) 
Relative viability of melanoma cell lines (A375) following treatment for 24 hours with 5 µM THC in the presence 
or absence of 10 µM Cathepsin B inhibitor (CathBi; CAO74-me). Each bar is relative to melanoma cells treated 
with vehicle only (mean +/- SEM, n=3). Statistics were acquired using one way ANOVA with Bonferroni post-hoc 
test, * p<0.05, ** p<0.01 comparing 6 µM THC to untreated melanoma cells for control DMSO or 6 µM THC 
alone with 6 µM THC combined with CathBi. (B) Representative confocal images from 3 replicate experiments 
of cathepsin B (Green) and LAMP2 (Red) co-localisation in A375 melanoma cells treated individually or in 
combination with THC and CathBi (scale bar represents a length of 20 µm).  
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6.2.5: The role of Autophagy in THC-induced lysosome membrane permeabilization. 
 
  Results from previous chapters have revealed an essential role for autophagy in 
THC-induced cell death in melanoma cells in vitro. However, the link between autophagy, 
lysosome membrane permeabilization and apoptosis remains unclear. In order to determine 
a requirement for autophagy in THC-induced lysosome membrane permeability, RNAi-
mediated knockdown of Atg7 was achieved by reverse transfection in metastatic melanoma 
cell lines A375 and SKMEL-28. Cathepsin B release from lysosomes was confirmed by dual 
staining of melanoma cells to determine cathepsin B co-localisation with LAMP2 and 
visualised using immunofluorescence and confocal microscopy. THC treatment in Ctrl siRNA 
transfected melanoma cell lines resulted in cathepsin B release and lysosome swelling as 
previously observed (Figures 6.12, 6.13). Atg7 knockdown alone however did not result in 
cathepsin B release and prevented THC-induced cathepsin B release in all tested melanoma 
cell lines compared to THC treated cells transfected with Ctrl siRNA (Figures 6.12, 6.13).  
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Figure 6.12: Atg7 knockdown prevents THC-induced LMP and cathepsin B release from lysosomes in A375 
melanoma cells. Representative image from 3 replicate experiments for immunofluorescence of cathepsin B 
(Green) and LAMP2 (Red) co-localisation in A375 melanoma cells transfected with (A) Ctrl siRNA or (b) Atg7 
siRNA treated  for 18 hours with 5 µM THC. Nuclear staining was achieved using DAPI (Blue) (scale bar 
represents a length of 20 µm). 
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Figure 6.13: Atg7 knockdown prevents THC-induced LMP and cathepsin B release from lysosomes in SKMEL-
28 melanoma cells. Representative image from n=3 experiments for immunofluorescence of cathepsin B 
(Green) and LAMP2 (Red) co-localisation in SKMEL-28 melanoma cells transfected with (A) Ctrl siRNA or (b) 
Atg7 siRNA treated  for 18 hours with 5 µM THC. Nuclear staining was achieved using DAPI (Blue) (scale bar 
represents a length of 20 µm). 
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6.3: Discussion 
 
  Results from this chapter demonstrate THC is able to induce autophagy and cell 
death independently of Ambra 1, as verified by inhibition of cell viability, increased LC3-I/II 
conversion and increased levels Cleaved Caspase 3 observed in A375 cells in which Ambra 1 
expression had been stably knocked down. Ambra 1 is a member of the Beclin-1/Vps34 
complex which is required for the nucleation phase of autophagy (Fimia, Di Bartolomeo et al. 
2011; Roy and Debnath 2010) and has been suggested to be a key player in the canonical 
autophagy pathway where it essentially acts as a protein-protein interacting platform (Fimia, 
Corazzari et al. 2012). However, additional cofactors such as UVRAG and Atg14 can also 
activate Beclin-1 complex activity independent of Ambra 1 (Itakura, Kishi et al. 2008; 
Simonsen and Tooze 2009) suggesting Ambra 1 is not always necessary for autophagy 
induction. Interestingly, treatment with THC alone appeared to down-regulate Ambra 1 
which could be due to cleavage of Ambra 1 by caspases as described by Corazzari et al 
(Corazzari, Fimia et al. 2012). Despite extensive research into the function of Ambra 1 in 
autophagy most of these studies have been undertake in neuronal cells and cancers such as 
glioma with little direct evidence about the function of Ambra 1 in melanoma. Results from 
the present melanoma studies reveal autophagy induction by THC and bortezomib is able to 
occur independently of Ambra 1, suggesting a non-canonical autophagic process is taking 
place in which the requirement of Ambra 1 may not be essential.  
  Ceramide accumulation may also not be required for THC-induced inhibition of cell 
viability. The accumulation of ceramide occurs as a result of cannabinoid treatment in 
several cancer types (Blázquez, González-Feria et al. 2004; Galve-Roperh, Sánchez et al. 
2000, Gómez del Pulgar, Velasco et al. 2002; Mimeault, Pommery et al. 2003) and many 
studies have revealed that ceramide acts as a mediator of the ER stress response in 
eukaryotes (Hannun 1996). Its accumulation has been suggested to occur by four means; i) 
activation of de novo synthesis in the endoplasmic reticulum by ceramide synthetase and 
serine-parlmotyl transferases (SPT) (Chalfant, Rathman et al. 2002; Perry, Carton et al. 2000) 
ii) inhibition of ceramide hydrolysis (Lucci, Han et al. 1999; Strum, Small et al. 1994) iii) 
activation of sphingomyelin hydrolysis (Senchenkov, Litvak et al. 2001) and iv) stimulation of 
glucosylceramide hydrolysis (Senchenkov, Litvak et al. 2001). ISP-1 inhibits ceramide 
accumulation in glioma by prevention of its de novo synthesis which is due to inhibition of 
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serine palmitoyl transferase-1 (SPT1) suggesting that ceramide accumulation in glioma is 
required for THC-induced ER stress and subsequent autophagy and apoptosis. However, in 
the present studies ISP-1 did not prevent THC-induced inhibition of cell viability of 
melanoma cells. As such, whether ceramide accumulation is occurring via a different 
mechanism or even if it is required in melanoma for downstream responses induced by THC 
remains to be verified. It is also possible that the concentration of ISP-1 used in these 
studies, although adequate to prevent ceramide accumulation in glioma, was inadequate to 
prevent its accumulation in melanoma cells and hence additional studies are required to 
truly disregard ceramide accumulation as a mechanism required for THC to exert its effects.  
  Knockdown of the pseudokinase TRB3 prevented inhibition of melanoma cell 
viability by THC suggesting that TRB3 is required for THC-induced cell death in melanoma. 
Increased TRB3 expression as a result of p8 overexpression was identified as a crucial step 
for THC-induced autophagy and apoptosis in glioma and pancreatic cells, verified both in vivo 
and in vitro (Carracedo, Gironella et al. 2006; Carracedo, Lorente et al. 2006; Salazar, 
Carracedo et al. 2009; Salazar, Carracedo et al. 2009). Genetic inhibition of TRB3 in glioma 
prevented cannabinoid induced autophagy and cell death suggesting this protein is crucial 
for connecting ER stress events to autophagy and subsequent downstream events in 
response to THC. The key step is likely TRB3 mediated Akt inhibition which would in turn 
inhibit mTORC1 activity and induce autophagy. As such it is likely these events are occurring 
in melanoma as a result of THC treatment (although further studies will be required to verify 
this).  
  The ability for THC to induce apoptosis has been extensively shown with several key 
events associated with apoptosis signalling being identified (Carracedo, Gironella et al. 2006; 
Casanova, Blázquez et al. 2003;  Galve-Roperh, Sánchez et al. 2000; Ruiz, Miguel et al. 1999; 
Sánchez, Galve-Roperh et al. 1998; Sarfaraz, Afaq et al. 2005) however the release of 
cytochrome C in response to THC has yet to be verified. Analysis of cytochrome C staining 
revealed THC treatment caused the release of cytochrome C from mitochondria, resulting in  
a diffuse staining pattern likely due to MOMP, revealing for the first time a possible 
mechanism of caspase activation induced by THC in melanoma cells. As a further point of 
interest, nuclear staining of cytochrome C was observed in A375 cells after THC treatment. 
Although the amount of research related to this event is limited, nuclear translocation of 
cytochrome C during apoptosis has been observed previously (Nur-E-Kamal, Gross et al. 
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2004). It was found that cytochrome C released from mitochondria during apoptosis 
gradually accumulated in the nucleus of HeLa cells which was shown by both 
immunofluorescence and subcellular fractionation. Interestingly the nuclear localisation of 
cytochrome C was suggested to be directly involved in the remodelling of chromatin as 
evidenced by chromatin condensation and the release of acetylated histone H2A into the 
cytoplasm (possibly by its displacement from chromatin) inducing what the authors termed 
nuclear apoptosis (Nur-E-Kamal, Gross et al. 2004). As such this may also be a mechanism of 
apoptosis induction occurring as a result of cytochrome C release and nuclear localisation 
observed in response to THC.  
  LMP has been speculated as a potential mechanism of apoptosis induction in 
response to THC (personal communication with Guillermo Velasco) which may lie upstream 
of apoptotic events, however there is little direct evidence to support this hypothesis. LMP 
occurs when lysosomes become damaged causing the release of its constituents into the 
cytoplasm resulting in indiscriminate degradation and ultimately apoptosis or necrosis 
depending on the scale of lysosomal damage. In these studies treatment with THC resulted 
in large swollen lysosomal structures and reduced colocalisation of cathepsin B with LAMP2, 
revealing for the first time that LMP is induced in response to THC. Further supporting 
evidence was revealed by the combined treatment with THC and bafilomycin (an established 
LMP inhibitor preventing lysosomal acidification (Yamamoto, Tagawa et al. 1998; Yoshimori, 
Yamamoto et al. 1991) where both inhibition of cell viability and cathepsin B release was 
prevented compared to THC treatment alone. Larger lysosomes (often observed in cancers) 
have been suggested to be more susceptible to LMP (Glunde, Guggino et al. 2003; Ono, Kim 
et al. 2003) and the release of cathepsin B from lysosomes (indicated by reduced co-
localisation of cathepsin B with LAMP2) in addition to the swollen lysosomal structures 
indicates this is happening as a result of THC treatment. Additionally, cathepsin B release has 
been found to induce cytochrome C release and apoptosis in hepatocytes (Guicciardi, 
Deussing et al. 2000) and as both these events have been shown in the present studies, as 
well as the inhibition of cytochrome C release by use of a cathepsin B inhibitor, it is likely 
that a similar mechanism of THC-induced apoptosis occurs in melanoma cells. It should be 
noted however, that the cathepsin b inhibitor (CAO74-me) had only a partial effect on the 
release of cytochrome C as a mixed pattern of loss of mitochondrial integrity and 
cytochrome C were observed. The cathepsin B inhibitor used in these studies results in an 
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irreversible binding of the inhibitor to cytosolic cathepsin B. As such, eventually the inhibitor 
will be used up and any further release of cathepsin B would no longer be inhibited which 
may account for the partial prevention of cytochrome C release observed despite preventing 
inhibition of THC-induced inhibition of cell viability. In order to prove that this is the case a 
range of different cathepsin B inhibitor concentrations would have to be applied and 
analysed to see if full prevention of cytochrome C release could be attained. Additional 
methodology could also be applied to verify the release of cathepsin B, as well as other 
cathespins, into the cytosol including immunoblots of subcellular fractions (i.e. cytosolic 
against lysosomes) (Michallet, Saltel et al. 2004) or measure lysosome-impermeable 
cathepsin substrates such as pepstatin BODIPY (Yin, Stearns et al. 2005). Interestingly it has 
been found that not all lysosomes are permeabilized at the same time (Ono, Kim et al. 2003) 
(although the reasons for this remain unknown) which could account for the lysosomal 
structures observed which appear intact and are still co-localised with cathepsin B. The 
cause of LMP by THC has yet to be defined but several observations could account for this 
event (Emert-Sedlak, Shangary et al. 2005; Guicciardi, Deussing et al. 2000; Sever, Altintas et 
al. 2007). Cancer cells often exhibit large amounts of ROS and treatment with THC has been 
shown to cause a dramatic increase in intracellular ROS levels likely due to their release from 
mitochrondria during their disruption (Goncharov, Weiner et al. 2005; Sarafian, Kouyoumjian 
et al. 2003). ROS can induce LMP but only in subcellular regions such as near the 
mitochondria as ROS have a spatially limited range of action. This may also explain why some 
lysosomes remain intact during THC treatment and others do not. Another mechanism 
particularly relevant to cancer cells and melanoma may relate to the presence of iron within 
the lysosomes. Lysosomes are the main reservoir of chelatable iron which accumulates upon 
degradation of iron-containing proteins such as cytochromes and ferritin. Iron catalyses 
fenton reactions within lysosomes producing highly reactive pro-oxidants which may then 
damage lysosomal membranes if the levels of iron are too great (as found in some 
pathologies associated with Iron overload (Link, Pinson et al. 1993; Mak and Weglicki 1985). 
Fenton reactions have also been suggested to occur in response to THC treatment, 
increasing glioma cell death due to oxidative stress (Goncharov, Weiner et al. 2005). An 
interesting link between melanoma and iron-containing proteins has been found with the 
expression of ferritin within melanoma cells by Baldi and colleagues (Baldi, Lombardi et al. 
2005). In these studies, authors increased ferritin expression in melanoma cells which 
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contribute to tumour progression by modulating cell growth and reducing sensitivity to 
oxidative stress (Baldi, Lombardi et al. 2005). Although the level of iron containing proteins 
has not been assessed in these studies it is possible that the increased levels of ferritin and 
iron containing proteins in melanoma may contribute to LMP induced by THC. Increased 
autophagy in response to THC could then potentially result in increased invagination and 
degradation of such proteins within the lysosomes ultimately leading to LMP, cathepsin B 
release and apoptosis.  
  In conclusion THC-induced autophagy and cell death appears to be Ambra 1 
independent and additionally the requirement for ceramide accumulation may also be 
unnecessary for THC-induced cell death, revealing differences in the underlying mechanisms 
activated by THC in melanoma compared with those found in glioma. Still, prevention of 
THC-induced inhibition of cell viability upon TRB3 knockdown suggests THC treatment in 
melanoma follows some of the predicted pathways identified in glioma. Additionally these 
studies have identified novel findings and specifically that the induction of lysosome 
membrane permeabilization resulting in the release of cytochrome C contributes to the 
potency of THC in its induction of autophagy and apoptosis of melanoma (Figure 6.14). 
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6.4 Summary 
 
•  Ambra 1 is not required for THC-induced autophagy and apoptosis in melanoma. 
•  Treatment of melanoma cells with THC results in cytochrome C release which is a likely 
cause of apoptosis. 
•  Treatment with THC results in LMP and cathepsin B release. 
•  Inhibition of cathepsin B activity prevents THC-induced inhibition of cell viability.  
•  Bafilomycin treatment prevents LMP and cathespsin B release, as well as prevention of 
THC-induced inhibition of cell viability. 
•  Inhibition of cathepsin B partially prevents cytochrome C release, suggesting cathepsin B 
activity is required for THC-induced apoptosis. 
•  Autophagy is required for cathepsin B release as knockdown of Atg7 prevented LMP in 
A375 and SKMEL-28 cells.  
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7.1 Prelude to final discussion 
  
  To date cutaneous metastatic melanoma remains largely untreatable most likely 
attributable to the notorious resistance of these tumours to apoptosis induction by current 
chemotherapies. As the incidence of this disease has steadily increased globally in the last 
fifty years particularly in those of European decent (Thompson, Scolyer et al. 2005) there is a 
high demand for developing new treatment regimes to overcome apoptotic resistance. The 
underlying mechanisms of apoptosis have been extensively studied leading to development 
of several chemotherapeutics however, due to apoptotic resistance much research focussed 
on alternative approaches to induce cell death. A rekindled interest in the autophagy 
pathway has revealed the importance of this pathway in cancer development and survival 
and as such presents new targeting opportunities for cancer treatment  (Qu, Yu et al. 2003, 
Yue, Jin et al. 2003). To an extent apoptotic resistance can partially be attributed to the 
ability of tumours to use autophagy as a pro-survival mechanism, leading to development of 
several novel therapeutic strategies shown to inhibit autophagy in advanced cancers as a 
means through which to overcome apoptotic resistance (Bertout, Patel et al. 2008; Zhang, 
Bosch-Marce et al. 2008). However, a number of factors impact on the success of this 
approach. Firstly, the most commonly used lysosomal inhibitor, hydroxychloroquine (HCQ) 
(Garber 2011) is not a specific inhibitor of autophagy and more-over its use is associated 
with several off target effects including blockade of autophagy in normal organs such as the 
muscles and kidneys leading to development of muscle weakness and renal insufficiency 
(Albay, Adler et al. 2005; Kimura, Takabatake et al. 2013) in addition to well documented 
cases of retinoid damage and potential blindness through prolonged HCQ treatment 
(Mavrikakis, Papazoglou et al. 1996; Tehrani, Ostrowski et al. 2008). As such more specific 
autophagy inhibitors are currently in clinical development including Verteporfin, an FDA 
approved benzoporphyrin derivative used in photodynamic therapy shown more recently to 
inhibit drug and starvation-induced autophagy even in absence of light activation (Donohue, 
Tovey et al. 2011). Another effective inhibitor is lucanthone, an autophagy inhibitor also 
found to induce lysosome membrane permeabilization and which possessed significantly 
greater potency against breast cancer models compared with chloroquine (Carew, Espitia et 
al. 2011). However, a major caveat to inhibiting autophagy is that blockade of autophagy 
itself may lead to the development of secondary tumours (Qu, Yu et al. 2003; Yue, Jin et al. 
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2003). As such, the alternative approach of harnessing autophagy to promote cell death may 
represent a better therapeutic strategy. In this context recent studies of the antidiabetic 
drug metformin (Bailey and Turner 1996) demonstrate the potent ability of this agent to 
inhibit growth of several tumour types, including breast, colorectal and pancreatic cancer 
(Ben Sahra, Le Marchand-Brustel et al. 2010; Liu, Fan et al. 2009; Wang, Li et al. 2008) 
concurrent with the induction of autophagy (Buzzai, Jones et al. 2007). More recently 
metformin has also been shown to exert antiproliferative effects on melanoma cells, with 
little or no effect on normal melanocytes (Tomic 2011). Furthermore, these studies revealed 
prolonged exposure of melanoma cells to metformin resulted in the induction of autophagy, 
inhibition of which, through RNAi-mediated knockdown of either Atg5 or LC3-I/II also 
resulted in decreased apoptosis (Tomic 2011). These studies thus suggest metformin-
induced apoptosis is dependent on autophagy, and reveal an alternative mode through 
which to harness autophgay modulation. Further studies also confirmed the growth 
inhibitory effects of metformin in vivo using B16 mice injected with B16 melanoma cells of 
human melanoma as well as the induction of both autophagy and apoptosis markers in this 
mouse model (Tomic 2011). In addition to metformin, evidence also reports the potential of 
cannabinoids, and in particular tetrahydrocannabidiol (THC), as agents with potent anti-
cancer effects derived through the ability to induce autophagy mediated apoptosis in human 
glioma cells with minimal adverse effects observed in patients (Duntsch, Divi et al. 2006; 
Salazar, Carracedo et al. 2009; Sánchez, Galve-Roperh et al. 1998; Sánchez, de Ceballos et al. 
2001; Velasco, Carracedo et al. 2007). Furthermore, evidence for the requirement of 
Autophagy in THC-induced apoptosis of glioma cells is evidenced by in vitro studies 
demonstrating knockdown of Atg1, Atg5 or Ambra 1 prevented apoptosis (Salazar, 
Carracedo et al. 2009). 
  As several links between autophagy and apoptosis are being identified such as the 
discovery of direct interactions of anti-apoptotic Bcl-2 proteins with the autophagy 
regulatory protein Beclin-1 (Feng, Huang et al. 2007; Decuypere, Jan et al. 2012), the 
importance of this pathway in cancer development is becoming ever more apparent and 
hence a target for therapeutic development. This thesis has focussed on the identification of 
potential avenues to exploit autophagy for the therapeutic benefit of metastatic melanoma 
and in particular the use of THC. Studies have focussed on the role of Mcl-1 in autophagy 
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leading to studies of the therapeutic potential of THC and the underlying molecular 
mechanisms through which it modulates autophagy to promote cell death. In line with 
previous observations demonstrating Bcl-2 family members are crucial regulators of 
apoptosis in melanoma and the role of anti apoptotic Mcl-1 (Balmanno and Cook 2009; 
Boucher, Morisset et al. 2000 Tang, Tron et al. 1998; Zhai, Jin et al. 2008) in autophagy, data 
derived from this thesis suggests manipulating Mcl-1 splice variant expression may represent 
a potential novel therapeutic strategy. Secondly, in comparison to the effects of bortezomib-
induced apoptosis, a recognised inducer of pro-survival autophagy (Armstrong, Corazzari et 
al. 2011), data demonstrate the ability of THC to induce autophagy mediated apoptosis of 
melanoma cells, the effect of which is amplified by the induction of lysosomal membrane 
permabilization, collectively suggesting a novel therapeutic strategy through which to 
harness autophagy modulation for the clinical management and benefit of metastatic 
disease.  
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7.2: Mcl-1 as a therapeutic target in melanoma 
 
7.2.1: Influence of oncogenic BRAF signalling on Mcl-1 splice variant expression  
 
Previous studies have demonstrated the increased expression of anti-apoptotic Bcl-2 
protein family members in primary melanomas. In particular the increased expression of Bcl-
2 and Bcl-xl has been observed in early stage tumours while increased Mcl-1 expression is 
frequently observed in more advanced stage tumours (Tang, Tron et al. 1998; Zhuang, Lee et 
al. 2007). Additionally Mcl-1 has been shown to be crucial for melanoma survival (Zhuang, 
Lee et al. 2007) and as such, its increased expression likely contributes to the 
chemoresistance of melanoma. Increased expression of anti-apoptotic Bcl-2 family members 
(Boucher, Morisset et al. 2000) may be mediated by RAS/RAF/MEK/ERK signalling frequently 
hyper-activated in melanoma by genetic mutations most commonly in BRAF or NRas (Davies, 
Bignell et al. 2002; Balmanno and Cook 2009). Hence it is likely that activated 
RAS/RAF/MEK/ERK signalling directly influences Bcl-2 family protein expression levels in 
melanoma. Furthermore, the Bcl-2 protein family plays a functional role in autophagy. As 
Beclin-1 is a BH3-only protein it is also a binding target of Bcl-2 (Decuypere, Jan et al. 2012; 
Feng, Huang et al. 2007), and Erlich et al showed that Beclin-1 binds to Bcl-2 and Bcl-xl with a 
high affinity, and as well as, with an albeit weaker interaction, with Mcl-1 (Erlich, Mizrachy et 
al. 2007). As such, Bcl-2 anti-apoptotic proteins including Mcl-1L are able to inhibit Beclin-1-
dependant autophagy.  
Mcl-1 encodes two splice variants known as Mcl-1 short (Mcl-1S) and Mcl-1 long 
(Mcl-1L) with either pro-apoptotic or anti-apoptotic function respectively (Bae, Leo et al. 
2000; (Bingle, Craig et al. 2000; Shieh, Liu et al. 2009). Despite identification of high Mcl-1 
levels in melanoma the influence of BRAF mutational status on Mcl-1 expression or for the 
expression of differing Mcl-1 splice variants in melanoma has to date remained poorly 
defined. Results from this thesis support and extend previous observations revealing 
activating mutations in BRAF result in increased expression of both anti-apoptotic Mcl-1L 
and pro-apoptotic Mcl-1S in vitro (McKee et al 2013 In press). Results confirmed increased 
Mcl-1L mRNA and protein expression in melanoma cells bearing mutant BRAF
V600E
. As such 
this suggests that BRAF/MEK/ERK signalling may contribute to apoptosis resistance through 
overexpression of anti-apoptotic Mcl-1 (McKee et al 2013 In press). Mcl-1S mRNA levels on 
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the other hand were not increased suggesting that increased Mcl-1S protein expression 
observed in melanoma cells bearing oncogenic BRAF was possibly due to a stabilisation 
event of the protein rather than increased transcription and/or splicing of the Mcl-1 gene 
(Domina, Vrana et al. 2004).  
 
7.2.2: The role of Mc-1 in autophagy and apoptosis in melanoma 
 
Several anti-apoptotic Bcl-2 family members including Mcl-1 are interacting partners 
of Beclin-1 (Decuypere, Jan et al. 2012; Erlich, Mizrachy et al. 2007; Feng, Huang et al. 2007) 
and as such associated with autophagy. Since initial results from the present study 
demonstrated increased total Mcl-1 expression in A375 and G361 melanoma cells with a 
significantly higher expression of anti-apoptotic Mcl-1L in BRAF mutated (A375, G361) 
compared with BRAF wild-type cells (CHL-1, SKMEL-23), further studies were undertaken to 
determine a functional role of total Mcl-1 in autophagy regulation in response to treatment 
with the autophagy modulatory agents THC and bortezomib. Both agents induced apoptosis 
in A375 metastatic melanoma cells as revealed by inhibition of viability and increased levels 
of Cleaved Caspase 3. Interestingly, bortezomib treatment also increased the levels of Mcl-1L 
in A375 cells transfected with control and Mcl-1 siRNA. This effect was most likely due to 
inhibition of the proteasome (the principle mechanism of bortezomib action (Attar, De 
Angelo et al. 2008; Horton, 2007; Ogawa, Tobinai et al. 2008; Papandreou, Daliani et al. 
2004; Richardson, Mitsiades et al. 2008; Yin, Zhou et al. 2005) and the prevention of 
proteasomal mediated degradation of Mcl-1. Both THC and bortezomib also induced 
autophagy as evidenced by increased LC3-II expression compared to expression in untreated 
A375 cells and initial findings following treatment of A375 cells with either agent in 
combination with the lysosomal inhibitor chloroquine also suggested THC-induced cell death 
was dependent on autophagy while bortezomib-induced cell death appeared to be 
independent of autophagy. However, there were a number of limitations to this approach 
since even partial knockdown of Mcl-1 expression resulted in significant induction of 
apoptosis. The analysis of the effect of Mcl-1 knockdown on autophagic signalling was 
therefore not possible. Nevertheless, these findings further highlight the importance of Mcl-
1 for melanoma cell survival in vitro. Despite the limitations with the Mc-1 knockdown 
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studies, partial knockdown of Mcl-1 resulted in the induction of autophagy to some extent as 
shown by increased levels of LC3-II in Mcl-1 siRNA transfected A375 cells compared to Ctrl 
siRNA transfected cells, thus supporting the hypothesis that Mcl-1 amplification, in addition 
to prevention of apoptosis, may contribute to oncogenesis stimulated by the inhibition of 
Beclin-1-dependent autophagy.  
 
7.2.3 Future potential of Mcl-1 as a therapeutic target  
 
Resistance to apoptosis is one of the key obstacles to overcome in order to develop 
more effective treatments for cancer. Increased anti-apoptotic Bcl-2 family members in 
addition to other factors including p53 mutations, BRAF/NRAS mutations or alterations in 
PI3K/Akt/mTOR signalling events to name but a few, may account for such resistance 
(Grossman and Altier 2001; Zhai, Jin et al. 2008). As such the high levels of anti apoptotic 
Mcl-1 mRNA observed in the present study in all tested cell lines (CHL-1, SKMEL-23, A375, 
G361) support previous observations of increased Mcl-1 in advanced melanomas and its 
association with apoptotic resistance induced by chemotherapy (Zhai, Jin et al. 2008). 
Results showing Mcl-1L expression is further increased in cells lines bearing oncogenic BRAF 
(A375, G361) compared with BRAF wild-type cells (CHL-1, SKMEL-23) also support the 
potential contribution of Mcl-1 to the chemoresistance in BRAF mutated tumours. It should 
be noted however, that melanomas without BRAF activating mutations may still have 
activated MEK/ERK signalling, as observed in some patient tumours (Passeron, Lacour et al. 
2011), possibly due to activation of other signalling pathways, as observed for the 
development of resistance following prolonged treatment with the BRAF inhibitor, 
vemurafenib (Johannessen, Boehm et al. 2010) which may therefore also influence Mcl-1 
expression. Of particular note, signalling via the protein signal transducers and activators of 
transcription 3 (STAT3) has been found to play an important role in melanoma development 
and progression and has recently been found as an important factor in BRAF inhibitor 
resistance (Liu, Cao et al 2013). STAT3 is a member of a family of seven proteins (STATs1, 2, 
3, 4, 5a, 5b, and 6) which are involved in transmission of signals from the plasma membrane 
to the nucleus in order to modulate transcription of several genes involved in the regulation 
of key processes in cancer survival such as cell differentiation, proliferation, angiogenesis, 
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metastasis, and immune responses (Johnston and Grandis 2011; Al Zaid Siddiquee and 
Turkson 2008). When activated in melanoma STAT3 promotes growth of melanoma cells and 
survival (Niu, Heller et al 1999; Niu, Bowman et al 2002) and target genes of STAT3 include 
Mcl-1 and Bcl-xl, increasing their expression and further contributing to melanoma 
resistance to apoptosis (Zhuang, Lee et al 2007). Apoptotic resistance in both BRAF mutated 
and BRAF wild-type tumours, which may also have activation of alternative signalling 
pathways and exhibit high anti-apoptotic Mcl-1 expression, may therefore potentially be 
overcome through the use of specific Mcl-1 inhibitors rather than broad spectrum BH3 
mimetics. However, several questions remain unanswered in order to understand the 
potential of Mcl-1 as a therapeutic target in melanoma including its interaction with Beclin-1 
in addition to the influence of alternative pathways of MEK/ERK activation on Mcl-1 
expression. As such, future studies could include: 
  
• Studies of the interaction of Mcl-1 with Beclin-1, the prevention of this interaction and the 
resulting effects on autophagy modulation involving perhaps the expression of a Beclin-1 
construct bearing a mutation in the Mcl-1 binding site and the comparison of effect in BRAF 
mutant and wild-type cells in response to autophagy induction.  
• Further studies into the application of BH3 mimetics which specifically target Mcl-1  
• Additional studies of the impact of downstream MEK/ERK signalling on Mcl-1 splice variant 
expression through the use of MEK or ERK specific inhibitors.  
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7.3 Autophagy modulation as a therapeutic target in melanoma 
 
7.3.1 THC and Bortezomib-induced autophagy 
 
  The importance of autophagy in cancer development has highlighted potential new 
therapeutic targets. Typically treatments have focussed towards inhibiting autophagy 
including through indirect inhibition with the lysomal inhibitor hydroxychloroquinone (HCQ) 
(Garber 2011). HCQ raises intralysosomal pH (Poole and Ohkuma 1981) and also impairs 
autophagic protein degradation (Glaumann and Ahlberg 1987; Levy and Thorburn 2011) and 
has been combined with several anticancer drugs resulting in its inclusion in a number of 
phase I and II clinical trials for tumours exhibiting high levels of basal autophagy (Garber 
2011). However alternative strategies suggest autophagy may be more appropriately 
harnessed to induce tumour cell death through the combination of current 
chemotherapeutics with autophgay inducing agents such as metformin or cannabinoids 
(Buzzai, Jones et al. 2007; Salazar, Carracedo et al. 2009; Tomic 2011). Initially autophagy-
inducing agents such as mTOR inhibitors (Rapamycin, RAD001, CC1-779 and AP23573) were 
used for the treatment of different human cancers, for example Rapamycin (Faivre, Kroemer 
et al. 2006) has been shown to exert significant anti-tumour properties in several cancer 
models (Faivre, Kroemer et al. 2006). However, clinical trials of mTOR inhibitors have been 
disappointing and have consequently led to the search for more effective autophagy 
inducing agents able to exert a cytotoxic effect (Buzzai, Jones et al. 2007; Salazar, Carracedo 
et al. 2009; Tomic 2011). Cannabinoids in particular are able to drive cancer cells to cell 
death through induction of autophagy (Salazar, Carracedo et al. 2009) and in particular THC, 
the most extensively studied for its medicinal usage (Carracedo, Gironella et al. 2006; 
Carracedo, Lorente et al. 2006; Gómez del Pulgar, Velasco et al. 2002; Salazar, Carracedo et 
al. 2009; Salazar, Carracedo et al. 2009; Sánchez, Galve-Roperh et al. 1998). In glioma the 
underlying mechanism of THC-induced apoptosis appears to result from ceramide 
accumulation leading to the activation of an ER stress response and subsequent, Akt 
inhibition, autophagy induction and ultimately cell death (Duntsch, Divi et al. 2006; Salazar, 
Carracedo et al. 2009; Sánchez, Galve-Roperh et al. 1998; Sánchez, de Ceballos et al. 2001; 
Velasco, Carracedo et al. 2007). Results from this thesis demonstrate THC is also able to 
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induce autophagy in melanoma as evidenced by increased autophagosomes and the 
induction of autophagic flux in BRAF
V600E
 (A375) and BRAF
WT
 (CHL-1) cells stably expressing 
RFP-GFP-LC3 as well as through the use of chloroquine, in which THC-induced cell death was 
prevented. However, the use of a single autophagy inhibitor alone, or even the knockdown 
of a single key autophagy gene, is not enough to fully support the claim that THC requires 
autophagy to induce cell death (Mizushima, Yoshimori et al. 2010). Combining data derived 
from THC treatment of melanoma cells in which knockdown of both Beclin-1 and Atg7 
expression in A375 and CHL-1 cells prevented THC-induced cells death however, in addition 
to the observed effects in response to combined treatment with chloroquine provides strong 
evidence for the requirement of autophagy for apoptosis induction in response to THC. 
Importantly therefore, these data thus suggest similar mechanisms of THC-induced 
autophagy and apoptosis are apparent in multiple tumour types (melanoma, glioma, 
pancreatic). Nevertheless, differences have been observed within this thesis compared to 
studies in glioma. The most noticeable example of this is for that of the induction of 
ceramide accumulation, which is reported to be a prerequisite for THC-induced ER stress, 
autophagy and apoptosis (Gómez del Pulgar, Velasco et al. 2002; Salazar, Carracedo et al. 
2009) in glioma. The importance of this event in glioma was confirmed as ISP (a selective 
inhibitor of serine palmitoyltransferase, the enzyme that catalyzes the first step of 
sphingolipid biosynthesis (Ogretmen and Hannun 2004)) prevented THC-induced autophagy 
and cell death. However, using 5 µM ISP treatment in A375 melanoma cells had little effect 
on the inhibition of melanoma cell viability. As such, whether ceramide accumulation is 
occurring via a different mechanism or even if it is required in melanoma for downstream 
responses induced by THC remains to be verified. However, knockdown of the protein kinase 
tribbles 3 (a negative regulator of NFκB shown to be required for THC-induced autophagy 
and cell death in glioma (Salazar, Carracedo et al. 2009) did prevent THC-induced inhibition 
of cell viability indicating the existence of similar downstream signalling events to ceramide 
accumulation to those reported in studies of THC-induced autophagy and apoptosis of 
glioma cells (Salazar, Carracedo et al. 2009). 
  Comparing the effects of THC and bortezomib-induced autophagy revealed 
opposing effects of autophgay induction on cell death of melanoma cells. While knockdown 
of the autophagy regulatory genes Beclin-1/Atg7 or chloroquine treatment prevented THC-
induced inhibition of melanoma cell viability, this had no effect on bortezomib-induced cell 
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death. Both agents however, were still able to induce autophagy even in the absence of 
Beclin-1 as shown by increased LC3-II expression in A375 cells in response to subsequent 
treatment with THC or bortezomib. However, rapamycin treatment still resulted in the 
induction of LC3-II expression even in the absence of Beclin-1 in both A375 and CHL-1 cells. 
Collectively these data thus suggest the role of Beclin-1 in autophagy regulation in 
melanoma may not be canonical and that this protein may in fact exert additional 
autophgay-independent functions required for THC-induced cell death which are not 
necessarily required for a similar response to bortezomib. Additionally, these data suggest 
autophagy induction in melanoma may occur even in the absence of Beclin-1. This 
hypothesis nevertheless requires validation through use of alternative siRNA sequences to 
knockdown Beclin-1.  
  The identified requirement of Beclin-1 in THC-induced cell death of melanoma is 
also an important factor to consider when stratifying patients for potential treatment. 
Although the panel of patient tumours studied in this thesis is relatively small, differences in 
Beclin-1 expression were clearly observed in which tumours exhibited either little or no 
expression or alternatively high expression of this protein. Furthermore previous 
publications have also observed a bi-phasic expression pattern of Beclin-1 in patient tumours 
where Beclin-1 expression was found to be either high or low in different patient tumours 
(Sivridis, Koukourakis et al. 2011). As such this would lead one to speculate that only those 
patients expressing Beclin-1 may benefit from treatment with THC as Beclin-1 knockdown in 
A375 and CHL-1 cells prevented THC-induced apoptosis and inhibition of cell viability.   
 
7.3.2 Potential therapeutic applications of autophagy modulation by THC  
 
  The importance of autophagy in cancer development and survival is becoming ever 
clearer, however, targeting autophagy through use of either specific inhibitors is essentially a 
‘double edged sword’. On one hand autophagy inhibition may over-come induction by 
chemotherapeutic drugs as a mechanism to counter act apoptotic signals or to block pro 
survival autophagic signalling frequently observed in advanced stage tumours (Bertout, Patel 
et al. 2008; Zhang, Bosch-Marce et al. 2008). On the other hand however, this approach may 
prevent the tumour suppressive function of autophagy and facilitate the development of 
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secondary tumours (Qu, Yu et al. 2003; Yue, Jin et al. 2003). Alternatively, autophagy 
induction resulting in apoptosis as observed in response to THC (Salazar, Carracedo et al. 
2009) may represent a better and more effective strategy. However, as autophagy is 
typically utilised as a pro-survival mechanism in many tumour types, if the correct balance 
for beneficial effects of THC as an anti-cancer agent are not achieved this may in theory 
prove more beneficial to advanced stage tumours rather than cause their demise. 
  Results from this thesis nevertheless suggest THC may be useful in the promotion of 
melanoma cell death in vivo, as evidenced by its clear effects on the induction of apoptosis 
and inhibitory effects on cell viability in vitro. However, in vivo studies are lacking at this 
stage and hence would be required to further verify the findings in vitro and provide further 
evidence to support its clinical use in the treatment of metastatic melanoma. Despite the 
lack of in vivo data, the potential use of THC in combination with temozolmide, a main-stay 
chemotherapeutic in the treatment of melanoma, has been shown in glioma to induce 
synergistic responses (Torres, Lorente et al. 2011) highlighting the potential application of 
THC in combination well established chemotherapeutics for melanoma treatment. As such 
future studies of THC may include:  
 
• In vivo studies of mouse xenografts of human melanoma treated with THC alone or in 
combination with temozolomide.  
• Studies of THC clinical derivatives, such as Sativex (GW Pharmaceuticals Ltd) and the effect 
of such agents on the induction of autophagy and apoptosis of melanoma in vitro and in 
vivo. 
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7.4 Bioinformatics for identifying Beclin-1 complex protein-protein 
interactions in melanoma 
 
7.4.1 Protein-protein interactions of Beclin-1 
 
  Identification of protein-protein interactions utilizing well established methods such 
as co-immunoprecipitation pull down assays, bimolecular fluorescence complementation 
assays and chemical cross-linking approaches are some of the most effective practical 
approaches to determining direct interactions of a protein of interest (Hu, Chinenov et al. 
2002; Berggård, Linse et al. 2007). This can prove very useful in understanding functional 
roles as well as providing additional avenues of future research to explore. However it is 
often easy to overlook articles which have already identified many important interactions of 
a particular protein of interest. Furthermore, pooling of this data can prove even more 
taxing by more traditional approaches. To overcome these obstacles, the development of 
several bioinformatics tools in recent years have provided a mechanism for accurate data 
mining approaches to provide a platform for gathering such information. The tool adopted 
by studies in this thesis, Cytoscape, is an open source bioinformatics software platform used 
for visualizing molecular interaction networks equipped with multiple functions enhanced by 
the use of specific plugins designed by the scientific community (Shannon, Markiel et al. 
2003; Yeung, Cline et al. 2008). The plugin of choice used to visualise known protein-protein 
interactions for a protein of interest has been designed by Biological General Repository for 
Interaction Datasets (BioGRID) which gathers constantly updated interaction data for several 
organisms (Homo sapiens included) from several databases; Saccharomyces Genome 
Database, Flybase, GeneDB, TAIR, and Entrez Gene (Chatr-Aryamontri, Breitkreutz et al. 
2013). The data provides several useful pieces of information in addition to the identified 
genetic and protein-protein interactions including the source of the information and the 
techniques used to obtain results and allowing for further in depth analysis of each identified 
interaction in addition to methodical approaches which can be utilized and adapted for 
personal experiments. Unexplained findings observed following knockdown of Beclin-1 and 
subsequent treatment with THC, bortezomib or rapamycin in which autophagy was still 
induced despite the confirmed reduction in Beclin-1 expression lead to utilization of such 
software in order to define more specific targets for further analysis and provide further 
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insight into possible roles for this protein in a variety of cellular pathways. In recent years 
several publications have revealed interacting partners for many members of the autophagy 
pathway including Beclin-1 (Behrends, Sowa et al. 2010). As such a wealth of information 
revealing potentially crucial protein-protein interactions for Beclin-1 is already available. 
Using the BIOGRID plugin on Cytoscape revealed 34 known protein-protein interactions for 
Beclin-1. Several of these interactions where identified for proteins involved in cellular 
pathways particularly important to the theme of this project including autophagy and 
apoptosis as well as the cell cycle the involvement of which may explain more fully the role 
of Beclin-1 in THC-induced cell death and autophagy. 
 
7.4.2 Ambra 1; an important Beclin-1 interacting protein 
 
Utilising the BIOGRID plugin for cytoscape, Ambra 1 (or activating molecule in Beclin-
1 regulated autophagy protein 1) was highlighted as an important Beclin-1 interacting 
protein. Ambra 1 was chosen to further investigate its contribution to THC-induced 
autophagy and cell death in melanoma due to several factors; its interaction with Beclin-1, 
its known role in autophagy (Fimia, Stoykova et al. 2007; Itakura, Kishi et al. 2008; Roy and 
Debnath 2010; Simonsen and Tooze 2009) and links with apoptosis (Corazzari, Fimia et al. 
2012). Furthermore previous studies in glioma have shown that Ambra 1 is essential for THC-
induced autophagy and cell death (Salazar, Carracedo et al. 2009) and that this process does 
not require Beclin-1 (personal communication with Guillermo Velasco, Complutenese 
University of Madrid, Spain). Interestingly as shown in chapter 6, in contrast to studies of 
THC-induced autophagy in glioma, Ambra 1 does not appear to be required for autophagy 
induced by THC in melanoma since stable knockdown of this protein did not prevent THC-
induced inhibition of cell viability or cell death. Additionally bortezomib also induced 
autophagy in the absence of Ambra 1. These data thus further support a non-canonical 
mechanism of THC-induced autophagy in melanoma in which the classical Beclin-
1/Vps34/Ambra 1 complex is not necessarily required for induction of cell death or in the 
induction of THC or bortezomib-induced autophagy. 
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7.4.3 Future studies of Beclin-1 functions in melanoma 
 
  The identification of Beclin-1 protein-protein interactions has revealed several 
pathways of interest that Beclin-1 maybe involved in for which there is little information 
available in the literature to be able to elaborate further. At least three different functional 
Beclin-1 complexes have been identified thus far in the literature; the Beclin-
1/Vps34/Vps15/Ambra 1/Atg14L complex; the Beclin-1/Vps34/Vps15/UVRAG complex; and 
the Beclin-1/Vps34/Vps15/UVRAG/Rubicon complex which are each involved in autophagy 
regulation (Matsunaga, Saitoh et al. 2009). The variety of complexes that Beclin-1 has 
already been shown to form in addition to direct interactions with anti-apoptotic Bcl-2 
proteins suggests that further studies are required to truly understand the complex 
functions of this protein within cells be they cancerous or normal. Additional articles have 
provided evidence for functions of Beclin-1 outside of autophagy (Djavaheri-Mergny, Maiuri 
et al. 2010; Frémont S 2013; Wirawan, Vande Walle et al. 2010). Beclin-1’s role in cell cycle 
regulation was suggested to be required for chromosome congression and proper outer 
kinetochore assembly (Frémont S 2013). Additionally, Beclin-1 can be cleaved by caspases 
thus preventing its pro-autophagic activity (Wirawan, Vande Walle et al. 2010) and the C-
terminal fragment produced from this celavage event functions in amplifying mitochondrial 
mediated apoptosis (Djavaheri-Mergny, Maiuri et al. 2010). This, in addition to further 
interactions identified in this thesis using Cytoscape suggests that Beclin-1 may in fact have 
several important functions independent of its role in autophagy. As such future studies 
could address:  
 
• Protein-protein interactions to verify other Beclin-1 interacting proteins revealed in the 
Cytoscape search and their function in melanoma. 
• The functional role of Beclin-1 in the additional cellular pathways identified by the present 
cytoscape data mining data including those involved in apoptosis and the cell cycle, including 
investigating the effects of their modulation on apoptosis and cell cycle function. 
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7.5 THC as an apoptosis inducing agent for melanoma therapy 
 
7.5.1 THC induces intrinsic apoptosis in melanoma 
 
The realisation that cannabinoids induce apoptosis as a mechanism of cell death has 
lead to intense interest in their clinical usage in cancer therapy. Many articles have 
highlighted the capability of THC to induce apoptosis (Carracedo, Gironella et al. 2006; 
Carracedo, Lorente et al. 200 6; Salazar, Carracedo et al. 2009; Salazar, Carracedo et al. 
2009) with some pilot data suggesting similar effects in melanoma (Blázquez, Carracedo et 
al. 2006; Kenessey, Bánki et al. 2012; Scuderi, Cantarella et al. 2011; Zhao, Yang et al. 2012). 
Data from this thesis confirms not only is THC able to induce death of melanoma cells but 
that cell death specifically results from the induction of apoptosis. Treatment with THC 
resulted in the inhibition of cell viability in all tested cell lines (CHL-1, A375, SKMEL-28) using 
a dose range of 4-10 µM THC with complete inhibition of cell viability observed by 10 µM 
concentrations and was paralleled by increased levels of Cleaved Caspase 3, the initiation 
event for the execution phase of apoptosis. Combined treatment of THC with the pan 
caspase inhibitor ZVAD-fmk prevented inhibition of melanoma cell viability in both A375 and 
CHL-1 cells also confirming the induction of apoptosis in melanoma cells by THC. Finally 
cytochrome C release, an early event in intrinsic apoptosis (Cai, Yang et al. 1998, van Loo, 
van Gurp et al. 2002; Schimmer 2004), was also observed in response to THC treatment 
further suggesting the activation of intrinsic apoptosis signalling mediated through 
mitochondria. Coupled with observations showing THC treatment had little effect on the cell 
viability of primary melanocytes with inhibitory effects only observed at much higher doses 
than required to induce apoptosis of melanoma cells (>7 µM as opposed to >3 µM) these 
data thus highlight the potential suitability of this agent as therapeutic agent for metastatic 
melanoma.   
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7.5.2. Alternative modes of THC induced apoptosis  
 
  Additional studies (further discussed in section 7.6) suggest the toxicity of THC is 
further enhanced through its ability to induce lysosome membrane permeabilization.  
However, further understanding of the downstream apoptotic events induced by THC will be 
crucial to elucidating the potential of THC as a chemotherapeutic agent. Data derived from 
this thesis provide strong evidence for key events in THC-induced intrinsic apoptosis. 
However, downstream signalling events of caspase 3 cleavage involved in the execution 
pathway remain to be identified and additional observations such as cytochrome C nuclear 
localisation observed in THC treated A375 cells by fluorescence microscopy, an event 
suggested to induce apoptosis directly (Nur-E-Kamal, Gross et al. 2004), suggests other 
signalling mechanisms are occurring which may be required for THC-induced apoptosis. As 
such, this will require further study to determine the importance of these events in THC-
induced apoptosis. Several additional molecular events have been shown to occur in 
response to THC in other tumour types. The most noteworthy of these events is the 
induction of reactive oxygen species (observed in THC treated glioma cells) (Marcu, Christian 
et al. 2010) which is an event known to induce apoptosis through several mechanisms 
including; direct death receptor activation, mitochondrial mediated intrinsic apoptosis 
induction and JNK mediated extrinsic and intrinsic apoptosis induction to name a few (Circu 
and Aw 2010; Dhanasekaran and Reddy 2008; Ryter, Kim et al. 2007). However, whether 
these events are occurring in melanoma remain to be seen and the contribution of ROS 
induction towards THC-induced cell death has not been determined. To further elucidate 
other signalling events that contribute to THC-induced apoptosis, future studies could 
include: 
 
• Studies to determine the importance of nuclear localised cytochrome C towards THC-
induced apoptosis in melanoma cells. 
• Studies to determine the impact of THC treatment on the induction of oxidative stress and 
the contribution of ROS induction to THC-induced melanoma cell death determined by 
studies of ROS induction.  
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• Further studies to determine whether death receptor activation and JNK actiavation are 
occurring in response to ROS induction would also be important to understand mechanisms 
of cell death induced by THC.  
• Assessment of events downstream of the execution pathway of apoptosis such as 
degradation of chromosomal DNA, degradation of nuclear and cytoskeletal proteins, 
formation of apoptotic bodies to confirm intrinsic apoptotic cell death is caused by THC in 
melanoma.  
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7.6 Lysosomes; the missing link between THC induced autophagy 
and apoptosis? 
 
7.6.1: THC induces lysosome membrane permeabilization in melanoma cells 
 
  The importance of lysosomes in cell death has long been established. Initially 
described as ‘suicide bags’ (De Duve 1959), increased evidence now shows lysosome 
membrane permeabilization (LMP) is a key event contributing to cell death (Aits and Jäättelä 
2013; Boya and Kroemer 2008). LMP results from lysosomal damage causing the release of 
constituents including hydrolytic enzymes such as proteases, lipases, and nucleases (Aits and 
Jäättelä 2013; Boya and Kroemer 2008). Damage can be induced by several stimuli such as; 
p53, Bax, ROS, PLA2, active caspases and bacteria and viral proteins (Boya and Kroemer 
2008), resulting in indiscriminate degradation within the cell and ultimately cell death, which 
depending on the amount of lysosomal damage may result from necrosis (in the case of 
large scale damage) or apoptosis (where moderate damage is induced). LMP typically occurs 
as a partial and selective process causing apoptosis via the released hydrolytic enzymes 
resulting in mitochondrial outer membrane permeabilization, cytochrome C release and 
caspase activation (Guicciardi, Deussing et al. 2000). Results from the present study have 
observed each of these events in melanoma cells  in response to treatment with THC as 
evidenced by observations demonstrating cathepsin B was no longer co-localised with 
LAMP2 in A375 or SKMEL-28 cells following treatment with THC (suggesting they are no 
longer contained with lysosomes); cytochrome C  exhibited a cytoplasmic staining pattern in 
THC treated A375 cells suggesting they have been released from the mitochondria; and 
activation of caspase 3 was observed in THC treated A375 and CHL-1 cells. Each of these 
observations suggests LMP is thus a crucial factor contributing to THC-induced apoptosis of 
melanoma cells. 
  Additionally, fenton reactions which are known to occur in response to chelatable 
iron overload within the lysosome, have also been suggested to result from THC treatment 
of glioma cells resulting in increased cell death mediated by oxidative stress (Goncharov, 
Weiner et al. 2005). Since increased ferritin expression in melanoma cells may contribute to 
melanoma progression by modulating cell growth and reducing sensitivity to oxidative stress 
(Baldi, Lombardi et al. 2005), which also leads to LMP induction, it is possible therefore that 
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increased levels of ferritin and iron containing proteins may contribute to LMP induced by 
THC.  
 Recycling of cellular components through autophagy utilizes a lysosome based 
mechanism of degradation in which the autophagosome ultimately fuses with the lysosome 
to degrade its constituents (Roy and Debnath 2010). As such lysosomes may play a crucial 
role in cannabinoid-induced apoptosis with increased sphingolipid accumulation in addition 
to ROS generation further supporting the possibility of THC-induced induction of LMP. 
Indeed data derived from this thesis demonstrates for the first time LMP induction by THC as 
shown by release of cathepsin B from lysosomes and the inhibition of this process by 
bafilomycin. Additionally, prevention of LMP by inhibition of autophagy through Atg7 
knockdown in A375 and SKMEL-28 cells was also observed demonstrating THC-induced 
autophagy leads to LMP and release of cathepsin B. As inhibition of cell viability was also 
prevented by a cathepsin B inhibitor in A375 cells and the use of this agent in combination 
with THC partially prevented cytochrome C release it is therefore likely that cathepsin B, at 
least in part, is a key event in THC-induced apoptosis as a result of LMP. 
 
7.6.2 Future directions for understanding the role of LMP in THC induced apoptosis 
 
Results from the present study reveal the potential importance of cathepsin B release 
from lysosomes in the induction of apoptosis in melanoma cells in response to THC. 
However cathepsin B is only one of many proteases leaked from the lysosome during LMP 
(Emert-Sedlak, Shangary et al. 2005; Guicciardi, Deussing et al. 2000; Sever, Altintas et al. 
2007). Many cathespins are active at neutral pH and cathepsin D release has also been 
shown to induce apoptosis in other tumour types (Emert-Sedlak, Shangary et al. 2005; Sever, 
Altintas et al. 2007). Therefore identifying whether additional cathepsins are also released 
from the lysosome and function in downstream apoptotic signalling events will provide 
further insight into the impact of LMP in THC-induced apoptosis. Additionally studies of how 
autophagy may regulate the release of cathepsins from the lysosome will enhance the 
understanding of autophagy mediated LMP and its requirement or not for THC-induced cell 
apoptosis or whether it is simply an amplification step in the induction of cell death. 
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Therefore, to elaborate on these findings and determine more fully the relationship between 
autophagy and LMP in THC treatment of melanoma cells future studies might entail:  
 
• Further assessment of the functional impact of additional lysosomal cathepsin release (e.g. 
cathepsin D) on LMP induction in response to THC.  
• Real time analysis of autophagosome-lysosomal fusion in relation to THC-induced LMP, 
cytochrome C release and cell death.   
• Additional studies to verify the requirement of autophagy for THC-induced LMP.  
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7.7 Final remarks 
 
  This thesis aimed to identify novel therapeutic strategies through which to harness 
autophagy modulation for the clinical benefit of metastatic melanoma and has revealed 
novel potential avenues to exploit for drug development. The discovery that activated 
BRAF/MEK/ERK signalling causes increased expression of anti-apoptotic Mcl-1L suggests a 
potential mechanism of apoptotic resistance in melanoma which maybe further enhanced in 
those tumours bearing BRAF mutations. As such targeting Mcl-1L using specific Mcl-1 
inhibitors rather than broad spectrum BH3 mimetics, maybe offers a more effective 
therapeutic approach, particularly for patients bearing BRAF/NRAS mutant melanomas or for 
patients who have developed resistance to BRAF-specific inhibitors (Jang and Atkins 2013). 
Additionally, increased expression of Mcl-1S may offer a potential anti-cancer effect in 
melanoma cells, possibly through reducing the functional impact of increased Mcl-1L (Shieh, 
Liu et al. 2009). As such targeting Mcl-1 pre-mRNA with Mcl-1 antisense morpholino 
oligonucleotides to increase Mcl-1S expression may be a further mechanism to exploit. 
Furthermore data derived from this thesis show in contrast to pro-survival autophagy 
inducing agents such as bortezomib (Armstrong, Corazzari et al. 2011), THC-induced 
apoptosis of melanoma cells which is dependent on the induction of autophagy. 
Additionally, the ability of THC to induce LMP in metastatic melanoma cells, which appears 
to be dependent on autophagic signalling suggests for the first time, a potential link between 
autophagy and apoptosis through the permeabilization of lysosomes and the release of 
cathepsin B leading to loss of mitochondrial integrity, cytochrome C release and enhanced 
cell death. As such the amplified effect of THC-induced autophagy and LMP suggest a novel 
means through which to increase the potency of this cannabinoid providing a strong rational 
for its development and clinical use in the treatment of metastatic melanoma. Current 
clinical trials of sativex (GW Pharmaceuticals Ltd), a 50:50 mixture of THC and CBD in 
combination with temozolomide are underway for the treatment of recurrent glioma with 
promising results which together with ongoing studies in melanoma already showing a 
potent synergistic effect in vitro (Hill and Lovat un published data) will hopefully lead the 
way to a new era of autophagy modulatory therapy for metastatic melanoma with improved 
clinical outcome. 
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